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General introduction and aims of this thesis 
 
   
Chapter 1 
Introduction 
Differentiated thyroid carcinoma (DTC) is a rare disease with unique features. 
The central role of therapy with radioiodine (RaI)-131 (131I) for instance is 
unique for DTC. Another special aspect is that despite the good prognosis, a 
substantial proportion of patients develop metastases, that are not life 
threatening but may impair quality of life considerably, a situation that is not 
often encountered in general oncology. 
The focus of the present thesis is the therapy with 131I, and long term follow-up 
of patients with DTC. Although many aspects of diagnosis, initial therapy and 
follow-up procedures have been covered in recently published guidelines and 
consensus papers (published by the American and European Thyroid 
Associations and by the Dutch CBO thyroid carcinoma consensus group 
(www.cbo.nl) [1;2], many questions with regard to the clinical approach to 
patients with DTC still remain to be answered. This thesis addresses some 
important clinical questions, related to the application of conventional (131I) and 
experimental therapies with radionuclides in DTC. 
 
Characterization of thyroid carcinomas 
Human thyroid tumors are derived either from epithelial follicular cells or from 
parafollicular C-cells. Follicular cell-derived tumors represent a wide spectrum 
of lesions, ranging from benign adenomas to differentiated (follicular (FTC) and 
papillary (PTC) and undifferentiated (anaplastic) carcinomas. 
Thyroid cancer, comprising less than 1% of all cancers in the Netherlands, has a 
good prognosis in general. In the Netherlands, the incidence of DTC is 2 per 
100.000 inhabitants per year [3;4]. However, the prevalence of patients with 
DTC is relatively high due to the good prognosis (approximately 4000 patients 
in the Netherlands) [3]. In general, 80-90% of newly diagnosed thyroid 
carcinomas are differentiated tumors with a median age at diagnosis of 45 to 50 
years [5]. These tumors are two to four times as frequent in women as in men. 
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DTC has a relatively favorable prognosis with a 10-yr survival of 70-95% 
(Table 1). This high survival rate is the result of the biological behavior of most 
of these tumors and the efficacy of primary therapy, consisting of surgery and 
RaI therapy. However, when distant metastases occur, the prognosis is worse as 
the results of RaI therapy, which is virtually the only curative treatment option, 
are moderate. Depending on the localization and size these metastases may 
affect quality of life for years. 
 








Metastases 10-yr survival 
(%) 
Papillary 65 5-70 Lymphatic 90-95 
Follicular 20 30-70 Haematogenous 70-80 
Medullary 5-10 5-70 Lymphatic 50-60 
Anaplastic 5-10 >50 Both <5 
 
PTC mainly infiltrates diffusely into the thyroid gland and once they 
metastasize, it is generally to the locoregional lymph nodes. Pathological 
examination reveal papillary structures and in approximately 80% also follicles. 
Most of the PTC, are not encapsulated. FTC have almost always a tumor capsule 
and, in contrast to PTC, metastasize haematogeneously. A more aggressive 
variant of FTC is the so-called Hürthle-cell carcinoma, which has a poor 
capacity of RaI accumulation. Most DTC produce thyroglobulin (Tg). 
The tumor-node-metastases (TNM) classification system is based primarily on 
pathologic findings and separates patients into four stages, with progressively 
poorer survival with increasing stage [8]. Recently, the 6th edition of the TNM 
system has become available [9]. The most important difference with the 5th 
edition is the fact that the dimension of T1 has been extended to 1.5 cm and that 
tumors with limited extrathyroidal extension are designated T3 instead of T4, 
which has implications for the prognosis of DTC [10]. Therefore, some experts 
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propagate to continue the use of the 5th edition. In the studies in this thesis the 5th 
edition of the TNM staging system is used [11]. 
 
Initial therapy of DTC 
In most patients with DTC, initial therapy consists of (near-) total thyroidectomy 
followed by ablation with 131I for the thyroid remnants 4 to 6 weeks after 
surgery. The rationale for this strategy is to eliminate microscopic or gross 
residual tumor tissue in the thyroid remnant or outside the thyroid bed. 
Furthermore, ablation of the thyroid remnant increases the specificity of follow-
up strategies for recurrent DTC. Once a complete ablation has been achieved, 
increasing Tg values and/or RaI uptake in the head and neck region or chest, two 
main sites for recurrences, are indicative for recurrent DTC. Although there is 
still some controversy about the extent of thyroid surgery, there are strong 
arguments in favor of total or near-total thyroidectomy (leaving only as limited 
thyroid tissue as is necessary to keep vital structures intact) in all patients [12]. 
Total or near-total thyroidectomy results in a lower recurrence rate than more 
limited thyroidectomy, because many papillary carcinomas are multifocal and 
bilateral [13;14]. Furthermore, total thyroidectomy facilitates total ablation with 
131I and reveals a higher specificity of Tg as a tumor marker. In low risk patients 
(those with T1N0M0 (5th Edition) papillary carcinomas, if unifocal), a hemi-
thyroidectomy may be appropriate. A total thyroidectomy is indicated in tumor 
stages T2 and higher [15-17] The argument against total thyroidectomy is that it 
increases the risk of surgical complications such as recurrent laryngeal-nerve 
injury and hypoparathyroidism. However even with total thyroidectomy, some 
thyroid tissue may remain, as detected by pre-ablative scanning with 131I. 
Lymph node metastases are frequently found in patients (65%) with papillary 
carcinomas [5;15]. Among patients with follicular carcinomas, a small 
proportion of the patients (about 35%) have lymph node metastases. In some 
studies, the presence of lymph node metastases is considered as an independent 
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risk factor for recurrence of the tumor in both types thyroid carcinoma [17;18]. 
In another study, this was only found in patients with stages T3 and T4 papillary 
carcinoma [19]. However, modified lymph node dissection has not been shown 
to improve recurrence and survival rate [17;20], although this is debated by 
others [21]. Various forms of extended or radical surgery were related to better 
prognosis, but the results were not conclusive [17;18;22;23]. 
Although controversy exists about the routine application of 131I for ablation of 
thyroid remnants, many clinics follow this procedure. There are several reasons 
for routine ablation after surgery [24]: (a) to enable detection of a carcinoma 
recurrence by RaI scanning; (b) RaI can destroy microscopic foci of carcinoma 
in the thyroid remnant; (c) possible carcinoma outside the thyroid bed may be 
detected and treated by RaI; (d) to improve the specificity of Tg as tumor marker 
of recurrent carcinoma all normal thyroid tissue has to be destroyed. 
In patients with small (<1,5 cm) intrathyroidal tumors, the effect of thyroid 
ablation on recurrence and mortality rates is not clear [17;25]. In patients with 
tumor stages T2-4 without metastases, a favorable effect on recurrence appears 
to be present in a considerable number of publications, whereas a beneficial 
effect on survival is probably only been observed in patients with irradical 
surgery [17;18;22;26]. However, in a multivariate analysis in this group 131I 
ablation therapy was a significant predictive factor for recurrence, but not for 
survival [22]. 
In addition, doubts have arisen about the safety of routine RaI ablation, and a 
recent paper suggested a relation between excess non-thyroidal malignancies 
and RaI [27;28]. This has led to a more careful positioning of RaI ablation in 
recent papers [2;29]. 
In conclusion, there is consensus about the efficacy of 131I ablation therapy in 
patients with: (a) tumor stages T2-4; (b) evidence for remaining thyroid tumor 
remnants and (c) metastases [30;31]. 
Regarding the initial ablation strategies with 131I, two general protocols are 
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commonly used in the Netherlands. The first one, the so-called uptake-related 
strategy (described in Chapter 2), is based on a 24-hour uptake measurement 
using a low activity of 131I or Iodine-123 (123I). The amount of RaI uptake 
measured in the neck region is categorized into three subgroups: >10%, 5-10% 
and <5% uptake resulting in ablation activities of 1100, 1850 and 2800 MBq of 
131I, respectively. As the uptake generally is supposed to represent the amount of 
thyroid tissue, it can be seen that in a larger remnant, a lower amount of activity 
is given. The rationale of this quantitative approach is to avoid unnecessary 
exposure [32] and locoregional side-effects, which may be caused when a high 
amount of activity is given in patients with large thyroid remnants [33;34]. In 
this regimen, no adjustments are made in the case of cervical lymph node 
metastases. The second ablation strategy, the so-called fixed-dose or tumor-
related strategy (described in Chapter 3), is based on the initial tumor stage. A 
standard activity of 3700 MBq of 131I is given in patients with T0-3, N0, M0 
disease. In patients with T4 and/or N1 disease and in patients with M1 disease, 
activities of 5550 MBq and 7400 MBq are given respectively. This ablation 
strategy is irrespective of the 24-hour uptake measurement. 
In most clinics a standard activity of 1200 to 4000 MBq of 131I is given for 
thyroid ablation. A meta-analysis found that a single administration of about 
1200 MBq failed to fully ablate the remnant (46%) more often than did 2800 to 
3700 MBq (27%) [35;36]. 
The efficacy of 131I therapy depends on the radiation dose delivered to the 
thyroid remnant or tumor [37]. The radiation dose is negatively affected by 
decreased uptake and the shorter effective half-life of 131I in tumor tissue 
compared with normal thyroid tissue [38-40]. 
Strategies to increase RaI uptake include the establishment of high TSH values, 
either by thyroid hormone withdrawal or by therapy with recombinant human 
(rh) TSH [41;42]. Another method to increase 131I uptake is to deplete the 
plasma inorganic iodine pool before 131I therapy. Low plasma iodine 
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concentrations may increase the expression of the sodium iodine transporter 
which subsequently leads to increasing thyroid remnant RaI uptake [38;43;44]. 
Iodine depletion can be achieved by limiting iodide intake through a low-iodine 
diet (LID). The LID in our hospital involves 4 days of iodine restriction aiming 
at a maximum urinary excretion of 49 ug/day [45]. Many clinics now use a LID 
before thyroid ablation. Pluijmen et al. [46] concluded that LID during thyroid 
remnant ablation improves the efficacy of ablation. 
 
Follow-up 
In our institution, the efficacy of ablation therapy is evaluated after 6 months by 
RaI scintigraphy and Tg values after withdrawal of thyroxine treatment (during 
4 weeks) or after intramuscular injection of rhTSH [42]. If any uptake is 
detected on the RaI total body scan (WBS) and/or serum Tg is detectable (i.e. 
above cut-off level) an additional treatment with 131I is given. For routine 
diagnostic scans, 185 MBq 131I is given followed by a WBS three days 
thereafter. Assuming an equivalent fractional uptake after the administration of a 
low diagnostic activity of 131I, an uptake too low to be detected with 185 MBq 
may be detected after the administration of high therapeutic activities (6100 – 
7400 MBq). This is the rationale for the administering of therapeutic activities in 
patients with elevated serum Tg concentrations, even if the results of diagnostic 
scanning are negative. The post-therapeutic WBS should be obtained four to 
seven days later [5]. 
If no uptake on WBS is detected and serum Tg is undetectable (i.e. below cut-
off level), subsequent follow-up is based on Tg measurements during thyroxin 
therapy. 
The goals of follow-up after initial therapy are to maintain an adequate 
thyroxine therapy and to detect and prevent persistent or recurrent thyroid 
carcinoma. Recurrences are usually detected during the early years of follow-up 
but may be detected later, even after more than 15 years after initial treatment. 
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The most important tools in follow-up protocols are serum measurements of Tg, 
diagnostic WBS and neck-ultrasound. 
Tg is a glycoprotein that is produced only by normal or neoplastic thyroid 
follicular cells. It should not be detectable in patients who have undergone total 
thyroid ablation. The presence of thyroglobulin in such patients reveals the 
presence of persistent and/or recurrent disease. The type of analysis (RIA or 
immunometric assay) affects the interpretation of serum Tg values [47]. Tg 
auto-antibody (TgAb) interference, which can lead to under- or overestimation 
of the serum total Tg concentration, regardless to the type of method used [47-
51] is the most serious specificity and sensitivity problem affecting serum Tg 
measurements. Auto-antibodies against Tg are present at high concentrations in 
sera from patients with autoimmune thyroid disorders (51-97%) and at low 
concentrations in healthy individuals [50]. The incidence of serum TgAbs in 
DTC is between 15 and 30%. 
 
Therapy in metastatic disease 
Distant metastases, usually in the lungs and bones, occur in 10 to 15% of the 
patients with DTC. Lung metastases are most frequent in young patients with 
papillary carcinomas. In general, bone metastases are more common in older 
patients and in those with follicular carcinomas. 
In case of residual disease or metastases, surgery can be attempted when the 
lesion is accessible. In other cases, 131I therapy will be given in patients with 
metastases that take up RaI. The remission rate in pulmonary metastases treated 
with 131I is ~50%, varying from 90% in patients with microscopic metastases to 
only 10% in macronodular disease [31;52;53]. The remission rates of bone 
metastases in the same studies are worse, varying between 7-20%. A major 
problem in this category of patients is the diminished or lost ability of thyroid 
cancer cells to accumulate RaI, indicated by a negative post-therapeutic WBS. 
In these cases the prognosis is poor, as alternative treatment options (external 
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radiotherapy or chemotherapy) have limited success [54]. Bone metastases may 
cause considerable pain and functional impairments. In addition, these bone 
metastases may become problematic, because these patients may still have a 
very long survival. Bone metastases may escape attention during WBS, as they 
may not accumulate RaI. Bone scintigraphy may show decreased or moderately 
increased uptake [55]. Bone metastases are often difficult to visualize on 
radiographs, at least in the initial stages. 
The treatment of symptomatic bone metastases may be cumbersome, especially 
if the lesions do not accumulate 131I. In such patients, external irradiation [31] or 
selective embolization of bone metastases [56-60] is needed. Palliative surgery 
can also be considered, when there are neurological complications. Surgery may 
also be useful to debulk large tumor masses. 
Despite RaI, no conventional therapy is available in metastatic DTC where RaI 
uptake has been lost. Results of conventional chemotherapy are disappointing. 
The classical chemotherapeutic agent adriamycin (alone or combined with 
cisplatin and bleomycin) may induce temporary remissions or stationary disease 
in about 30-50% of the patients [54;61]. The same has been reported for 
paclitaxel [62]. However, most remissions last only a few months and at the cost 
of a considerable reduction in quality of life, thus leading to the 
recommendation that there is no place in principle for chemotherapy [1;63]. 
Therefore much attention is focused on experimental treatment options, which 
can be subdivided in redifferentiation therapy, novel agents such as tyrosine 




One of the mechanisms by which cells can block the expression of certain genes 
is by enzymes that methylate these genes or deacetylate the histones that 
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envelope a particular gene. In an in-vitro study in thyroid carcinoma, the 
demethylating agent 5-azacytidine led to re-induction of NIS expression, 
accompanied by RaI uptake in thyroid cancer cell lines [64]. In parallel, the 
histone deacetylase inhibitor Depsipeptide has been reported to reinduce NIS 
mRNA expression and RaI uptake in DTC [65;66], although toxicity may be a 
serious problem [67]. 
Retinoids 
Retinoids are derivatives of vitamin A (i.e. retinol). Beneficial effects of 
retinoids have been reported in promyelocytic leukaemia and several types of 
carcinoma [68-70]. It has been suggested that retinoids have beneficial effects 
on iodide uptake in vitro and in humans. A limited number of human studies 
have been performed on the effects of retinoids on 131I uptake with mixed results 
[71-75], all using the retinoic acid receptor (RAR) agonist 13-cis retinoic acid. 
Bexarotene (Targretin, Ligand Pharmaceuticals, San Diego) is a retinoid X 
receptor (RXR) agonist, which also induces RAR by transcriptional activation. 
[76]. A prospective controlled clinical trial to investigate the efficacy of this 
novel ligand Bexarotene in 12 patients with metastases of DTC and decreased or 
absent 131I uptake showed that Bexarotene may partially restore 131I uptake in 
some, but not all, metastases of DTC [77]. However, a clinical trial to study the 
effectiveness of high activities of 131I together with Bexarotene in DTC patients 
demonstrated that this therapy did not result in restoration of susceptibility to 
RaI therapy [78]. 
Neovascularization 
Molecular pathways involved in neovascularization have been demonstrated in 
thyroid carcinoma [79]. The cascade of approaches to target tumor-induced 
neovascularization has led to a number of promising compounds that are now 
being tested in clinical trials in prevalent tumors. Reports have been published 
on beneficial effects of anti-VEGF receptor antibodies in thyroid carcinoma cell-
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lines [80] and endostatin in animal experiments [81]. A recently published 
clinical trial, including thyroid carcinoma patients was also successful [82]. 
Some compounds belonging to the class of tyrosine kinase inhibitors (see 
below) also inhibit angiogenesis by inhibiting VEGF production and/or 
activation of the VEGF receptor. 
Tyrosine kinase inhibitors 
Another intriguing development is the advent of tyrosine kinase inhibitors. The 
development of imatinib mesylate (Gleevec) is prototypical for the innovative 
design of modern drugs with the molecular pathogenic defect as a starting point. 
Following imatinib, other small molecules have been developed, aimed at other 
tyrosine kinase activated pathways such as the epithelial growth factor receptor 
(EGFR) activated pathway [83;84]. Activation of tyrosine kinase pathways is 
relevant for thyroid carcinoma. Several studies have been published reporting 
successful treatment with the tyrosine kinase inhibitors aimed at RET, vascular 
endothelial growth factor (VEGF) or the EGFR [85-87]. Recently, 2 studies 
have been published in which multiple target tyrosine kinase inhibitors were 
used [88] and sorafenib [89]. Both studies reported a promising response rate in 
metastatic DTC patients. 
Radiolabeled somatostatin analogues 
Another therapeutic modality in patients with ¹³¹I non-responsive multiple 
metastases is the treatment with radiolabeled somatostatin analogues. In chapter 
8 a study with high activities of 111In-DTPA-octreotide is described. The 
therapeutic effect of 111In-DTPA-octreotide on DTC metastases is based on the 
internalization of the radiolabeled octreotide through somatostatin receptors 
which are found in both papillary and follicular thyroid cancer [90]. Once in the 
cell, short-range Auger electrons emitted by the 111In will cause DNA damage. 
The diagnostic value of 111In-octreotide in thyroid cancer has already been 
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confirmed [91-94]. More recent reports have focused on somatostatin analogues 
labeled with β-particle-emitting radionuclides [95;96]. 
 
Aims of this thesis 
Although many aspects of diagnosis, initial therapy and follow-up procedures 
have been covered in recently published guidelines and consensus papers, this 
thesis addresses some important clinical questions, related to the application of 
conventional (131I) and experimental therapies with radionuclides in DTC. In this 
thesis, specific questions we focussed on are: 
a) What is the short-term outcome of an uptake-related ablation strategy in 
differentiated thyroid cancer ? (chapter 2) 
b) What is the difference in outcome between an uptake-related strategy and 
a fixed-dose strategy in thyroid remnant ablation? (chapter 3) 
c) Is there a relation between the ablation failure and a pre-ablation 24-hour 
131I uptake measurement in DTC? (chapter 4) 
d) Is it possible to predict the outcome of the uptake-related ablation strategy 
in differentiated thyroid cancer at the time of initial diagnosis?  
(chapter 5) 
e) Is there a relation between the incidence of second primary tumors in 
thyroid cancer patients and treatment with RaI in the cohort studied? 
(chapter 6) 
f) Is there a place for 111In-DTPA-octreotide scintigraphy for the detection 
of non-functioning metastases from DTC during follow-up? (chapter 7) 
g) Once the diagnostic value of 111In-DTPA-octreotide scintigraphy has been 
established, is there also a role for this radiopharmaceutical in the 
treatment of RaI non-responsive thyroid cancer? (chapter 8) 
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Chapter 2 
Abstract  
In our hospital, a 24-h radioiodine-131 (131I) uptake-related ablation strategy is 
used in patients with differentiated thyroid cancer to destroy thyroid remnants 
after primary surgery. In this strategy, low doses of 
131I are used, but data in the 
literature on its efficacy are conflicting. Therefore, we performed the present 
study to evaluate the clinical outcome of this ablation strategy. In this study, 
patients (n=235) were selected who underwent thyroidectomy for differentiated 
thyroid cancer, followed by an ablative dose of ¹³¹I. Approximately 6 months 
after ablation, treatment efficacy was evaluated using radioiodine scintigraphy 
and thyroglobulin (Tg) measurements. Successful ablation was defined as the 
absence of radioiodine uptake in the neck region (criterion 1). Tg values were 
determined 3-12 months after ablation (criterion 2). Based on criterion 1, 
unsuccessful ablation was found in 43.0% of cases. Pre-treatment uptake values 
were statistically significantly lower (p=0.003) in successfully ablated patients 
(mean 5.4%) than in unsuccessfully ablated patients (mean 8.2%). Based on 
criterion 2, unsuccessful ablation was found in 52.4% of patients. The uptake-
related ablation strategy, using low doses of 
131I, shows a relatively high 
treatment failure rate. Based on these results it is suggested that a lower ablation 
failure rate could be achieved by applying higher 
131I doses in the ablation of 
thyroid remnants in differentiated thyroid carcinoma patients. In the case of 
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Introduction  
The therapy of choice in patients suffering from differentiated thyroid cancer, 
subdivided into papillary and follicular thyroid carcinoma, is (near-) total 
thyroidectomy. This is routinely followed by the administration of radioiodine-
131 (131I) to destroy any remaining benign or malignant thyroid tissue, so-called 
ablation. There are several reasons for routine ablation after surgery [1]: (a) to 
be able to detect a carcinoma recurrence by radioiodine scanning; (b) 
radioiodine can destroy microscopic foci of carcinoma in the thyroid remnant; 
(c) possible carcinoma outside the thyroid bed may be detected and treated by 
radioiodine; (d) to use thyroglobulin (Tg) as tumor marker of recurrent 
carcinoma all normal thyroid tissue has to be destroyed. 
Iodine-131 has been used for many years to ablate thyroid remnants following 
thyroid surgery, but a single optimal dose has not yet been established [2]. 
According to Mazzaferri [3], more studies are required to establish the optimal 
dose necessary for ablation of the thyroid remnant. In this respect, data in the 
literature are inconsistent; some studies conclude that a dose of 1110 MBq of 
131I may be as effective as a high dose such as 3700 MBq [4-6], while other 
authors suggest that a higher dose of 131I will improve the rate of successful 
remnant ablations [7-9]. 
In our hospital, relatively low doses of 131I have been used for many years for 
ablation in patients without distant metastases. The applied 131I dose, which was 
based on data in the literature [10-14], depends on the 24-h 
131I pre-treatment 
uptake value in the neck region and ranges from 1100 to 2800 MBq. To assess 
the outcome of this strategy and because of inconsistencies in the literature 
regarding the appropriate ablative dose of 
131I [4-9], we performed a 




Materials and methods 
Study population and equipment.  
Patients were selected who received ablation treatment with 
131I at the Leiden 
University Medical Center (LUMC) between January 1986 and December 1999 
(n=418), to destroy thyroid remnants after thyroidectomy for differentiated 
thyroid cancer. This period was selected as before 1986 standardised records 
regarding the applied dose of 
131I were not available. Furthermore, follow-up of 
at least 2 years was required. 
Consecutive exclusion criteria were: first dose of 
131I before 1986 (n=37), a first 
dose of 
131I given in another hospital (n=15), radioiodine treatment more than 1 
year after thyroidectomy (n=24), only hemi-thyroidectomy (n=6), 
131I doses not 
according to the standard protocol (n=64) and distant metastases (n=30). In ten 
cases, proper assessment for the presence of distant metastases by evaluating the 
post-ablative scintigram was not possible owing to scattered radiation on the 
post-ablative scintigram. In 11 patients, whole-body scintigraphy 3-10 days after 
ablation (post-ablative scintigram) was not performed. To assess whether these 
patients were free of distant metastases at the time of ablation, records of follow-
up scintigrams and/or other data from the medical files were studied. Patients 
were excluded from analysis when these data revealed distant metastases (n=3) 
or when follow-up data were not available or incomplete (n=3). Histopathology 
in one of the 236 remaining patients revealed no malignancy in the thyroid 
gland, but only an ectopic localisation of thyroid carcinoma. This patient was 
also excluded. After withdrawal of 183 patients for the foregoing reasons, 235 
patients were left for evaluation. 
From the medical files, age, gender, histopathological data, treatment 
characteristics and laboratory data were recorded. Records of scintigrams were 
analysed and coded. 
Tumor staging was scored according to the criteria of the TNM Atlas [15]. 
For all scintigrams, a Toshiba gamma camera (Tokyo, Japan) was used. A high-
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energy collimator (matrix sizes of 256x1,024 and 256x256, window of 20% 
centered at 360 keV) for the 
131I scintigrams, a low-energy collimator (matrix 
sizes of 256x1,024 and 256x256, window of 20% centered at 159 keV) for the 
123I scintigrams was used. Anterior and posterior whole-body and planar views 
of the neck region were routinely obtained. For the whole-body scintigrams, 
scanning rates of 15 (131I) and 10 cm/min (123I) were used. 
 
Radioiodine treatment. 
The mean interval between thyroidectomy and the ablative dose was 7.0 weeks 
(standard deviation ±6.4 weeks). During this interval, no suppressive treatment 
with L-thyroxine was initiated. TSH values were measured at the time of 
ablation. 
In patients treated from 1992, low-iodine diets were used approximately 4 days 
before the ablative dose was given. In patients 4 treated until 1992, low-iodine 
diets were not strictly applied according to the currently used protocol. The 
rationale of a low-iodine diet was to achieve a reduction in the iodide pool of the 
body, in order to achieve the highest possible entrance of 
131I ions into the 
thyroid remnant. 
The 24-h 
131I pre-treatment uptake value in the neck region was measured using 
standard techniques (in %): 40 MBq of 
131I was given orally, followed by planar 
scintigraphy of the neck region 24 h later. A standard of 40 MBq 
131I that was 
calibrated on the day of admission and measured in a neck phantom after 24 h 
was used as a reference. Uptake of less than 5%, of between 5% and 10% and of 
more than 10% was followed by 2800, 1850 and 1100 MBq of 
131I in one dose, 
respectively. The rationale of this quantitative approach is to avoid unnecessary 
exposure [16] and local radioiodine side-effects [17;18]. In this regimen, no 





Documentation of treatment efficacy. 
Treatment efficacy was evaluated approximately 6 months after ablation using 
low-dose radioiodine diagnostic whole-body scintigrams obtained 3 days after 
administration of 
131I or 24 h after administration of 123I. For this purpose, 
hormonal supplementation was withdrawn. Records of these diagnostic 
radioiodine scintigrams were studied. The percentage of 
131I versus 123I 
diagnostic scans was 87.6% versus 12.4%, respectively. For the 
131I scintigrams, 
doses of 40 (1.2%), 100 (7.6%) or 185 MBq (91.2%) were used. In patients who 
received a second therapeutic dose of 
131I (n=81), records of whole-body 
scintigrams obtained approximately 1 week after this second therapeutic dose 
(i.e. post-therapeutic scintigram) were also evaluated. In the case of a second 
therapeutic treatment with 
131I, the average dose was 6163 MBq (standard 
deviation ±449 MBq). Unsuccessful ablation of the thyroid remnant was defined 
as the visible presence of radioiodine uptake in the neck region on the diagnostic 
and/or post-therapeutic scintigram (criterion 1). Results of ablation are presented 
for the whole group, for patients without clinically lymph node metastases (N0) 
and for patients with histopathologically proven lymph node metastases (N1). 
Scintigrams obtained up to 2 years after ablation were included for analysis. 
Available Tg values, determined 3-12 months after ablation, were also used to 
document ablation efficacy. Cut-off levels of ≤1µg/l (i.e. undetectable, criterion 
2a) and ≤3 µg/l (criterion 2b) were applied. If anti-thyroglobulin antibodies 
(Tgab) were measurable, interference effects in the determination of Tg could be 
substantial [19]. As IRMA assays were used, these interference effects generally 
would have resulted in underestimation of the Tg value. Therefore, Tg values 
were excluded from analysis in the presence of measurable Tgab and a 
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Data collection and statistical analysis. 
All collected data were put in a database using MS-Access97. For statistical 
analysis we used SPSS for Windows, version 10.0 and MS-Excel97. The 
quantitative data (continuous parameters) were analysed using Student's t test for 
normal distributed data or the Mann-Whitney U test for non-normal distributed 
data. For analysis of data on the nominal scale we used the Chi-squared test. 
Quantifiable data are given as minimal and maximal values as well as the mean 





Papillary thyroid carcinoma was diagnosed in 184 patients, 38 men and 146 
women (age at thyroidectomy 16.4-87.1 years; mean 42.1; SD ±14.2). Follicular 
thyroid carcinoma was diagnosed in 50 patients, 12 men and 38 women (age at 
thyroidectomy 14.8-85.5 years; mean 51.7; SD ±20.0). In one case, thyroid 
carcinoma was not otherwise specified (tcNOS) (Table 1). 
At the histological study of the surgically excised material, lymph node 
metastases were diagnosed in 53 papillary thyroid carcinoma patients. In 





Table 1. Population characteristics including tumor and lymph node stage. 
 
 














T2 107 22 
T3 28 5 
T4 31 14 
Tx 0 0 
 
Tumor stages in papillary thyroid 
cancer patients 
Total 184 53 
T1 1 0 
T2 29 0 
T3 14 0 
T4 5 0 
Tx 1 0 
Tumor stages in follicular thyroid 
cancer patients 
Total 50 0 
T1 0 0 
T2 1 0 
T3 0 0 
T4 0 0 
Tx 0 0 
Tumor stages in thyroid carcinoma 
not otherwise specified 
Total 1 0 
T1 19 12 
T2 137 22 
T3 42 5 
T4 36 14 
Tx 1 0 
Tumor stages: total numbers 
Total 235 53 
    
 
 36 
A retrospective analysis of an uptake-related ablation strategy 
Treatment efficacy (criterion 1) 
In 200 patients, diagnostic and/or post-therapeutic scintigrams were available for 
evaluation. In the remaining 35 cases, scintigraphic follow-up was not 
performed for unknown reasons. There was no significant difference between 
the group of patients with (n=200) and without (n=35) scintigraphic follow-up 
with respect to age at thyroidectomy (p=0.249), sex (p=0.123), tumor stage 
(stages T1-T3 versus stage T4, p=0.906), lymph node stage (p=0.088) or pre-
treatment uptake values (p=0.194). Therefore, we considered the outcome of 
ablation in the group of patients with follow-up scintigrams (n=200) as 
representative for the whole group of 235 patients. 
In 86 cases (43.0%), radioiodine uptake was seen in the neck region on the 
diagnostic and/or post-therapeutic scintigram, implying unsuccessful ablation. In 
eight of these 86 cases, diagnostic scintigraphy revealed no evidence for a 
persistent thyroid remnant, while a subsequent post-therapeutic scintigram 
performed up to 2 years after ablation did indicate uptake. 
Figure 1 demonstrates the percentage of unsuccessful ablations per histological 
type and tumor category without clinically lymph node metastases and with 
histopathologically proven lymph node metastases. No statistically significant 
differences could be found in ablation rates between papillary thyroid carcinoma 
and follicular thyroid carcinoma patients (p=0.738) or between tumor stages T1-
T3 and tumor stage T4 (p=0.510). 
In 59 of 151 clinically N0 patients (39.1%), ablation was unsuccessful, while in 
27 of 49 patients (55.1%) with histopathologically proven lymph node 
metastases, ablation was unsuccessful. This difference in ablation rate was 
statistically significant (p=0.049). 
As shown in Table 2, the frequency of unsuccessful ablations increased with 
rising 24-h 
131I pre-treatment uptake values: the uptake values were significantly 
lower (p=0.003) in successfully ablated patients (mean 5.4%; SD ±7.5%) than in 
unsuccessfully ablated patients (mean 8.2%; SD ±8.6%). 
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Table 2. Number of patients demonstrating uptake in the neck region on follow-up 
scintigraphy (criterion 1), in relation to the pre-treatment uptake values. 
 
Pre-treatment uptake value (U) Uptake in neck region on 
follow-up scintigraphy 













        34.4* 
5< U ≤10 7.7 ±1.4   31 17         54.8 
U >10 21.9 ±8.5   33 20         60.6* 
U unknown     8   5         62.5 
Total 200 86         43.0 
 
(* = statistically significant difference, p=0.006) 
 
 









ptc 38,0 55,6 42,9 53,8
ftc 39,4 50,0
T1/2/3N0 T1/2/3N1 T4N0 T4N1
 
Figure 1. Percentage of unsuccessful ablations according to criterion 1 (radioiodine uptake in 
the neck region on follow-up scintigraphy). Papillary thyroid carcinoma (PTC) and follicular 
thyroid carcinoma (FTC) patients. T1/2/3/N0: tumor stages T1, T2, T3 without clinically 
lymph node metastases; T1/2/3N1: tumor stages T1, T2, T3 with histopathologically proven 
lymph node metastases; T4N0: tumor stage T4 without clinically lymph node metastases; 
T4N1: tumor stage T4 with histopathologically proven lymph node metastases. 
 
With respect to age, no statistically significant difference in ablation results was 
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found (p=0.197). A statistically significant difference (p=0.014) in ablation 
failure rate was found between males (58.7%) and females (38.3%). However, 
in our population there was a statistically significantly (p=0.001) higher 
prevalence of lymph node metastases in male patients (43.5%) than in female 
patients (18.8%). 
No significant differences in treatment results (p=0.84) were found between 
patients treated until 1992 (low-iodine diets not strictly applied) and those 
treated after 1992 (low-iodine diets used 1 week before ablation). 
 
Treatment efficacy (criterion 2) 
With respect to Tg values, 191 and 187 evaluable cases were available for cut-
off levels of  ≤1 and  ≤3 µg/l respectively. This difference in evaluable cases is 
caused by exclusion of values in the presence of measurable Tgab and a 
corresponding Tg value below the cut-off level. In 100 cases (52.4%) a Tg value 
>1 µg/l was present, implying unsuccessful ablation (criterion 2a). A Tg value 
>3 µg/l was present in 38 cases (20.3%) (criterion 2b). In Tables 3 and 4 a 
subdivision is given according to the pre-treatment uptake value. 
Table 3. Number of patients with Tg values >1 μg/l (criterion 2a) determined 3-12 months 
after ablation, in relation to the pre-treatment uptake values. 
 
 Tg >1 μg/l 
 
Pre-treatment 












5< U ≤10   31 16 51.6 
U >10   30 15 50.0* 
U unknown    7   7 1100.0 
Total 191    100 52.4 
 
(* = No statistically significant difference, p=0.968) 
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Table 4. Number of patients with Tg values >3 μg/l (criterion 2b) determined 3-12 months 
after ablation, in relation to the pre-treatment uptake values. 
 
    Tg >3 μg/l 
 
Pre-treatment 
uptake value (U) 
No. of 
evaluable cases 









5< U ≤10   30  4 13.3 
U >10   30  9 30.0* 
U unknown     7  2 28.6 
Total 187     38 20.3 
 
(* = No statistically significant difference, p=0.195) 
 
TSH values 
TSH values at the time of ablation ranged from 3.1 to 330.0 mU/l (mean 71.0; 
SD ±42.2). In 15 patients, a TSH value below 20 mU/l was found at the time of 
ablation. Nine of these 15 patients had a pre-treatment uptake value ≥10%, and 
in only one of these nine was ablation successful according to criterion 1. In this 
patient there were no signs of residual thyroid tissue. 
 
Discussion  
In the present study the clinical outcome of a 24-h 131I uptake-related ablation 
strategy to destroy thyroid remnants after primary surgery for differentiated 
thyroid cancer was evaluated. In this strategy, rather low ablative doses of 131I 
are used. Depending on the extent of the thyroid remnant, unsuccessful ablation 
was found in 34%-61% of cases, which is relatively high. 
One criterion for successful ablation was the visible absence of radioiodine 
uptake in the neck region on follow-up scintigraphy, routinely performed 6 
months after ablation. Furthermore, Tg values were evaluated and cut-off levels 
of ≤1 and ≤3 µg/l were applied. The rationale for using a low cut-off level of ≤ 1 
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µg/l, in our laboratory defined as undetectable, is that in the case of circulating 
Tg, residual normal thyroid or tumor cells are present [20]. A cut-off 
level ≤3µg/l was based on data published by Duren et al. [21] and Ozata et al. 
[20]. 
Samaan et al. [22] retrospectively analysed 1599 patients who were treated for 
well-differentiated thyroid carcinoma. There were 736 patients who received 
radioiodine and this group was compared with the 863 patients who did not 
receive radioiodine. The authors concluded that treatment with radioactive 
iodine improves diseasefree interval and survival. In an article by Mazzaferri [3] 
on a large follow-up study, similar conclusions were reported. However, the 
optimal dose to achieve total ablation after one dose of 131I is still controversial. 
As already mentioned, some investigators conclude that a low dose, such as 
1110 MBq, may be as effective as a high dose, such as 3700 MBq, in achieving 
ablation [4-6] while others suggest that increasing the dose will improve the rate 
of successful remnant ablation [7;8]. However, the above-mentioned studies 
included a small number of patients, ranging from 13 to 63. Roos and Smith [2] 
concluded that the issue of the appropriate dose of 131I for ablation of thyroid 
remnants postoperatively still remains undetermined. In a meta-analysis 
including 11 studies and two additional cohorts of their own, Doi and Wood- 
house [9] compared the efficacy of remnant ablation following a single low dose 
(1074-1110 MBq) versus a single high dose (2775-3700 MBq). Their results 
demonstrate that a single high dose of 131I is more efficient in ablating residual 
thyroid tissue than a low dose. However, ablation rates are also influenced by 
remnant size [9; 16; 23]. In general, irrespective of the dose, the more extensive 
surgery is performed, the more likely ablation will be successful [9]. Arslan et 
al. [24] found a statistically significantly lower remnant thyroid volume 
(calculated by ultrasonography) in patients in whom ablation was achieved 
compared with patients in whom ablation failed. In patients with total ablation, 
partial ablation and no ablation, Beierwaltes et al. [25] found average pre-
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radioiodine treatment uptake of 5.22%, 9.91% and 13.11%, respectively. In the 
present study, we found statistically significantly lower pre-treatment uptake 
values in successfully ablated patients. This is in agreement with the above- 
mentioned studies. However, taking into account that better ablation results are 
achieved after more extensive surgery, Doi and Woodhouse [9] still concluded 
that the available data favor higher doses of 131I (2775 - 3700 MBq) for remnant 
ablation. 
In the study by Beierwaltes et al. [25], total ablation after thyroidectomy from 
the first dose of 131I, not less than 3700 MBq, was achieved in 87% of 267 well-
differentiated thyroid carcinoma patients with radioiodine uptake confined to the 
thyroid bed and an average pre-treatment percent uptake of 6.01%. Their results 
also demonstrated comparable ablation results when cervical lymph nodes were 
present (total ablation was achieved in 114 out of 129 patients after the first dose 
of more than 3700 MBq of 131I). They treated patients with 131I for ablation of 
remnants in the thyroid bed when there was significant 24-h 131I uptake 
(generally >0.5%) after 74 MBq of 131I. Within 1 year after ablation, they per- 
formed 131I scintigraphy in the hypothyroid state. The thyroid remnant was 
judged to have been totally ablated when no residual uptake was seen in the 
thyroid bed and the measured percent uptake in the neck was <1%. De Klerk et 
al. [26] evaluated 93 differentiated thyroid carcinoma patients referred for their 
first ablative treatment after thyroidectomy. The patients were treated with 3700 
MBq of 131I in the absence of lymph node or distant metastases and 5550 MBq 
of 131I in the presence of pre- or peri-operatively detected cervical lymph node 
metastases. Pre-ablative 131I diagnostic scintigraphy was not performed. One 
year after 131I ablation, a whole-body diagnostic 131I (370 MBq) scintigram was 
performed after discontinuation of thyroid replacement therapy for 4-6 weeks. 
Their main criterion for successful ablation was the absence of visual 131I 
residual neck uptake on diagnostic scintigraphy. This was achieved in 88% of 
the patients, with a mean uptake percentage in the neck of 0.23% (SD ±0.87%; 
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range 0.001-6.4%), measured 1 week after ablation. However, they reported a 
Tg value of <1 µg/l at 1-year follow-up in only 48% of the patients. We also 
found a discrepancy in ablation rate using criterion 1 (radioiodine uptake in the 
neck region) and criterion 2a (Tg value ≤1µg/l). This discrepancy amounted to 
16% in patients with comparable pre-treatment uptake of ≤5%. 
 
Factors that could have influenced the treatment results 
Stunning effect. It has been shown that relatively low diagnostic doses of 131I 
may lead to impaired ability of remnant thyroid tissue to concentrate the 
subsequent ablative dose of 131I (so-called stunning effect) and thereby reduce 
therapeutic efficacy [27;28]. Muratet et al. [28] suggested that the threshold 
dose of 131I above which the stunning phenomenon may have an adverse effect 
on treatment efficacy is between 37 and 111 MBq 131I. In a study by Morris et al. 
[29], no significant difference was found in ablation rates between patients who 
received 111-185 MBq 131I for diagnostic scanning before the ablative dose and 
patients who did not receive any 131I before the initial treatment dose. Since in 
the present study a dose of 40 MBq was usually applied in the pre-ablative 
uptake measurements, we assume that the stunning phenomenon made at most a 
slight contribution to the ablation failure rate. 
 
Low-iodine diet. For many years, low-iodine diets have been used to increase the 
131I dose delivered to the thyroid remnant [30;31]. The increase in thyroid 131I 
uptake after a low-iodine diet theoretically implies that a low-iodine diet will 
increase the effectiveness of ablative doses [32]. Nevertheless, Morris et al. [32] 
did not find a significant difference in ablation rate between patients who 
followed a regular diet and patients who followed a low-iodine diet before 
ablation. Between 4 and 42 months after the ablative dose they determined 
success of ablation according to the visual absence of uptake in the thyroid bed 
and neck region on a low-dose 131I diagnostic scintigram. However, significantly 
 43
Chapter 2 
more patients were treated with 3700 MBq of 131I in the low-iodine diet group 
and significantly more with 5550 MBq in the group of patients who followed a 
regular diet. In our study, low-iodine diets were not strictly applied in patients 
who were treated until 1992. In this group of patients we did not make a 
distinction in the analysis of treatment results between low-iodine diet and 
normal diet patients. However, no significant differences in treatment results 
according to criterion 1 were found between patients in whom low-iodine diets 
were not strictly applied (treated until 1992) and patients in whom low-iodine 
diets were applied according to the currently used protocol (treated from1992). 
One reason for the lack of difference in treatment results between low-iodine 
diet patients and patients in whom low-iodine diets were not strictly applied 
could be the short duration of iodine abstinence. Probably the iodide pool had 
not been significantly reduced. 
 
Discontinuation of thyroid hormone supplementation. 
The follicular cells of the thyroid gland trap and concentrate iodide from the 
blood, which is achieved by an active, energy-dependent transport process 
across the basolateral plasma membrane of the thyrocytes. The sodium/iodide 
symporter (NIS) gene encodes the protein responsible for the transport process 
[33]. Because thyroid cancers or metastases from thyroid cancer accumulate 
iodine to a lesser degree than normal thyroid tissue, intensive TSH stimulation is 
required in patients with thyroid cancer before administration of 131I in order to 
increase NIS expression and thus the ability of thyroid cancer tissue to take up 
131I [33]. To achieve intensive TSH stimulation, discontinuation of thyroid 
hormone supplementation is necessary. As expected, the TSH stimulation varied 
between patients, which theoretically could have had an impact on the success 
of ablation of the thyroid remnant. 
In the present study we did not take into account the effect of TSH values on the 
ablation results. It is possible that ablation results could be affected in the 
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presence of an inadequate degree of hypothyroidism, for example a TSH value 
below 20 mU/l. As mentioned above, in 10 of 15 patients who had a TSH value 
below 20 mU/l at the time of ablation, treatment with 131I was unsuccessful. In 
eight of these ten patients a pre-treatment uptake value of ≥10% was measured, 
probably indicating that a substantial amount of residual functioning thyroid 
tissue prevented sufficient TSH elevation. 
 
Limitations of the study 
In 35 patients scintigraphic follow-up was not performed, implying that 
presentation of treatment results for the whole patient group was not possible. 
No statistically significant differences in age, sex, tumor stage, lymph node 
stage or pre-treatment uptake values were found between the group of patients 
with (n=200) and the group without scintigraphic follow-up (n=35). We as- 
sumed that the similarity of the groups allowed inference of the same ablation 
results. 
Scintigrams were not independently reviewed by one individual, causing an 
element of uncertainty. As we defined unsuccessful ablation as the presence of 
radioiodine uptake in the neck region, we did not distinguish between residual 
normal thyroid tissue in the thyroid bed, pyramidal lobe or thyroglossal duct 
region and residual functioning thyroid cancer in cervical lymph nodes. 
Total ablation according to criterion 1 was considered as the absence of uptake 
in the neck region on follow-up scintigraphy. However, in our study population, 
follow-up scintigraphy indicated new uptake outside the neck region in two 
patients, likely corresponding to new distant metastases. Nevertheless, in the 
presented results these two patients were regarded as having had successful 
ablation of their thyroid remnant. 
In this retrospective study, data regarding the remnant mass were not available. 
Consequently, we could not provide exact information about a possible relation 
between tumor dosimetry, which is based on uptake values and remnant masses, 
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and subsequent failure rates. In our opinion, in current practice it is not feasible 
to correctly assess the size of small remnants by means of imaging techniques. 
Studies on the use of ultrasonography for the estimation of thyroid masses have 
been performed in hyperthyroidism, i.e. in patients with a thyroid in situ. Data 
on its use and, especially, on its accuracy and reproducibility in thyroidectomy 
patients are scarce or even not available. 
 
Conclusion 
The uptake-related ablation strategy as described in the present study shows 
relatively high failure rates. As we excluded Tg values from analysis in the 
presence of detectable Tgab and a Tg value below the cut-off level, the given 
ablation failure rate according to criterion 2 could actually be even higher. 
Furthermore, as described in our results, low-dose radioiodine diagnostic whole-
body scintigraphy may give a false-negative outcome. 
Based on these results and on studies in the literature, it is suggested that a lower 
ablation failure rate could be achieved when higher 131I doses are applied in the 
ablation of thyroid remnants in differentiated thyroid carcinoma patients. 
Because our results show high unsuccessful ablation rates in the group of 
patients with uptake values above 10% (statistically significantly higher com- 
pared with the group of patients with uptake values below or equal to 5%), 
surgical re-exploration for additional thyroid tissue removal may be suggested 
for this group of patients. However, further studies are required in which higher 
ablation doses are tested, even in the case of high uptake values. 
We found statistically different ablation results between male and female 
patients and between patients without and with lymph node metastases. In a 
study by Arslan et al. [24], a significantly higher total 131I dose was needed for 
successful ablation in males and in patients with a higher stage of disease. This 
is probably related to the fact that the less differentiated the tumor, the lower the 
uptake function and hence the need for a higher activity for the ablation of 
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possible malignant cells in the remnant. Therefore, in the case of lymph node 
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Chapter 3 
Abstract  
Introduction: The aim of the study was to compare the success rate of an uptake-
related ablation protocol in which the dose depends on an 131I 24-h neck uptake 
measurement and a fixed-dose ablation protocol in which the dose depends on 
tumor stage.  
Methods: All differentiated thyroid carcinoma patients with M0 disease who had 
undergone (near-) total thyroidectomy followed by 131I ablation were included. 
In the uptake-related ablation protocol, 1100 (uptake >10%), 1850 (uptake 5-
10%) and 2800 MBq (uptake <5%) were used. In the fixed-dosage ablation 
strategy, 3700 (T1-3, N0 stage) and 5550 MBq (N1 and/or T4 stage) were 
applied. We used 131I uptake on whole-body scintigraphy and thyroglobulin-off 
values to evaluate the ablation 6-12 months after treatment.  
Results: In the uptake-related ablation protocol, 60 out of 139 (43%) patients 
were successfully treated versus 111 out of 199 for the fixed-dose ablation 
protocol (56%) (p=0.022). The differences were not statistically significant for 
patients with T4 (p=0.581) and/or N1 (p=0.08) disease or for patients with T4N1 
tumor stage (p=0.937).  
Conclusion:The fixed-dose 131I ablation protocol is more effective in ablation of 
the thyroid remnant in differentiated thyroid carcinoma patients than an uptake-
related ablation protocol. This difference is not observed in patients with a N1 
and/or T4 tumor stage.  
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Introduction  
The therapy of choice in patients suffering from differentiated thyroid cancer 
(DTC), subdivided into papillary and follicular thyroid carcinoma, is (near-) 
total thyroidectomy. This is routinely followed by the administration of 
radioiodine-131 (131I) to destroy any remaining benign or malignant thyroid 
tissue, so-called ablation. There are several reasons for routine ablation after 
surgery [1;2]: a) to be able to detect a carcinoma recurrence by radioiodine 
scanning; b) radioiodine can destroy microscopic foci of carcinoma in the 
thyroid remnant; c) possible carcinoma outside the thyroid bed may be detected 
and treated by radioiodine and d) to use thyroglobulin (Tg) as tumor marker of 
recurrent carcinoma all normal thyroid tissue has to be destroyed. Although 131I 
has been used for many years to ablate thyroid remnants following thyroid 
surgery, a single optimal ablation strategy is still not established. Reports on the 
amount of 131I required to achieve successful ablation show a considerable range 
[3-7]. 
At the Leiden University Medical Center (LUMC) and the University Medical 
Center Utrecht (UMCU), two academic hospitals in the Netherlands, different 
ablation strategies have been used over the years. At the LUMC, a relatively 
low-dose uptake-related ablation strategy was applied until June 2002 [8], 
whereas in the UMCU a fixed-dose strategy with relatively high administered 
131I activities has been in use since January 1990 [9;10]. The aim of this study 





Patients were selected who received ablation treatment with 131I at the LUMC or 
UMCU from January 1990, as this date marks the start of the fixed-dose 
protocol in the UMCU. Both subgroups consisted of patients in whom surgery 
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has been performed in the University Medical Centres as well as in referring 
peripheral hospitals. All DTC patients with M0 disease who had undergone 
(near-) total thyroidectomy followed by 131I ablation were included. Tumor 
staging was scored according to the criteria of the fifth TNM Atlas. In all 
patients with N1 disease, a neck dissection was performed in addition to a 
resection of the thyroid and prior to ablation. So, in patients with N1 disease, 
this stage was established before ablation. All patients with M1 disease were 
excluded to avoid a bias. M1 disease as exclusion criterion was based on post- 
ablation whole-body scans with high 131I doses and radiological examinations, 
such as CT scanning and/or chest-X-rays, in patients with T4 and/or N1 disease. 
Finally, additional inclusion criteria were: a) ablation has been performed in 
accordance with either protocol and b) 6-12 months after ablation patients 
returned for follow-up studying consisting of Tg-off measurements and/or 131I 
whole-body scintigraphy. 
 
Uptake-related ablation protocol 
This treatment strategy was used at the LUMC until June 2002. All patients had 
undergone (near-) total thyroidectomy, followed by 131I ablation 4-6 weeks after 
surgery. During this interval, no suppressive treatment with L-thyroxine was 
initiated. Furthermore, low-iodine diets were prescribed to optimize the 
therapeutic outcome [11;12]. The 24-h pre-treatment radioiodine uptake 
percentage in the neck region was measured using standard techniques: 40 MBq 
of 131I was given orally, followed by planar scintigraphy of the neck region 24 h 
later. A standard of 40 MBq 131I that was calibrated on the day of admission and 
measured in a neck phantom after 24 h was used as a reference. An uptake of 
less than 5%, between 5 and 10%, and more than 10% was followed by 2800, 
1850 and 1110 MBq of 131I in one administration respectively. The rationale of 
this quantitative approach was to avoid unnecessary exposure [13] and local side 
effects from radioiodine [14;15]. In this regimen, no adjustments were made in 
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the case of cervical lymph node metastases.  
 
Fixed-dose ablation protocol  
This strategy was used in the UMCU from 1990 onwards. All patients had 
undergone (near-) total thyroidectomy, followed by 131I ablation 4-6 weeks after 
surgery. A standard activity of 3700 MBq was administrated in cases without 
any (known) metastases. In case of pre- or peri-operatively detected lymph node 
involvement or T4 tumor stage, an activity of 5550 MBq was given. Between 
surgery and ablation patients did not receive L-thyroxine supplementation, and 
they had been instructed to keep a low-iodine diet for approximately 1 week 
[11;12]. No pre-ablative diagnostic scintigraphy was performed.  
 
Follow-up strategy  
Between 6 and 12 months after 131I ablation, patients were evaluated by the 
measurement of Tg-off values, i.e. Tg values under thyrotrophin (TSH) 
stimulation. For this purpose, hormonal supplementation was withdrawn for 4 
weeks, whereas in a minority of the UMCU cohort recombinant human TSH 
was applied. In the UMCU study group, all patients underwent 131I whole body 
scintigraphy (WBS), whereas in the LUMC cohort 131I WBS was performed in 
case of Tg <1 µg/l. In both hospitals, scintigraphy was performed at least 3 days 
after administration of 131I. In case of increased Tg values or an abnormal WBS, 
additional treatment was given followed by WBS within 7 days after the 
administration of a therapeutic dose. Follow-up results 6-12 months after this 
treatment were not studied. Despite the increased use of ultrasonography in the 
follow-up of DTC patients, it was not routinely used in this study. 
 
Laboratory analysis 
From 1990, in both hospitals, various kits were used for the measurement of Tg 
and Tg antibodies. Test results for Tg cannot be considered reliable in the 
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presence of Tg antibodies [16;17]. As all assays were IRMA assays, the 
presence of Tg antibodies would have resulted in unreliable Tg values. 
Therefore, Tg values were excluded from analysis in the presence of measurable 
Tg antibodies and a corresponding Tg value below the cut-off level. As results 
of Tg measurements are not interchangeable between kits [18], Tg values in any 
patient were considered undetectable if they were below the lower detection 
limit of the kit used (i.e. cut-off level). Until 1997, serum Tg was measured 
using an IRMA, the Dynotest TG (Brahms Diagnostica GmBH, Berlin, 
Germany), with a detection limit of 1 µg/l. From 1997 onwards, the Dynotest 
TG-s (Brahms Diagnostica GmBH) was used, with a detection limit of 0.5 µg/l. 
Recurrent disease, however, was defined as Tg values >1µg/l. TSH values were 
measured by means of an immunofluorometric assay with the Delfia (Wallac, 
Turku, Finland) until 1997. Thereafter, an immunoluminometric assay was used 
with the Elecsys (Boehringer Mannheim). Serum Tg-antibodies were 
determined by the Ab-HTGK-3 IRMA test (DiaSorin Biomedics, Saluggia (VC) 
Italy). 
 
Criteria for successful ablation 
Ablation was considered successful if 6-12 months after ablation when patients 
fulfilled the following criteria: Tg-off values below the cut-off level of the assay 
used and negative 131I whole-body scintigraphy. 
 
Statistical analysis 
For statistical analysis, we used SPSS version 12.0.1 for Windows (SPSS Inc., 
Chicago, Illinois, USA). The quantitative data (continuous parameters) were 
analysed using the Mann-Whitney U-test. For categorical data, the χ2 -test was 
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Results  
Study population  
In this study, a total of 359 patients were included. According to the uptake-
related and fixed-dose ablation protocols, 153 and 206 patients were treated 
respectively. In Table 1, the patient characteristics and results of tests for 
differences between the two groups are displayed. Papillary microcarcinomas 
were not observed in the groups studied. In the uptake-related protocol, 20% of 
patients were treated with 1110 MBq 131I, 19% with 1850 MBq and 61% with 
2800 MBq. The mean 24-h 131I uptake value in this group was 6.86% (range: 
0.03-12.0%). In the fixed-dose protocol, 69% of patients were treated with 3700 
MBq 131I and 31% with 5550 MBq. In this group, 24-h uptake values were not 
measured. 
According to the evaluation with 131I WBS as single tool (Table 2), 89 out of 
153 (58%) patients had no iodine uptake in the neck at the first follow-up 
scintigraphy in the uptake-related ablation protocol. In 174 out of 206 patients 
(84%) treated according to the fixed-dose ablation, scintigraphy did not show 
radioiodine uptake in the neck. This difference was statistically significant 
(p<0.001). The scintigraphic ablation results in various subgroups as well as the 
differences between the protocols are displayed in Table 2, demonstrating 
significant differences between the different protocols in all subgroups with the 
exception of T4 tumor stages. 
Regarding the combination of 131I WBS and Tg measurement as evaluation 
tools, it was decided to exclude patients with Tg antibodies and a negative 
diagnostic 131I WBS to avoid a bias leaving 338 patients available for analysis. 
Of those treated according to the uptake-related ablation protocol, 60 out of 139 
(43%) patients were successfully treated. For patients treated according to the 
fixed-dose ablation protocol, 111 out of 199 (56%) patients had successful 
ablation. Again, this difference was statistically significant (p=0.022). The 
results of ablation in various subgroups and tests for differences between the 
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protocols are also displayed in Table 2. We found significant differences 
between the protocols for almost all subgroups defined. However, differences 
were not statistically significant for patients with papillary thyroid cancer 
(p=0.23) and for patients with N1 (p=0.08) and/or T4 (p=0.581) disease. In 
addition, 10 patients in the uptake-related dose group and 9 patients in the fixed-
dose group had T4N1 disease (p=0.006). In both subgroups, only one patient 
had a successful ablation (p=0.937) revealing a high failure rate in these tumor 
stages. All patients with radioiodine uptake in the neck and/or elevated Tg 
values 6-12 months after ablation, the so-called failures, underwent subsequent 
treatment with a high therapeutic 131I dose. The results of the post-therapy scans 
were not part of the present study, but all patients with uptake on the diagnostic 
follow-up WBS also demonstrated uptake on the post-therapy scan. The post-
therapy scans of patients with increased Tg values were not evaluated. 
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Table 2. Successful ablation results in the entire population and various subgroups according 
to 131I WBS and 131I WBS with Tg measurements. 
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PTC 73 (59) 133 (85) <0.001 47 (43) 75 (50) 0.230 
FTC 16 (53) 41 (82) 0.006 13 (45) 36 (72) 0.016 
N0 76 (61) 119 (85) <0.001 55 (48) 86 (63) 0.017 
N1 12 (44) 55 (83) <0.001 5 (20) 25 (40) 0.080 
T1-3N0 70 (62) 117 (85) <0.001 53 (51) 86 (65) 0.034 
T4 10 (45) 12 (75) 0.236 3 (15) 1 (8) 0.581 
 
Twenty-one patients with positive Tg-antibodies were excluded in the evaluation using 131I 
WBS and Tg measurements. PTC, papillary thyroid carcinoma; FTC, follicular thyroid 
carcinoma; N, lymph node stage; T, tumor stage. 
 
Discussion 
In the present study, two fundamentally different ablation strategies were 
compared. The rationale of the quantitative uptake-related protocol was to avoid 
unnecessary exposure [13] and minimize local radioiodine side effects [14;15], 
whereas the fixed-dose ablation protocol was designed to maximize the chance 
of successful ablation after one administration of 131I. The present study showed 
that the fixed-dose ablation protocol has a significantly higher rate of successful 
ablation compared with the uptake-related ablation strategy. However, of all 
subgroups, the fixed-dose ablation protocol failed to show a significant 
advantage in patients with extra thyroidal invasion of the primary tumor (T4 
tumors) and/or lymph node involvement (N1 stage). In addition, the results also 
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demonstrate the low sensitivity of 131I WBS in the follow-up of thyroid cancer 
patients compared with the Tg measurements. This finding is in agreement with 
the recommendation presented in the European guidelines indicating that for the 
control of successful ablation in low-risk patients Tg measurements are the first 
step in the follow-up and WBS is not recommended anymore.  
Several studies have shown that higher administered 131I activities lead to higher 
ablation rates, although estimations of the optimal activity vary between authors. 
A randomized trial reported by Bal et al. [19] revealed no differences in the 
rates of remnant ablation for activities over 925 MBq (25 mCi). With successful 
ablation defined as a follow-up scintigram of the neck with less than 0.2% 
uptake and Tg less than or equal to 10 µg/l, they achieved in 81.6% of the cases 
successful ablation with activities of 925 MBq or more after one administration. 
The absence of activity-related differences in success rates of ablation in the 
study by Bal et al. is in sharp contrast with the differences encountered in the 
present study between those treated with a lower activity (with a minimum of 
1110 MBq) and a higher activity (minimum 3700 MBq). The findings of Bal et 
al. are also in contrast with the results described in their earlier study [5], in 
which an activity of 1850 MBq (50 mCi) or more performed significantly better 
than an activity of 1110 MBq.  
Also in contrast to our results are the findings of Johansen et al. [4], who found 
a success rate of 81% after one administration of 1073 MBq and 84% after the 
first administration for those receiving 3700 MBq. However, they analyzed only 
63 patients in total, whereas their reported success rates have been based on 
scintigrams performed 3-4 months after ablation. They also reported that the 
elevated Tg values in the ablated subjects were not statistically significant. 
However, their lower detection level for Tg was 5 µg/l, which is higher than our 
cut-off levels (0.2-1.0 µg/l). The comparable ablation results of 1073 and 3700 
MBq could be caused by less sensitive follow-up (short follow-up period after 
ablation and higher cut-off levels for Tg).  
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An interesting comparison can be made with the uptake-related protocol 
published by Zidan et al. [20], who reported results of an uptake-related protocol 
with used activities varying from 3145 MBq (85 mCi) for the patients with 
lowest uptake to 1110 MBq (30 mCi) for those with the highest uptake. Despite 
the fact that their definition of a successful ablation was based solely on a 
diagnostic 131I WBS, they reported a higher overall success rate of 94%. 
However, compared with the uptake-related protocol as described in the present 
study, Zidan et al. used higher 131I activities (approximately 1100 MBq more) 
for uptake values between 6 and 15%.  
In two recently published articles, systematic meta-analyses were presented on 
the 131I activity for remnant ablation in patients with DTC. In the analysis by 
Hackshaw et al. [21], 41 case notes, 12 prospective cohorts and 6 randomized 
trials were used to compare the outcome in patients treated with 30 mCi with 
those treated with 100 mCi. The pooled ablation success rates in the 
observational studies were 10% lower using 30 mCi compared with the higher 
dose. The meta-analysis of the randomized trials revealed equivocal results. 
Despite these findings and because of the lack of randomized trials, these 
authors concluded that it is not possible to reliably determine whether ablation 
success rates using the low activity are similar to those using the high activity. 
This statement was in contrast with the analysis presented by Doi et al. [22]. In 
line with their previous report, they clearly stated that the available data 
continue to favor higher doses of radioiodine (ranging from 2775 to 3700 MBq) 
for remnant ablation, especially after near-total thyroidectomy. The use of high 
doses in these patients results in about one-third less risk of non-ablation than 
low doses. Our data support the use of higher doses in thyroid cancer. 
Regarding the results in the present study and the data published in the literature, 
it is highly important to stress the difference between the 131I activity 
administered and the absorbed dose of radiation in thyroid tissue. The absorbed 
dose causes the ablation effect. This dose depends on several factors, such as 
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uptake of 131I and retention time in the remnants, the mass of the thyroid 
remnant, different TSH values, the initial activity given and patient's 
preparation. Despite the fact that a standard amount of radioactivity is used in 
the present study protocols, it may still result in different ablation doses. 
In both academic hospitals, the aim of surgery is to do an optimal resection of 
malignant tissue, which is a combination of a (near-) total thyroidectomy 
combined with a neck dissection in case of lymph node metastases. In T4 
tumors, there seems to be, however, a high chance of residual malignant cells in 
the thyroid remnants. In addition, a comparable phenomenon has been described 
for N1 disease, in which even after a modified neck dissection micrometastases 
in left lymph nodes cannot be excluded. In the literature, it has been described 
that thyroid carcinoma cells take up and process iodine less efficiently than 
normal thyroid cells due to a lower expression of the sodium-iodine symporter 
[23-25]. In a recently published study on prognostic parameters in thyroid 
cancer, both N1 and T4 tumor stages significantly correlated with a high chance 
of local tumor recurrences [26]. Consequently, minimal residual disease could 
be a thorough explanation for the fact that our study did not show a statistically 
significant difference in ablation results between the two protocols in case of T4 
and/or N1 tumors. Even a mean activity of 131I up to 5000 MBq as used in the 
fixed ablation dose, which is twice as much as applied in the uptake-related 
strategy, fails to achieve a complete response in 60 and 92% of the patients with 
N1 and T4 tumor stage respectively. In addition, in only 1 out of 10 and 9 
patients with T4N1 disease in the uptake-related and fixed-dose strategies 
respectively, success was achieved. These findings are in agreement with data 
published by Rosaria et al. [27]. They studied 274 patients with DTC and found 
a clear relationship between ablation failures and the presence of metastases and 
tumors larger than 4 cm in diameter. However, also thyroid remnants with an 
uptake >5% resulted in a higher failure rate. 
It has to be realized that two factors could have influenced the treatment results 
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in the present study. First, the two centres used different follow-up strategies. 
An endocrinologist of the LUMC performed the clinical follow-up of patients 
who underwent ablation in the LUMC. The clinical follow-up of a part of the 
UMCU patients is in their own (referring) hospitals by means of 131I diagnostic 
scintigraphy and Tg measurements. This subgroup of UMCU patients only 
returns to the UMCU if additional radioiodine treatment is required (in case of 
unsuccessful ablation). This effectively may create a bias, as a number of 
patients with a successful ablation cannot be included in the present study. In 
this respect however, the missing data would have further increased the overall 
success rate in the fixed-dose group compared with the uptake-related protocol. 
Second, it has been shown that relatively low diagnostic activities of 131I may 
lead to impaired ability of remnant thyroid tissue to concentrate the subsequent 
ablative dose of 131I (so-called stunning effect) and thereby reduce therapeutic 
efficacy [28-31]. Although this phenomenon has been acknowledged for some 
time, the precise time interval and 131I activity after which it occurs is still a 
subject to discussion. If an applied activity of 40 MBq causes a lower 
concentration of 131I in the thyroid remnant, part of the effect seen in this study 
could have been attributed to the stunning effect with a probable bias against the 
uptake-related protocol. However, data on stunning effects caused by such low 
doses have not been reported yet. 
In the present study, we evaluated patients at 6-12 months after ablation, 
demonstrating a significant difference in short-term outcome. However, data on 
long-term recurrence rates are currently not available. The number of studies 
evaluating differences in long-term outcome in patients treated with high or low 
131I doses is scarce. Data presented by Chow et al. clearly demonstrated the 
influence of radioiodine after surgery regarding the 5-, 10- and 15-year local 
relapse rate [32]. In patients not treated by radioiodine after surgery, the 
cumulative relapse rate after 15 years follow-up was 20.9% compared with 9.2% 
in patients treated with radioiodine. In this study, patients who were treated 
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received a mean dose of 3400 MBq at initial stage. It was shown by Verburg et 
al., that a successful ablation itself seems to be a highly important prognostic 
factor for long-term outcome [33]. They found that of the patients with a 
successful ablation, 87% were still free of the disease after 10 years, whereas of 
the patients with an unsuccessful ablation, only 50% were free of disease 
(p<0.001). According to this finding, a higher recurrence rate may be expected 
during follow-up in the uptake-related protocol group compared with the group 
of patients treated according to the fixed-dose protocol. However, this statement 
is not supported by data recently published by Rosario et al. [34]. They treated 
82 patients with 3700 MBq 131I and 44 patients with 1100 MBq. At the end of a 
5-year follow-up period, the recurrence rate was 3.6% in patients who had 
received the high dose and 3.4% in those treated with the low dose (p=NS). 
Criteria used for patient's selection and risk factors were unfortunately not 
reported, which may have caused a selection bias. Therefore, more randomized 
trials are required to assess the short- and long-term outcome in relation to the 
ablation dose used in DTC ablation.  
 
Conclusion 
The fixed-dose ablation protocol, using relatively higher 131I activities, is 
generally more effective in thyroid remnant ablation than a 24-h 131I uptake-
related ablation protocol that uses relatively low activities. This difference, 
however, is not observed in patients with T4 and/or N1 tumor stages, which can 
be clarified by the presence of minimal residual malignant disease. The present 
study addressed the issue of ablation efficacy as judged by scintigraphy and Tg 
measurements after 6-12 months, whereas long-term outcome was not 
evaluated. Therefore, follow-up studies are necessary to solve whether this lack 
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Chapter 4 
Abstract 
Objective: Dosimetry studies have shown that activities of 131I as small as 10-20 
MBq may cause a stunning effect. A result of this stunning effect may be a 
lower success rate of the ablative 131I therapy for differentiated thyroid 
carcinoma (DTC). The aim of this study was to determine whether pre-
therapeutic uptake measurement with 40 MBq 131I causes a lower success rate of 
ablation.  
Design: retrospective chart review study. 
Patients, methods: In two hospitals the ablation protocols differed in one respect 
only: in the one hospital no diagnostic 131I was applied before ablation (group 1, 
n=48), whereas in the other hospital a 24-h uptake-measurement with 40 MBq 
131I was performed (group 2, n=51). Included were all DTC patients without 
distant metastases who had undergone 131I ablation between July 2002 and 
December 2005, and who had returned for 131I follow-up. Successful ablation 
was defined as absence of pathological 131I uptake on diagnostic whole-body 
scintigraphy and undetectable thyroglobulin-levels under TSH stimulation. 
Results: Overall, ablation was successful in 31/48 patients (65%) in group 1 and 
in 17/51 patients (33%) in group 2 (p=0.002). Multivariate analysis showed that 
pre-therapeutic uptake measurement using 40 MBq 131I was an independant 
determinant for success of ablation (p=0.002).  
Conclusions: After applying a diagnostic activity of 40 MBq 131I before 
ablation, the success rate of ablation is severely reduced. Consequently, the 
routine application of 131I for diagnostic scintigraphy or uptake measurement 
prior to 131I ablation is best avoided. 
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Introduction 
The therapy of choice in patients suffering from differentiated thyroid carcinoma 
(DTC) is (near-) total thyroidectomy. To DTC patients except for those with a 
papillary carcinoma <1 cm in diameter it is recommended to subsequently 
administer a high activity of 131I, with the intent to ablate remnant thyroid tissue 
[5]. There is still some discussion whether follicular thyroid carcinoma patients 
with a tumour diameter <1 cm should receive the 131I ablation treatment [29,34].  
In many centres this 131I ablation is preceded by pre-therapeutic uptake 
measurement using a small activity of 131I [41,42]. A potential disadvantage of 
this is the presumed stunning effect to thyroid remnants [16,35], i.e. a 
diminished uptake of ablative 131I activity after the application of a diagnostic 
131I activity.  
This stunning effect may be noticed either by a lower than expected 131I uptake 
on a post-ablation scintigram, or as a higher failure rate of ablation. The precise 
definition of stunning in the context of 131I ablation has not been established, 
with many authors only reporting a visual difference in 131I uptake by the thyroid 
remnant and only few offering quantitative evidence. Whereas not all authors 
agree that this phenomenon occurs [22,25,36], it has been demonstrated by 
others in malignant [12,16,17,26,30] and benign thyroid disease [14]. 
Dosimetry studies have shown that activities of 131I as small as 10-20 MBq may 
deliver a significant radiation dose to thyroid cells [16,23], suggesting that the 
stunning effect may be due to direct radiation damage to thyrocytes. This is also 
supported by a study from Postgard et al. which showed that absorbed radiation 
doses as little as 3 Gy already reduced iodine transport by 50% [33]. Evidence 
was presented of downregulation of the sodium iodine symporter expression in 
reaction to diagnostic activities [27], thus reducing the uptake of 131I [19].  
At the University Medical Center Utrecht (group 1) and at the Leiden University 
Medical Center (group 2), two academic hospitals with geographically partially 
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overlapping patient populations, comparable fixed activity ablation protocols 
were used since July 2002 [4]. However, there is one difference:  
- Group 1: no pre-therapeutic uptake measurement is performed,  
- Group 2: a pre-ablative 24-h uptake measurement is performed (40 MBq 
131I).  
Our aim was to determine whether this pre-therapeutic procedure with 40 MBq 
131I causes a lower success rate of ablative 131I therapy in post-operative DTC 
patients.  
 
Patients, material, methods 
Study population 
All DTC patients after thyroidectomy and without distant metastases (known 
before initial treatment or demonstrated by post-ablation scintigraphy or 
computed tomography / magnetic resonance imaging studies during initial 
treatment), who received 131I ablation treatment in one of our centres between 
July 2002 and December 2005, were included in a retrospective study. Further 
inclusion criteria were:  
- ablation had been performed in accordance with the hospitals’ protocols;  
- 6-12 months after ablation, patients had returned for diagnostic 
scintigraphy or additional treatment with 131I and for measurements of 
thyroglobulin (Tg) levels during TSH stimulation.  
 
Pre-ablative 24-h 131I uptake 
In group 1 the ablative activity was administered without prior diagnostic 
scintigraphy. In group 2 pre-ablative 24-h 131I uptake measurements were 
performed in order to assess the percentage of 131I taken up by the thyroid 
remnant using standard techniques: a capsule with 40 MBq 131I was given orally, 
followed by planar scintigraphy of the neck region 24 h later.  
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A standard of 40 MBq 131I, calibrated on the day of administration and measured 
in a neck phantom after 24 h, was used as a reference. The ablative 131I activity 
was administered on the day after the uptake measurement. Patients with a 131I 
uptake >15% would have been referred to the surgical department for evaluation 
of additional surgical treatment, but this never occurred.  
 
Fixed activity ablation protocol 
A fixed activity ablation protocol was used in the University Medical Center 
Utrecht from January 1990 onward and at the Leiden University Medical Center 
from July 2002 onward. All patients underwent 131I ablation 4-6 weeks after 
(near-) total thyroidectomy. Patients did not receive L-T4 medication between 
surgery and ablation. In both centres TSH-levels had to be equal to or greater 
than 30 mU/l before ablation could take place. Since the Netherlands is an 
iodine-sufficient country, in both centres patients had been instructed to keep a 
low-iodine diet for one week prior to ablation [8,32].  
An activity of 3700 MBq 131I was administered to patients without (known) 
metastases or 5550 MBq to patients with nodular involvement (detected pre- or 
peri-operatively). Node negative patients with extensive extrathyroidal tumour 
growth (n=8) or Hürthle carcinomas (n=6) also received 5550 MBq.  
 
Follow-up, laboratory analyses  
6-12 months after ablation, patients returned to their respective hospitals for 
follow-up. At the UMCU this was performed with rhTSH stimulation using 370 
MBq of 131I while at the LUMC levothyroxin was withdrawn for 4 weeks and 
185 MBq of 131I was given. In both centres TSH-levels were checked before 
administration of 131I and had to be ≥30 mU/l. At this follow-up blood was 
drawn for the measurement of TSH-stimulated Tg-levels. Concurrently, 
scintigraphy with a large-field-of-view camera and high-energy collimators in 
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both centres was performed, acquiring a scan of the entire body and separate 
planar acquisitions of the cervical region.  
In group 1 the BRAHMS Dynotest Tg-pluS kit for measurement of Tg-levels 
and levels of Tg-antibodies was used (BRAHMS Diagnostica GmbH, Berlin, 
Germany). The lower detection limit of this kit was 0.2 µg/l. In group 2 the 
BRAHMS Dynotest Tg-S kit for measurement of Tg-levels and levels of Tg-
antibodies was used (BRAHMS Diagnostica GmbH, Berlin, Germany), with a 
lower detection limit of 0.5 µg/l.  
In the presence of antibodies, test results for Tg are not reliable [21,39]. As the 
assays used in both hospitals were IRMA assays, interference from antibodies 
against Tg generally would have resulted in underestimation of Tg-levels. 
Hence, eight patients with Tg test results below the cut-off level and with 
negative whole body scintigraphy were excluded from analysis because Tg 
antibodies were present in their serum.  
 
Successful ablation, statistics 
As our primary definition, ablation was considered successful if 6-12 months 
after the initial 131I therapy patients fulfilled all of the following criteria: 
- no additional therapy of any kind for thyroid cancer between 131I ablation 
and first TSH-stimulated follow-up; 
- TSH-stimulated levels below the detection limit of the assay; 
- absence of pathologic 131I accumulations on whole-body scintigraphy, 
including absence of a visually discernable uptake focus in the thyroid 
bed as rated by the nuclear medicine physician at the time.  
In literature further measures are advised if Tg-levels meet certain cut-off levels, 
usually 1 µg/l [28] or 2 µg/l [6]. In order to study the clinical relevance of our 
findings we also analysed the overall success rate of ablation using both these 
cut-off levels combined with the other two criteria mentioned.  
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For statistical analysis we used SPSS version 12.0 for Windows (SPSS inc., 
Chicago, Illinois, USA). Statistical significance was defined as p<0.05. The 
quantitative data (continuous parameters) were analysed using the Mann-
Whitney U test. For categorical data the Chi-squared test was used. Multivariate 
analysis was performed using binary logistic regression with a forward selection 
method based on likelihood ratios. 
 
Results 
Study population, cut-off 
The 48 patients in group 1 received 131I ablation without a pre-ablative uptake 
measurement, whereas the 51 patients in group 2 first underwent a 24-h-131I-
uptake measurement. Patient characteristics for both groups as well as tests for 
differences between the two groups are given in table 1; none of these 
differences were statistically significant.  
 
Tg-levels undetectable 
Overall, ablation was successful in  
- 31/48 patients (65%) in group 1, and  
- 17/51 patients (33%) in group 2.  
The difference is statistically significant (p=0.002). Table 2 displays the results 
of analyses of various subgroups. In most subgroups, there was a significant 
difference between group 1 and group 2 with regard to success of ablation. In 
some subgroups (e.g., male patients or patients with follicular thyroid 
carcinoma) for which the group size was insufficient to show a significant 
difference, the distribution of successful vs. unsuccessful ablation approximated 
that of the total group. Remarkable was the lack of a significant difference 
between group 1 and group 2 for those patients who received 5550 MBq 131I.  
In order to exclude tumour size affecting the results, we compared all node 
negative patients without extrathyroidal tumor invasion (T1-3N0M0 according 
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to the 5th edition of the TNM system) [38] from group 1 (n=30), as no uptake 
data were available, with only those patients (n=18) from group 2 with an uptake 
of <5 %, reflecting a smaller thyroid remnant. In this analysis too group 1 did 
significantly better (p=0.024). Also we compared 6 node negative patients with 
extrathyroidal tumour invasion from group 2 with an uptake percentage >8% 
with 11 patients who showed an uptake <2 %, representing the highest and 
lowest uptake percentages, respectively. The difference between the two groups 
was not significant (p=0.62). 
For each group we also compared the results of those patients receiving 3700 
MBq with those receiving 5550 MBq. This resulted in p=0.047 for group 1, and 
p=0.83 for group 2.  
Multivariate analysis showed that having received a diagnostic 131I activity was 
the most significant factor influencing the chance of successful ablation 
(p=0.002). The only other significant influence was having extrathyroidal 
tumour growth (p=0.007).  
 
Tg-levels <1 µg/l and <2 µg/l 
Ablation was deemed successful by using as cut-off 
• Tg-levels <1 µg/l  
- 35/48 patients (73%) in group 1, and 
- 26/51 patients (51%) in group 2 
• Tg-levels <2 µg/l 
- 37/48 patients (77%) in group 1, and 
- 27/51 patients (53%) in group 2 
 
The differences are statistically significant: p=0.025(Tg <1 µg/l); p=0.012(Tg 
<2 µg/l). 
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Table 1. Baseline characteristics of patients treated without (group 1) and with (group 2) pre-
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Table 2. Comparisons the rates of successful ablation (defined as undetectable Tg-levels, no 
visible pathologic 131I uptake and no intermittent further treatment) of various subgroups in 





















9/14 (64%) 5/15 (33%) 0.10 
Females 
 
22/34 (65%) 12/36 (33%) 0.009 
Papillary carcinoma  
 
25/40 (63%) 11/39 (28%) 0.002 
Follicular carcinoma  
 
6/8 (75%) 6/12 (50%) 0.26 
No extra-thyroidal 
invasion and node 
negative  
 
23/30 (77%) 15/37 (41%) 0.003 
Extra-thyroidal tumor 
invasion and/or node 
positive  
 
8/18 (44%) 2/13 (15%) 0.09 
3700 MBq 
 
25/34 (74%) 11/32 (34%) 0.001 
5550 MBq 
 
6/14 (43%) 6/19 (32%) 0.51 
 
Discussion 
Our study shows substantial differences in efficacy of 131I ablation, correlated 
with pre-therapeutic administration of 40 MBq 131I: the success rate of ablation 
in the group without pre-ablative scintigraphy is nearly twice that of the group 
who underwent pre-therapeutic 131I uptake measurement.  
 
Stunning remains controversial 
Thyroid stunning remains a controversial issue. Jeevanram et al. [12] were the 
first to report a 25-75% decrease in uptake of therapeutic 131I activities after 
diagnostic scanning with 111-185 MBq 131I. Subsequently, several authors have 
 80 
Reduced success rate of ablation after a diagnostic activity of 40 MBq 131I 
  
reported various degrees of stunning of thyroid remnants after the administration 
of 131I activities ranging from 74 MBq [16], to 111 MBq [26], 185 MBq [11,17], 
and 370 MBq [30], all resulting in a less successful outcome than a control 
group that was scanned either with a much lower (37 MBq) 131I activity [26], 
with 123I [17,30], or without any pre-therapeutic 131I before ablation [11]. 
In contrast, McDougall et al. [22] and Cholewinski et al. [2] reported no visually 
apparent stunning after diagnostic activities of 74 MBq and 185 MBq 131I, 
respectively. However, in neither of the latter studies the success rates of 
ablation were reported. Dam et al. [3] reported that even though visually 
apparent stunning was encountered in a part of their patient population, there 
were no differences in the success rate of ablation between those who did and 
those who did not show stunning on pre- or post-ablation scintigraphy. Sisson et 
al. even argued that visually apparent stunning may not be attributed to a 
diagnostic activity, but rather to early effects from the subsequent ablation 
activity [37]. However they did not compare to patients who had not received 
diagnostic 131I activities. Silberstein [36] reported no difference in ablation 
success rates between patients receiving 14.8 MBq of 123I or 74 MBq of 131I for 
pre-therapeutic uptake measurement.  
The activity of 40 MBq 131I used in the study presented here is lower than those 
reported in the literature. Thus far there was only scant evidence as to whether 
or not stunning may be caused by such low 131I activities. Medvedec [23] 
performed a meta-analysis by fitting a regression model on results reported in 
four studies, and concluded that thyroid remnant stunning might already occur 
after administration of 131I activities as low as 10-20 MBq.  
 
Limitations 
Whether there is a time point at which a pre-therapeutic diagnostic activity does 
not influence the outcome of the following ablative activity is questionable and 
should be subject to further study; few data exist in literature and in this study 
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success of ablation is already diminished even if the diagnostic activity is given 
only 24-h before the ablative dose.  
The success of ablation treatment is influenced by the size of the thyroid 
remnant [18]. Even though it is possible that there were some patients in group 1 
with a considerably larger thyroid remnant, patients from group 2 did 
significantly worse even when only the smallest remnants were selected.  
 
Follow-up 
There are differences in the follow-up regime between group 1 and 2; both the 
method of stimulation (rhTSH vs. withdrawal) and the activity used (370 vs. 185 
MBq). Neither of these differences should significantly influence the results: it 
was shown that the activity used for follow-up does not influence the results 
[31], and a large international trial established that results after rhTSH-
stimulated follow-up are equivalent to those after levothyroxin withdrawal 
[20,40].  
From the results of this study it can be deducted that patients with a favourable 
prognosis suffer most from performing pre-therapeutic 131I uptake measurement: 
patients receiving 3700 MBq (who have low-risk tumours) show a difference 
between group 1 and group 2, whereas those receiving 5550 MBq (which are 
patients with higher risk tumours) do not show such a difference. In addition it 
turns out that in group 1 there is a large difference in success of ablation 
between those receiving 3700 and 5550 MBq 131I; this difference is absent in 
group 2. 
Most subgroups showed significant differences between group 1 and group 2; in 
those subgroups that were too small to achieve a statistically significant 
difference (e.g., male patients, and patients with follicular carcinoma) we found 
differences between group 1 and group 2 proportional to those in the entire 
group.  
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In order to establish the clinical relevance we also analysed the differences in 
success rate using different cut-offs for Tg-levels that have been mentioned in 
literature. Even though the difference was less pronounced than with the stricter 
criterium of undetectable Tg-levels, we still found a considerable, statistically 
significant difference in success rate between group 1 and group 2. This 
indicates that at the first TSH-stimulated follow-up patients in group 2 
considerably more often showed Tg-levels at such levels that additional 
diagnostic or therapeutic measures are indicated, and therefore poses a clinically 
relevant effect.  
Other conditions being equal, it is highly likely that the lower success rate of 
ablation in group 2, which was seen especially in those with a favourable 
prognosis, was caused by stunning from the pre-therapeutic uptake measurement 
procedure with 40 MBq 131I. Consequently, in order to maximize the success 
rate of 131I ablation and minimize the number of required additional 131I  
therapies, 24-h uptake measurements or diagnostic scintigraphy using 131I is best 
avoided in patients with differentiated thyroid cancer.  
 
Conclusion 
Whether pre-ablative diagnostic scintigraphy should be performed is in 
discussion. Pre-ablation dosimetry, especially using 124I, may for instance allow 
a precise determination of the absorbed dose per MBq 131I [7,13]; which may in 
turn lead to a reduction in the activity of 131I given, although individual 
dosimetry may become difficult in patients with a thyroid remnant mass <1 g 
[9]. Small amounts of 131I before 131I therapy may be useful in determining the 
largest activity that can be given without a risk for hematologic toxicity [15].  
The local situation, legal requirements or the frequent occurrence of large 
thyroid remnants may also necessitate a pre-ablative uptake measurements. In 
such cases 123I scintigraphy may also provide a valuable alternative; to date no 
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Chapter 5 
Abstract 
Background: This study addresses the questions whether patients with a high 
risk for recurrent thyroid cancer can be identified at initial stage, i.e. at the time 
of ablation. 
Methods: We evaluated tumor recurrence in consecutive patients treated for 
differentiated thyroid cancer (DTC). Prognostic factors were statistically 
analyzed. We defined prognostic parameters based on thyroglobulin (Tg) levels, 
24-h 131I uptake rates and TSH levels: (a) Tg/TSH, (b) Tg/24-h 131I uptake value, 
and (c) Tg/(TSHx24-h 131I uptake). 
Results: We included 190 patients (50 male, 140 female; mean age 47 years) 
with DTC for analysis, 146 without distant metastases and 44 with M1 tumor 
stage at initial presentation. The mean period of follow-up was 10.4 years (SD± 
3.7 years). In 18 out of the 146 DTC patients with M0 disease (12.4%), tumor 
recurrence was found during follow-up. Although tumor stage, age, and standard 
biochemical values significantly differ between patients with and without 
recurrent disease or between patients with M0 and M1 tumor stage, the newly 
defined parameter Tg/(TSHx24-h 131I uptake) was the best independent 
significant prognostic parameter in the assessment whether patients will develop 
a tumor recurrence during follow-up or not. 
Conclusion: High Tg/(TSHx24-h 131I uptake) ratios justify an adjustment of the 
131I activity for ablation therapy. To assess the optimal cut-off level for a dose 
adjustment, however, further studies are required in more patients, but the initial 
results are encouraging with respect to improving outcome in DTC patients. 
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Introduction  
Differentiated thyroid cancer (DTC) is a rather uncommon tumor with a high 
survival rate. The therapy of choice consists of (near-) total thyroidectomy 
followed by ablation with radioiodine-131 (131I). This combined treatment 
schedule is a prerequisite for an optimal tumor destruction as well as for an 
optimal patient follow-up [1]. The currently used follow-up strategy is based on 
regular thyroglobulin (Tg) measurements under thyroid stimulating hormone 
(TSH) stimulation (Tg-off levels) either using thyroid hormone withdrawal or 
rhTSH and 131I whole body scintigraphy (WBS). Later on, Tg levels without 
TSH stimulation may guide the clinician during the follow-up of DTC. The 
purpose of optimal follow-up protocols in thyroid carcinoma is the early 
detection of recurrent or metastatic thyroid cancer, as it has a great impact on 
morbidity and mortality. Indeed, patients with recurrent DTC have a less 
favorable prognosis than those with primary disease, as more than 50% of 
patients with a recurrence experience tumor-related mortality. One of the major 
issues in such cases is the fact that a tumor recurrence may loose the 131I uptake 
capacity [2]. In this respect, it has been stated that high ablation doses may be 
recommended to decrease the risk not only for persistent thyroid remnants but 
also for tumor recurrence. The question, however, could be raised whether this 
should be applied in all DTC patients or in subgroups only [3-6]. Therefore, it 
would be helpful to have one single or a combination of prognostic parameters 
at initial stage that can be used to identify patients with a high risk for tumor 
recurrence during follow-up. Thyroglobulin measured at initial stage may be of 
prognostic value, but its value cannot be disconnected from the TSH stimulation 
and the amount of residual disease after surgery, expressed as the 24-h 131I 
uptake value. In the present study, this value is a surrogate value for remnant 
size. Although ultrasonography or computed tomography (CT)-scanning of the 
head and neck region would give a better estimation of the residual thyroid 
volume after surgery than the uptake value, these imaging techniques are less 
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reliable shortly after surgery due to edema. Furthermore, contrast administration 
is required for optimal CT-scanning of the neck which interferes with 
subsequent 131I therapy. 
In the present study, data from 190 patients with newly diagnosed DTC were 
analyzed in order to assess the prognostic value of commonly determined initial 
parameters in the prediction of a tumor recurrence during follow-up. 
Furthermore, we studied the prognostic value of three newly defined parameters 
which are based on Tg under endogenous TSH stimulation, TSH levels, and/or 
the 24-h 131I uptake value, all measured at the time of ablation. With the results, 
we might be able to adjust the 131I ablation activity to decrease the risk of a 
recurrence and to improve morbidity and mortality. 
 
Material and methods  
Study population 
Data were collected from the records of consecutive patients with DTC who 
received ablation treatment with 131I at the Leiden University Medical Center 
(LUMC) between January 1986 and December 1999. This included a total of 
255 patients with pathologically verified DTC, i.e. either papillary, follicular, 
mixed papillary follicular, or follicular Hürthle carcinoma. For the current 
evaluation, a follow-up period of at least 1 year was required. Exclusion criteria 
were: missing biochemical parameters, the presence of Tg-antibodies (Tg-abs 
levels >50 µg/l), or TSH levels <20 U/l at the time of ablation (n=49), unknown 
uptake (n=17), and/or follow-up of <1 year (n=10). As a result, 65 patients were 
excluded, resulting in a total study population of 190 patients. Out of these 190 
patients, 146 had no distant metastases, whereas 44 had metastases at the time of 
initial diagnosis. 
Hospital records were reviewed and the following (prognostic) data were 
recorded: age, gender, histopathological data, treatment characteristics, and 
laboratory values. Records of scintigrams were analyzed and coded. Tumor 
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staging was scored according to the criteria of the fifth tumor node metastasis 
(TNM) Atlas. We defined three new parameters as follows: (i) Tg/24-h 131I 
uptake, (ii) Tg/TSH, and (iii) Tg/(TSHx24-h 131I uptake) (Tg is expressed in µg/l 
and TSH in U/l). 
 
Radioiodine treatment 
Therapy for DTC consists of (near-) total thyroidectomy, followed 4-6 weeks 
later by radioiodine ablation therapy. During this interval, no treatment with L-
thyroxin was initiated in order to increase TSH levels. The 24-h 131I pre- 
treatment uptake value in the neck region was measured using standard 
techniques: 40 MBq of 131I was given orally, followed by planar scintigraphy of 
the neck region 24 h later. This uptake value is regarded as a surrogate value for 
remnant size in the present study. Although stunning may occur during 
diagnostic scanning with 131I, a recent study by Dam et al. [7] demonstrated that 
treatment efficacy is not influenced by activities <185 MBq [7-9]. In addition, 
follow-up studies and subsequent treatment are used to achieve a complete 
ablation. In case of a possible stunning effect, ablation failures will be depicted 
6 months after initial treatment (see evaluation of treatment efficacy). 
A standard 131I activity of approximately 2800 MBq was given orally 24 h after 
the uptake measurement and adjusted in case of large thyroid remnants. The 
rationale of this quantitative approach is to avoid unnecessary exposure and 
local radioiodine side effects. In this regimen, no adjustments were made in the 
case of cervical lymph node metastases. Treatment of patients with M1 tumor 
stage at initial presentation as well as subsequent treatment for either initial 
ablation failures or recurrent disease was done with 6100 MBq of 131I. Seven 
days after each treatment, whole-body scans were made according to the 





Evaluation of treatment efficacy 
Six months after the ablation therapy, L-thyroxin was withdrawn for at least 4 
weeks. Subsequently, radioiodine diagnostic whole-body scintigrams were 
obtained 3 days after the administration of 185 MBq of 131I or 24 h after the 
administration of 370 MBq 123I. For all scintigrams, a Toshiba gamma camera 
(Tokyo, Japan) was used. A high-energy collimator (matrix sizes of 256 X 1024 
and 256 X 256, window of 20% centered at 360 keV) for the 131I WBS, a low-
energy collimator (matrix sizes of 256 X 1024 and 256 X 256, window of 20% 
centered at 159 keV) for the 123I WBS was used. 
Anterior and posterior whole-body and planar views of the neck region were 
routinely obtained. For the whole-body scintigrams, scanning rates of 15 (131I) 
and 10 cm/min (123I) were used. In addition, Tg levels were determined at the 
time of the diagnostic whole-body scan to document the ablation efficacy. For 
successful ablation, a cut-off level of Tg of ≤1 µg/l was applied. Patients with an 
unsuccessful ablation, documented by scintigraphy and/or a Tg level >1 µg/l 
during TSH stimulation after 4 weeks of L-thyroxin withdrawal, received a 
second treatment with 131I. 
Recurrent disease was defined as increased Tg levels, abnormal WBS, or both 
but not within 2 years after ablation and following at least one diagnostic session 
with normal test results. Persistent disease or ablation failures were defined if 




Until 1997, serum Tg was measured using an IRMA, the Dynotest TG (Brahms 
Diagnostica GmBH, Germany), with a detection limit of 1 µg/l. From 1997 
onwards the Dynotest TG-s (Brahms Diagnostica GmBH) was used, with a 
detection limit of 0.5 µg/l. Recurrent disease, however, was defined as Tg levels 
>1 µg/l. TSH levels were measured by means of an immunofluorometric assay 
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(IFMA) with the Delfia (Wallac, Turku, Finland) until 1997. Thereafter, an 
immunoluminometric assay (ILMA) was used with the Elecsys (Boehringer 
Mannheim, Germany). Serum Tg-abs were determined by the Ab-HTGK-3 
IRMA test (DiaSorin Biomedics, Italy). 
 
Data collection and statistical analysis 
All collected data were put in a database using MS-Access 2000. Statistical 
analysis was performed with SPSS 11.5 for Windows (SPSS Corporation, 
Chicago, IL, USA) and MS-Excel 2000. The quantitative data were analyzed 
using Cross-tabs with χ², Student's t-test, Cox regression, Cox regression 
forward stepwise, and by calculating curve coordinates. The prognostic value of 
the patient characteristics was quantified with the hazard ratio and its 95% 
confidence level. Throughout, a p value of 0.05 or less was considered 
statistically significant. Finally, three subgroups were identified for statistical 
analysis: patients with initially M0 stage DTC, irrespective of recurrent disease 
during follow-up; patients with initially M1 stage DTC; and finally, patients 
with initially M0 stage disease, but with recurrent DTC during follow-up. For 
the generation of the probability plot and prognostic stratification, only patients 
with initially M0 disease were used, whereas their results were compared with 
patients with M1 disease to assess the overall value of the study results. 
 
Results 
In the present study, 190 patients (50 male, 140 female; mean age 47.1 years) 
with DTC were included for further analysis, 146 without distant metastases and 
44 with M1 tumor stage at initial presentation. Papillary thyroid carcinoma, 
consisting of papillary and mixed papillary follicular, was diagnosed in 102 
patients. Follicular thyroid carcinoma was diagnosed in 44 patients. In the 
present study, 49 patients had lymph node involvement at the time of 
thyroidectomy. The mean period of follow-up was 10.4 ±3.7 years. In 18 out of 
 95
Chapter 5 
the 146 DTC patients with M0 disease (12.4%), tumor recurrence was found 
during follow-up. A total of 14 patients died in the group without metastases, 6 
from the differentiated thyroid carcinoma, whereas 8 died from other causes, 
such as second primary tumors. 
Table 1 shows subgroup characteristics of patients with initially M0 stage 
(n=146) and patients with M1 stage (n=44) DTC as well as for patients with 
initially M0 stage without (n=128) and with (n=18) recurrent disease 
respectively. Significant differences were found between almost all parameters 
tested between patients with M0 and M1 initial tumor stage. For age, we found a 
cut-off level of 59 years between those with a high and low risk for recurrent 
disease. In patients with M0 disease, age at diagnosis (>59 years), T stage, N 
stage, and all newly defined parameters were significantly different between 
those with and without tumor recurrence during follow-up. For the risk of 
recurrent disease, Tg levels (p=0.027), N stage (p=0.038), and Tg/TSH 
(p=0.021) were significant correlates for tumor recurrence. In stepwise analysis, 
an increased ratio of Tg/(TSHx24-h 131I uptake) was selected as the most 
reliable variable (p=0.001) for tumor recurrence (Figure 1), with a Hazard rate 
of 12.1 (95% CI: 6.61-22.13). Initial ablation failure was not found to be a 
significant indicator for tumor recurrence. The number of patients with initial 
ablation failure was not significantly different between the groups with and 
without recurrent disease (p=0.522). 
To assess whether the parameters studied may be indicative for bulky disease, 
we compared the parameters of patients having initially M1 disease with those 
having initially M0 disease and tumor recurrence during follow-up. In this 
respect, age at diagnosis was significantly different between these subgroups 
(p=0.021; see Table 2). Finally, we combined patients with M1 with patients 
with recurrent disease into one group to determine the accuracy of Tg/(TSHx24-
h 131I uptake) in the assessment of bulky disease at the time of ablation. 
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The area under the receiver operating characteristic (ROC) curve was 0.800 
(95% CI: 0.714-0.866). 
 
Table 1. Differences between differentiated thyroid cancer patients with and without 

























Gender: Male / Female 
 
32 / 114 
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0.521 






































































TSH (U/l) 77 (±36) 62 (±17) 0.023 77 (±37) 78 (±34) 0.949 
Tg (μg/l) 21 (±110) 1246 (±4066) 0.000 8 (±14) 120 (±321) 0.001 
Uptake (%) 6.1 (±7.3) 6.7 (±7.8) 0.621 6.3 (±7.6) 4.7 (±5.3) 0.125 
Tg/Uptake  3.9 (±9.2) 827.1 (±3312.3) 0.003 2.5 (±5.6) 15.3 (±19.9) 0.001 
Tg/TSH  0.4 (±2.3) 51.2 (±207.9) 0.003 0.1 (±0.2) 2.7 (±6.6) 0.001 
Tg/(TSHx24-h 131I uptake) 0.07 (±0.19) 38.00 (±170.55) 0.007 0.04 (±0.07) 0.31 (±0.49) 0.001 
Initial ablation  failure *    43 (34%) 8 (44%) 0.522 
 
RD, recurrent disease; T stage, tumor stage; N stage, node stage; TSH, thyroid stimulation 
hormone; Tg, thyroglobulin. 





Figure 1. Probability plot of tumor recurrence with its 95% confidence interval in patients 
with initially MO tumor stage. Tg tryroglobulin; TSH, thyroid-stimulating hormone. 
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Table 2. Differences between differentiated thyroid cancer patients with initially distant 







Patients with initially 





Gender: Male / Female 
 
13 / 31 
 
5 / 13 
 
0.889 









































TSH (U/l) 62 (±17) 78 (±34) 0.225 
Tg (μg/l) 1246 (±4066) 120 (±321) 0.276 
Uptake (%) 6.7 (±7.8) 4.7 (±5.3) 0.311 
Tg/Uptake  827.1 (±3312.3) 15.3 (±20.0) 0.334 
Tg/TSH  51.2 (±207.9) 2.7 (±6.6) 0.357 
Tg/(TSH x 24-h 131I uptake) 38.00 (±170.55) 0.31 ( ±0.49) 0.383 
 
RD, recurrent disease; T stage, tumor stage; N stage, node stage; TSH, thyroid stimulating 





In the present study, we have assessed the value of clinical and biochemical 
parameters in prognostic stratification of patients with DTC at the time of 
ablation with radioiodine. Although T stage, N stage, age, and standard 
biochemical values at the time of diagnosis significantly differ between patients 
with and without recurrent disease or between patients with M0 and M1 tumor 
stage, we found a considerable overlap between these parameters to be of 
clinical value. Nevertheless, current study revealed the newly defined parameter 
Tg/(TSHx24-h 131I uptake) determined at initial stage to be the strongest 
independent significant prognostic factor for tumor recurrence during follow-up. 
The Leiden University Medical Center is a reference center for patients with 
relatively complicated DTC, which is reflected in the high number of patients 
(n=44) with M1 disease at initial stage. In 12% of the patients with initially M0 
disease tumor recurrence was seen during follow-up, which is in agreement with 
previous publications by others [10-12]. All patients had been treated by near-
total thyroidectomy and subsequent ablation with radioiodine approximately 6 
weeks after surgery. In a recent report [3], we have described that the use of 
rather low ablation doses results in failure rates up to 60% and, consequently, in 
a high number of additional treatments up to more than a year after initial 
operation. Although a relation between the initial treatment failure and recurrent 
disease was suggested, this could not be established in the present study, as 
differences in failure rates between patients with and without recurrent DTC 
were not statistically significant. This finding is in agreement with the data 
published by Falvo et al. [13]. 
In a recent report by Haigh et al. it was shown that survival of patients with 
DTC was not significantly influenced by the extent of initial thyroidectomy [14]. 
The authors found 10-year survival rates of 72 and 78% respectively for total 
and partial thyroidectomy. In contrast to these results, however, Cushing et al. 
[15] reported on the prognostic value of the extension of initial surgery. They 
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studied 333 patients with a mean age of 39.7 years and found that a total 
thyroidectomy revealed better results than a near-total or partial thyroidectomy. 
Regarding the number of patients with advanced disease at initial presentation in 
their study, it is not surprising that non-total thyroidectomy did not only result in 
a high frequency of large thyroid remnants, but also in a high number of patients 
with tumor remnants. 
The fact that the presence of lymph node metastases is a predictive factor for 
recurrence, irrespective of initial surgery (partial or total thyroidectomy) [16], 
again underlines the issue that an optimal assessment and subsequent resection 
of the total tumor mass at initial stage is highly important for prognosis and 
survival. In addition, subsequent treatment with radioiodine, therefore, is almost 
a prerequisite for an optimal starting point, especially in extensive disease, as it 
destroys normal thyroid tissue as well as small tumor remnants. Indeed, Haq et 
al. [17] clearly showed the superior value of a combined therapeutic approach 
over surgery alone. Despite the low number of patients with recurrent disease in 
the present study, we found a significant difference in N stage between patients 
with and without recurrent disease (p=0.001). 
Different staging classifications have been proposed over the past decades in 
hopes of a better identification of high risk patients, i.e. patients with bulky 
disease. In this respect, the TNM tumor staging system is still the most 
commonly used system. Although it can be used to differentiate low-risk from 
high-risk patients, it was found to be less valuable in identifying intermediate-
risk groups [10;18]. The age for men, gender and histological subtype (AMES) 
classification, a system based on age, gender, and histological parameters, as 
well as the European Organization for Research and Treatment of Cancer 
(EORTC) classification were both tested in a prognostic study on 499 DTC 
patients by Jukkola et al. [10], revealing that these methods were not 
reproducible. Finally, the metastasis, age, completeness of resection, local 
invasion, tumor size (MACIS) scoring classification, which is based on age, 
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tumor size, incomplete surgery, extra-thyroidal invasion, and distant metastases, 
was found to leave the definition of the intermediate and high risk groups too 
wide. Consequently, most of the staging classifications are found to have more 
or less practical limitations. 
One of the most well-known prognostic parameters is age at the time of 
diagnosis. In this respect, we observed not only a significant difference between 
patients with M0 disease (42.6 years) and those with M1 disease (61.9 years; 
p=0.001), but also between M0 tumor stage patients with (50.7 years) and 
without (41.5 years; p=0.013) recurrent disease. Falvo et al. [13] performed a 
study on biologically aggressiveness of DTC in elderly patients, in which an age 
exceeding 70 years represented the most unfavorable prognosis. Haq et al. [17] 
reported a comparable age of 70 years and older in relation to a poor outcome. 
Both Volante et al. [19] and Siironen et al. [20] described an age of >45 years in 
close relation to an aggressive tumor behavior. Based on the present data, 
however, it can be concluded that age at initial diagnosis is indicative for tumor 
extension, but it is not an independent prognostic parameter that can be used to 
identify patients with a high risk for tumor recurrence. Indeed, regarding age, 
the overlap between the subgroups defined is too much to be useful in clinical 
practice. 
As tumor extension at initial presentation is highly important for the assessment 
of prognosis and clinical outcome, it would be helpful to have a test that better 
reflects tumor burden than current staging and imaging techniques. In one of the 
most interesting publications on this subject, a clear relation between tumor 
burden and thyroglobulin levels was described [21]. The authors reported not 
only that the number of metastatic lesions was linked with serum Tg/TSH levels, 
but also their total volume. The diagnostic value of Tg was confirmed and 
established in subsequent reports and it was demonstrated that the value of 
stimulated Tg levels, i.e. levels measured after hormonal withdrawal, clearly 
identifies persistent or recurrent disease. In a study by Giovanella et al. [11], 
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post-surgery Tg levels above 4.5 µg/l identified 94% of patients with 
metastasis, which, according to the authors, could be taken into account in 
treatment planning. Bernier et al. showed that Tg levels measured at the time of 
ablation and 5 days later expressed as TgD5/TgD0 ratio were highly suggestive 
for treatment failure [22]. The larger the ratio, the better the final outcome. In 
other studies, Tg levels measured at 3 or 6 months after ablation were found to 
be strongly correlated with metastatic disease and the authors concluded that 
levels measured at these time intervals are indicative for an intensive follow-up 
scheme or additional treatment [23;24]. Others have shown that the best positive 
predictive value for the detection of a local recurrence is brought by the slope of 
the Tg levels [25;26]. Finally, Kim et al. [27] showed that Tg levels measured at 
the time of immediate postoperative 131I remnant ablation correlated well with 
serum Tg levels at the time of diagnostic whole-body scanning during follow-
up. High Tg levels were indicative for tumor persistence or recurrence of disease 
in the earliest postoperative period.  
Under normal circumstances, i.e. in normal thyroid tissue, an optimal re-uptake 
and storage mechanism should prevent leakage of Tg into the bloodstream. In 
clinical practice, however, it has been found that this physiologic mechanism is 
not fulfilling this task completely with measurable Tg levels as a consequence in 
patients with normal function of the thyroid gland. Increased Tg production and 
a distortion of the physiological process, as seen in infection and malignancy, 
results in a misbalance and in increased serum Tg levels compared with normal 
circumstances, a phenomenon that is enhanced by TSH stimulation. Indeed, 
from data in literature, it is known that Tg measurements after hormonal 
withdrawal have a higher accuracy than Tg-on levels in the detection of 
malignancy. In this respect, a TSH stimulation >20 U/l is regarded as 
prerequisite for an optimal Tg measurement. In general, patients who are 
admitted for ablation with radioiodine have normal thyroid tissue remnants in 
the neck region. Despite the optimal TSH stimulation at that time to facilitate an 
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optimal 131I uptake, Tg levels should be relatively low in the case of a normal 
function of the remnant, as the re-uptake and storage mechanisms are intact. On 
the other hand, the levels may be significantly increased in remnants harboring 
malignant cells. In the present study, we have evaluated whether an increased Tg 
level is caused by a large nearly stimulated thyroid remnant or a small remnant 
with stimulated thyroid cancer cells. For this purpose, we have normalized the 
Tg levels for both the amount of functional thyroid tissue, expressed in a 24-h 
uptake value, and the amount of TSH stimulation. Although we used a low dose 
131I 24-h uptake scan before therapy, it has become more and more common 
practice to perform a post-therapy scan with uptake measurements over the neck 
region. In this respect, one of the major issues for discussion is the possible 
stunning effect that may occur even when using activities of 131I in the range of 
40 MBq [7-9]. Since therapeutic activities of 131I are nowadays more based on 
tumor stage instead of uptake values, post-treatment uptake values may be 
advised for prognostic stratification to avoid stunning effects by pre-treatment 
scans. 
We found significant differences in Tg levels at initial presentation between 
patients with (mean level, 8 µg/l) and without (mean level, 120 µg/l) recurrent 
disease during follow-up, whereas TSH stimulation and 24-h uptake values were 
not different. In the univariate analysis, T and N stage were significantly 
different between the two groups, but, using the stepwise forward multivariate 
analysis, Tg/(TSHx24-h uptake) remained the most significant independent 
parameter, irrespective of N and T stage. Moreover, except from age, we did not 
find significant differences in all parameters tested between patients with 
initially M1 disease and patients with M0 stage demonstrating recurrent disease 
during follow-up. Even the newly defined parameters that were based on Tg 
levels did not show any significance anymore, suggesting that high values 
indicate bulky DTC. Consequently, patients with M0 stage and high 
Tg/(TSHx24-h uptake) ratios at initial presentation should be regarded as 
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patients with initially M1 disease and therefore be treated with higher 131I doses. 
In addition, a close clinical follow-up scheme is recommended for these 
patients. Finally, it has to be realized that at severe malignancy the Tg 
production may be low and not high as found in the present study, which may 
cause a false negative effect on this new parameter. In such cases, radioiodine 
uptake is often also severely diminished, as the expression of the sodium-iodine 
symporter is commonly the first factor being affected in a dedifferentiation 
process of thyroid cancer. This condition, however, is very rare at initial 
presentation, whereas such features are more common in anaplastic tumors, 
which were excluded in the present study. 
 
Conclusion 
In the present study, we have evaluated the prognostic value of clinical and 
biochemical parameters measured at the time of ablation for DTC. Based on 
these values, we have defined a new parameter, Tg/(TSHx24-h uptake), which 
was hypothesized to be a better prognostic indicator for the presence of 
malignant cells after total or near-total thyroidectomy for DTC. Although T 
stage, N stage, age at the time of diagnosis, and standard biochemical values 
significantly differ between patients with and without recurrent disease or 
between patients with M0 and M1 tumor stage, the newly defined parameter was 
the best independent significant prognostic parameter in the assessment whether 
patients will develop a tumor recurrence during follow-up or not. From the 
present data, it can be concluded that high ratios justify an adjustment of the 131I 




1. Utiger RD. Follow-up of patients with thyroid carinoma. New England Journal of 
Medicine 1997; 44:493-495. 
2. Stojadinovic A, Shoup M, Nissan A, Ghossein RA, Shah JP, Brennan MF, Shaha AR. 
Recurrent differentiated thyroid carcinoma:biological implications of age, method of 
detection, and site and extent of recurrence. Annals of Surgical Oncology 2002; 9:789-
798. 
3. Verkooijen RBT, Stokkel MPM, Smit JWA, Pauwels EKJ. Radioiodine-131 in 
differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation 
strategy. European Journal of Nuclear Medicine and Molecular Imaging 2004; 31:499-
506. 
4. Maxon HR III, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith 
H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differentiated thyroid 
cancer a quantitive radiation dosimetric approach: outcome and validation in 85 patients. 
Journal of Nuclear Medicine 1992; 33:1132-1136. 
5. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas J, Jamar F, Jarzab B, 
Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W. Post-surgical use 
of radioiodine ( 131I) in patients with papillary and follicular thyroid cancer and the issue 
of remnant ablation: a consensus report. European Journal of Endocrinology 2005; 
153:651-659. 
6. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European 
consensus for the management of patients with differentiated thyroid carcinoma of the 
follicular epithelium. European Journal of Endocrinology 2006; 154:787-803. 
7. Dam HQ, Kim SM, Lin HC, Intenzo CM. 131I therapeutic efficacy is not influenced by 
stunning after diagnostic whole-body sanning. Radiology 2004; 232:527-533. 
8. Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on 
the biokinetics of thyroid remnants. Journal of Nuclear Medicine 2004; 45:619-625. 
9. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the 
controversy of thyroid stunning. Nuclear Medicine Communications 2004; 25:883-889. 
10. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated 
thyroid carcinomas and their implications for current staging classifications. Endocrine-
Related Cancer 2004; 11:571-579. 
11. Giovanella L, Ceriani L, Bhelfo A, Keller F. Thyroglobulin assay 4 weeks after 
 106
A new functional parameter to predict DTC recurrence during follow-up 
  
thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clinical 
Chemistry and Laboratory Medicine 2005; 43:843-847. 
12. Lo CY, Chan WF, Lam KY, Wan KY. Follicular thyroid carcinoma: the role of histology 
and staging systems in predicting survival. Annals of Surgery 2005; 242:707-715. 
13. Falvo L, Catania A, Sorrenti S, D'andrea V, Berni A, De Stefano M, De Antoni E. 
Prognostic significance of the age factor in the thyroid cancer: statistical analysis. Journal 
of Surgical Oncology 2004; 88:217-222. 
14. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant 
of survival in low- or high-risk papillary thyroid cancer. Annals of Surgical Oncology 
2005; 12:81-89. 
15. Cushing SL, Palme CE, Audet N, Eski S, Walfish PG, Freeman JL. Prognostic factors in 
well-differentiated thyroid carcinoma. Laryngoscope 2004; 114:2110-2115. 
16. Borson-Chazot F, Causeret S, Lifante J, Augros M, Berger N, Peix J. Predictive factors 
for recurrence from a series of 74 children and adolescents with differentiated thyroid 
cancer. World Journal of Surgery 2004; 28:1088-1092. 
17. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at 
presentation: prognostic factors and outcome. Clinical Endocrinology 2005; 63:87-93. 
18. Rodriquez-Cuevas S, Labastida-Almendaro S, Cortes-Arroyo H, Lopez-Garza J, Barroso-
Bravo S. Multifactorial analysis of survival and recurrences in differentiated thyroid 
cancer. Journal of Experimental and Clinical Cancer Research 2002; 21:79-86. 
19. Volante M, Cavallo GP, Papotti M. Prognostic factors of clinical interest in poorly 
differentiated carcinomas of the thyroid. Endocrine Pathology 2004; 15:313-317. 
20. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, Haglund C. 
Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. 
Tumor Biology 2005; 26:57-64. 
21. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli 
JP, Schlumberger M. Relationship between tumor burden and serum thyroglobulin level 
in patients with papillary and follicular thyroid carcinoma. Thyroid 2002; 12:707-711. 
22. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, Jeanguillaume C, 
Bigorgne JC, Jallet P. Prognostic value of an increase in the serum thyroglobulin level at 
the time of the first ablative radioiodine treatment in patients with differentiated thyroid 
carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2005; 
32:1418-1421. 




24. Hall FT, Beasly NJ, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Predictive value of 
serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003; 113:77-81. 
25. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive 
predictive value of serum thyroglobulin levels, measured during the first year of follow-
up after thyroid hormone withdrawal, in thyroid cancer patients. Journal of Clinical 
Endocrinology and Metabolism 2003; 88:1107-1111. 
26. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, 
Boichot C, Cochet A, Brunotte F. Predictive value for disease progression of serum 
thyroglobulin levels measured in the postoperative period and after (131I) ablation 
therapy in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 2004; 
45:988-994. 
27. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK. Serum 
thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are 
useful of early prediction of clinical recurrence in low-risk patients with differentiated 




















The incidence of second primary tumors in thyroid 
cancer patients is increased, but not related to 





























Robbert B.T. Verkooijen, Jan W.A. Smit, Johannes A. Romijn, Marcel P.M. Stokkel. 







   
Chapter 6 
Abstract 
Objective: The aim of the present study is to assess the prevalence of second 
primary tumors in patients treated for thyroid cancer. Furthermore, we wanted to 
assess the standardized risk rates for all second primary tumors, but especially 
for breast cancer, as data in the literature indicate an excessive risk in 
differentiated thyroid cancer (DTC) patients for this tumor. 
Materials and methods: We included consecutive patients, who received 
ablation treatment with 131I at the Leiden University Medical Center between 
January 1985 and December 1999 (n=282). The mean period of follow-up was 
10.6±4.1 years. 
Results: Thirty-five of the 282 patients (12.4%) had a second primary tumor 
(SPT), either preceding or following the diagnosis of thyroid cancer. Five other 
patients had three primary tumors, including DTC. As a result, 40 additional 
tumors were found in this group, revealing an overall prevalence of 14.2%. 
Twenty tumors (7.1%) preceded the thyroid cancer with a mean interval of 5.7 
years (range: 0.5-22.0 years), whereas 20 tumors (7.1%) occurred after this 
tumor with a mean interval of 6.7 years (range: 1.0-15.0 years). In 13 female 
patients, breast cancer was found as SPT. The standardized incidence rate (SIR) 
for all cancers after the diagnosis of DTC in this study population was not 
increased (1.13; confidence interval (CI): 0.68-1.69). However, we found an 
increased SIR of 2.26 (CI: 1.60-3.03) for all cancers either following or 
preceding DTC, which is mainly caused by a SIR of 3.95 (CI: 2.06-6.45) for 
breast cancer. 
Conclusion: Patients with DTC have an overall increased standardized incidence 
rate for second primary tumors, but not for second primary tumors following 131I 
therapy. These findings suggest a common etiologic and/or genetic mechanism 
instead of a causal relation. 
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Introduction 
Differentiated thyroid cancer (DTC) is the most frequent endocrine gland 
malignancy accounting for approximately 0.5-1.5% of all malignancies. The 
overall survival rate is high and currently even close to 99% in papillary 
carcinomas [10;22]. The standard treatment for DTC is a (near-) total 
thyroidectomy followed by ablation therapy using high doses of radioiodine-131 
(131I), except in small papillary thyroid cancer or minimal invasive follicular 
carcinomas. Although many reports have focused on the relationship between 
131I administration and the occurrence of second primary tumors, some studies 
found [e.g. 19] a relationship between 131I administration and the occurrence of 
bone and soft tissue, colorectal and salivary gland cancers. Other studies 
reported an overall increased incidence of breast and kidney cancer among 
women treated for thyroid cancer, but this was not related to the exposure of 131I 
[6;20;23]. 
The aim of the present study is to assess the prevalence of second primary 
tumors in patients treated for thyroid cancer using an uptake-related ablation 
strategy. Furthermore, we wanted to assess the standardized risk rates for all 
second primary tumors, but especially for breast cancer, as data in literature 
indicate an excessive risk in DTC patients for this tumor. 
 
Materials and methods 
We included consecutive patients, who received ablation treatment with 131I at 
the Leiden University Medical Center (LUMC) between January 1985 and 
December 1999 (n=282) for DTC. This period was selected, as since 1985 
standardized ablation doses were given. The mean period of follow-up was 10.6 
±4.1 years. From the medical files, age, gender, histopathological data, ablation 
dose, and subsequent 131I treatments were recorded. Furthermore, data with 
respect to second primary tumors were gained, including site and interval. 
In addition, malignancies preceding the diagnosis of DTC were recorded. 
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However, in situ and basal cell carcinomas were excluded. All information with 
respect to malignancies was obtained from the medical records as well as from 
the central hospital registration system for malignancies. This oncology 
documentation system, the ONCDOC, gathers information about tumors, 
follow- up, recurrences, second primaries, therapeutic interventions, survival, 
etc. To define the extent of thyroid carcinomas, the sixth edition of the tumor, 
node, metastasis (TNM) staging was used. 
The ratio of the observed (O) numbers to the expected E) number (i.e. the 
standardized incidence ratio; SIR) was computed using cancer incidence data 
from the general population. These specific incidence rates were derived from 
the Dutch national cancer registry (www.ikcnet.nl) by gender, 5- and 15-year 
age groups and were multiplied by the accumulated person-years in the study 
cohort to estimate the expected number of cancer cases. 
 
Radioiodine treatment 
The mean interval between a thyroidectomy and the ablative treatment in the 
present population was 5.4 ±4.0 weeks. During this interval, patients did not 
receive any thyroid hormone supplementation with the aim of increasing the 
thyroid-stimulating hormone levels. All patients treated from 1992 were put on a 
low-iodine diet that started 4 days prior to ablation to facilitate an optimal 
uptake of 131I in the thyroid remnant. Before 1992, low-iodine diets were not 
routinely prescribed [15]. 
The ablation dose of 131I was determined by the 24-h 131I pre-treatment uptake 
value in the neck region. Therefore, patients received 40 MBq of 131I orally, 
which was followed by planar scintigraphy of the neck region 24 h later. Uptake 
values less than 5%, between 5 and 10%, and values more than 10% were 
followed by 2800, 1850, and 1100 MBq of 131I in one dose respectively. The 
rationale of this uptake-related approach is to avoid unnecessary exposure and 
local radioiodine side effects [25]. 
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Overall, we treated 282 patients, 219 female, and 63 male (age 47.5 ±17.5 
years). During long-term follow-up, 64 patients died. The mean period of 
follow-up was 10.6 ±4.1 years. Tumor characteristics are presented in Table 1, 
demonstrating that T2, N0 tumor stage and papillary thyroid cancer were most 
frequently observed. 
The mean 24-h 131I uptake was 6.3 ±7.7%. The mean ablation dose given was 
2616 ±1103 MBq of 131I, whereas the overall cumulative dose given ranged 















































24 hr 131I Uptake (%) 6.3 (±7.7) 
Mean 131I ablation dose (MBq) (SD) 




7657 (1100 – 49000) 
 
T-stage, tumor stage; N-stage, node stage; M-stage, metastasis stage.  
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Additional tumors 
Overall, 35 patients (12.4%) had a second primary tumor either preceding or 
following the thyroid cancer (Table 2). Five other patients had three primary 
tumors, including DTC, according to the medical files. As a result, in 40 patients 
additional tumors were found in this group, revealing an overall prevalence of 
14.2%: 20 tumors (7.1%) preceded the thyroid cancer with a mean interval of 
5.7 years (range: 0.5-22.0 years) and 20 tumors (7.1%) occurred after this tumor 
with a mean interval of 6.7 years (range: 1.0-15.0 years). In 13 out of 219 
female patients (5.9%), breast cancer was documented. Regarding the mean 
period of follow-up of 10.6 years, we found an overall prevalence of 0.67% of 
second primaries per year following DTC and 0.5% per year when excluding 
breast cancer. Finally, the total follow-up years, defined as the mean period of 
follow-up times the number of patients studied, was 2989 years. Regarding this 
parameter, it resulted in an overall prevalence for second primaries following 
DTC of 0.0024 and 0.0018% per person follow-up year with and without breast 
cancer respectively. 
In Table 3, the standardized incidence ratios are described. The SIR of second 
primary tumor (SPT), following treatment of thyroid cancer was not increased 
(1.13; 95% CI: 0.68-1.69). However, the SIR of all SPT, i.e. including all 
cancers occurring before as well after the diagnosis of DTC, was increased 
(2.26; 95% confidence interval (CI): 1.60-3.03). This was mainly due to an 






































































13 (4 – 22) 
4.3 (2 – 10) 
3.3 (0.5 – 6) 



















































6.6 (2 – 11) 
4 (1 – 7) 
8.5 (2 – 15) 
7 








Overall 20  5.7 (0.5 - 22) Overall 20  6.7 (1 – 15) 
 
Table 3. Ratio of observed to expected second primary tumors (SPT) following differentiated thyroid cancer (DTC) 
and both preceding and following differentiated DTC. 
 
Site of SPT 

































































0.01 – 0.62 
0.46 – 3.18 
0.06 – 0.82 
0.62 – 3.06 
0.01 – 2.52 
0.01 – 3.81 
- 




























0.01 – 3.45 
0.08 – 1.15 
2.06 – 6.45 
0.23 – 1.30 
0.92 – 3.68 
0.11 – 3.67 
0.51 – 7.11 
- 
1.60 – 3.03 
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Oi, observed number of second primary tumors; Ei, expected number of second primary tumors; SIR, standardized  






Patients with DTC have a very good prognosis, which is achieved by surgery 
and postoperative ablation with 131I therapy. Our data indicate that this treatment 
is not associated with increased incidence of malignancies following treatment 
of DTC. However, the data indicate that there is an increased incidence of 
second primary tumors in thyroid cancer patients if we consider their lifetime 
risks for cancer, especially of breast cancer. 
Regarding the incidence and prevalence of SPT in general, an 1/3 rule has been 
hypothesized, which means that approximately 33% of the patients with a 
malignancy will develop an SPT, 33% of these patients with an SPT a third 
malignancy, and so on [17]. A well-described phenomenon, in this respect, is the 
field cancerization concept, which states that organ systems exposed to the same 
carcinogenic agents have a greater chance of transforming into a malignancy. 
One of the most striking examples of this concept is the combination of head 
and neck cancer with lung malignancies [8]. Another explanation for SPT may 
be the presence of a genetic base for multiorgan cancer [7]. These authors 
studied a multiorgan cancer susceptibility gene, the CHEK2 protein, in 4008 
cancer cases and 4000 controls. This CHEK2 protein participates in the DNA 
damage response in many cell types. The missense variant I157T was associated 
with an increased risk of breast cancer, colon cancer, kidney cancer, prostate 
cancer, and thyroid carcinoma. Therefore, the authors concluded that cancers 
associated with mutations of the CHEK2 gene might be much greater than 
previously thought. 
In some studies, an increased incidence of breast carcinoma has been suggested 
in women with thyroid carcinoma. Vassilopoulou-Sellin et al. [24] published 
one of the first studies on this, including 41686 patients with breast carcinoma 
and 3662 with thyroid carcinoma, which were retrospectively analyzed. Among 
18931 women with a diagnosis of breast carcinoma, 11 developed DTC more 
than 2 years after the initial diagnosis of breast cancer. The observed incidence 
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of DTC was not different from that in a similar group of women without breast 
cancer. Among 1013 women with a diagnosis of thyroid carcinoma, 24 
developed breast cancer more than 2 years after the primary tumor. In that 
group, the observed incidence of breast cancer in women of age 40-49 years was 
significantly higher than the expected incidence for women in the same age 
group. However, in a study by Sadetzki et al. [20], opposite results were 
observed. This group found an overall significant elevated risk for DTC 
following breast cancer in 49 207 female studied. The observed number of cases 
of DTC after breast cancer was 59, revealing a standardized incidence ratio of 
1.34 (95% CI: 1.03-1.72), as the expected number of cases was 43. This ratio 
was 1.07 for breast cancer following DTC. In addition, the authors concluded 
that considering the long latency required for carcinogenesis and the excess risk 
of SPT soon after the index tumor argues against the hypothesis of primary 
tumor treatment as initiator. The authors suggested that early exposure to 
common risk factors or genetic susceptibility for both malignancies to be 
plausible. Cengiz et al. [6] observed an increased frequency of thyroid 
pathology in breast cancer patients compared with controls, but it has to be 
realized that the high percentage of thyroid disorders in that study might be 
related to the fact that Turkey is an endemic region for thyroid diseases. In a 
study by Simon et al. [23], only women with a history of thyroid cancer were 
found to have an increased risk, but this was restricted to parous women. The 
overall odds ratio in this respect was 3.5 (95% CI: 1.5-8.1). However, they 
concluded that, despite the increased incidence, there was no association 
between thyroid cancer treatment and the risk on breast cancer. Finally, Pal et al. 
[14] performed a study on double primary cancers of the breast and thyroid in 
women and assessed a molecular and genetic base. 
Their data did not support the hypothesis that a significant proportion of double 
primary cancers are due to hereditary factors. In the present study, we found a 
standardized incidence ratio of 1.52 (95% CI: 0.46-3.18) for breast cancer 
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comparable with the data published by Berthe et al. [4]. Moreover, an increased 
overall incidence (the SIR increases up to 3.95 (95% CI: 2.06-6.45) for breast 
cancer in thyroid cancer patients was observed, when taking also the tumors 
preceding DTC into account. Based on data in literature, it is highly unlikely 
that ionizing radiation is involved in the genesis of breast cancer in DTC 
patients. Genetic predisposition and probably environmental factors seem to be a 
better explanation for the coincidence, as at least half of the breast tumors 
appear before treatment with 131I for DTC. 
A relation between the total dose of 131I and SPT has been reported for solid 
cancers and leukemias with increasing cumulative activity of the dose 
administered [19]. The question remains whether this is related to the 
administration of 131I solely or also to an increased organ sensitivity for 
carcinogens in general. Hemminki et al. [11] described an increased risk of 
cancer by site and histopathology, in which familial risks with SIRs over 4.0 
were found for ovary cancer, thyroid cancer, and clear cell carcinoma. For this 
purpose, they used a nationwide Swedish Family cancer database on 10.2 
million individuals and 1 million tumors to calculate SIRs for familial cancers. 
Their results called for a closer description of tumor-susceptibility genes. It was 
the group of Fisher, who firstly studied the expression of five gene family 
members in relation to different cancers [9]. It is beyond the scope of this article 
to report on these findings in detail, but an important finding was the 
observation of significantly elevated expression levels of osteopontin in cancer 
of the breast, ovary, uterus, and thyroid compared with normal tissue levels. In 
this study, the relative mRNA expression units quantified using ImageQuant for 
normal tissue and these tumor subtypes were as follows: 18000 and 54000 
respectively, for normal breast tissue and breast cancer: 14000 and 70000 
respectively, for normal tissue of the uterus and cancer of the uterus: 20000 and 
126000 respectively, for normal ovary tissue and ovary cancer: 4000 and 16000 
respectively, for thyroid tissue and thyroid cancer. Especially, the relation 
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between these glycoproteins and matrix metalloproteinases, critical for the 
development of wound healing and cancer progression, is suggestive for a 
common genetic base. Ronckers et al. recently published a large report on 
thyroid cancer and multiple primary tumors [18]. They studied the risk of 
thyroid cancer after an earlier primary cancer, as well as the risk of developing 
multiple cancers after an earlier thyroid cancer in the US, using the cancer 
registry program of more than 2 million patients. They observed an absolute 
excess risk for all cancers following DTC of 7.64, which is mainly based on an 
increased risk for female breast, prostate, and kidney cancer. Breast cancer 
contributed 36% of all second cancers after DTC. Patients <40 years of age at 
diagnosis of DTC had a 39% increased risk of a second cancer, whereas for 
older patients this was 6%. On the other hand, breast cancer patients had a 1.3-
fold risk of developing DTC. Several other cancer sites showed significantly 
increased risks in both directions, including salivary glands, prostate, breast, 
kidney, scrotum, brain, and leukemia. Although 131I therapy may play a role in 
the induction of some of these tumors, the high incidence of tumors preceding 
DTC suggest etiologic similarities. Finally, Adjadj et al. [1] reported 
comparable results obtained from 2365 women who were treated for thyroid 
carcinoma. In this series, 48 women developed subsequent breast carcinoma, 
revealing an overall SIR of 1.3, but even up to 2.5 for patients treated at an age 
ranging from 4 to 30 years. The authors did not find a correlation between the 
high SIR and radiation treatment with 131I, but the co-occurrence may be related 
to a genetic deregulation, as the H23 gene, which is overexpressed in both DTC 
and breast cancer. It is still not clear why the gene coding for H23 antigen 
mRNA is overexpressed in these cancers. As one of its forms is probably a 
transmembrane receptor-like protein, it may be an element of signal transduction 
and, therefore, reflect an involvement in cell growth [26;27]. 
Recent reports have focused on malignancies within the scope of certain cancer 
syndromes. Mutations in MLH1 and MSH2, genes coding for mismatch repair 
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enzymes that are involved in the repair of DNA replication errors, are associated 
not only with an increased risk of hereditary nonpolyposis colorectal cancer, but 
also with other malignancies, such as cancer of the stomach, urinary tract, and 
thyroid. [5;12;13]. It may be an explanation for some of the present findings 
related to thyroid cancer. However, a correlation between MSH2 mutations and 
breast cancer as SPT in thyroid cancer patients, or vice versa, has never been 
described. Another gene that is associated with cancer syndromes is the PTEN 
gene, which is located on chromosome 10q23. This phosphatase suppressor 
tumor gene downregulates cell survival through apoptosis and/or G1 cell cycle 
arrest. It is characterized by an increased risk of benign and malignant tumors of 
the breast, thyroid, and endothelium [2;3;16]. Consequently, these studies stress 
the need to better screen for clonal PTEN rearrangements and gene mutations, 
especially in DTC patients presenting with second primaries of the breast. 
Recently, Sandeep et al. published a large multinational record linkage study on 
second primary cancers in thyroid cancer patients [21]. The study was conducted 
at 13 population-based cancer registries in Europe, Canada, Australia, and 
Singapore and included a cohort of 39002 patients with primary thyroid cancer. 
During an observation period of 356035 person-year, 2821 second primary 
tumors were observed resulting in an overall SIR of 1.31 (CI: 1.26-1.36). 
Remarkable increased incidence rates were found for cancer of the oral cavity 
(SIR: 1.43), small intestine (SIR: 2.11), bone (SIR: 3.62), soft tissue sarcoma 
(SIR: 3.63), kidney (SIR: 2.33), endocrine glands (SIR: 6.75), lymphoma (SIR: 
1.68), and leukemias (SIR: 2.26). The SIR for breast cancer was 1.31, which is 
definitely lower than present findings. However, this discrepancy can be fully 
ascribed to the differences in number of patients studied and in period of follow-
up. The group of Sandeep et al. also found and increased incidence of second 
primary thyroid cancer after cancers of the lung, larynx, esophagus, and salivary 
gland. Although a relation between initial treatment, such as radiotherapy, for 
the index tumor and subsequent thyroid cancer may be suggested, the short 
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interval and age of initial treatment do not support this hypothesis. Nevertheless, 
we fully ascribe their conclusion that clinicians should maintain a high index of 
suspicion, both for second primaries following treatment for thyroid cancer and 
for cancer of the thyroid as SPT. 
A limitation of our study is the small number of patients included in the 
database. Patients who received ablation treatment with 131I at the LUMC 
between January 1985 and December 1999 were selected for analysis. The mean 
period of follow-up is more than 10 years, which gives a good estimate of the 
relative risk and its relation to the induction of SPT. In most other series on this 
subject, the interval between therapy and the occurrence of a therapy-related 
SPT is up to 5 years.  
In conclusion, we studied the incidence of second primary tumors in relation to 
DTC and found an overall increased SIR for all cancers, but especially for breast 
cancer. Despite the relatively small number of patients studied, the present 
results are highly suggestive for a common etiologic and/or genetic mechanism. 
In this respect, further study is required, but in agreement with recently 
published data by others, close clinical follow-up of thyroid cancer patients may 
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In this prospective study, we evaluated the diagnostic and prognostic value of 
111In-octreotide scintigraphy (SRS) in papillary and follicular thyroid carcinoma 
(DTC) with increasing thyroglobulin (Tg) levels but no response to treatment 
with 131I. Twenty-three consecutive patients (13 female, 10 male; mean age 55 
years, range 13-81 years) with progressive DTC were selected for the study. All 
patients had non-functioning metastases, defined by no or slight uptake of 131I in 
metastases. Diagnosis of tumor progression was based on rising Tg levels during 
follow-up and was confirmed by radiological examination. Uptake on SRS was 
scored from 0 to 4. Data on initial tumor stage, histology, age, gender, Tg levels, 
TSH levels, 131I treatment doses, intervals and survival were gathered. Seven 
patients died during follow-up. The overall sensitivity for the detection of 
metastases was 74%. The sensitivity was better in patients in whom 131I whole-
body scintigraphy did not show any abnormal uptake (82%;14/17) than in 
patients with faint 131I uptake (50%; 3/6). The 10-year survival rate was 
significantly different between patients with an uptake score of 0 or 1 (100%) 
and those with an uptake score of 2, 3 or 4 (33%) (p=0.001). Gender, log Tg and 
uptake on SRS significantly correlated with survival, but in stepwise analysis, 
111In-octreotide uptake was selected as the most prognostic independent variable 
(hazard rate 6.25, p=0.006). We conclude that 111In-octreotide scintigraphy is a 
valuable clinical tool for the detection of non-functioning DTC metastases. The 
uptake seems to correlate with prognosis and survival. 
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The prognosis of well-differentiated thyroid cancer is very good, with a 10-year 
survival rate ranging from 85% to 93% [1-3]. In a minority of patients, how- 
ever, a variable degree of dedifferentiation may occur, accounting for a poorer 
outcome. This dedifferentiation is seen in approximately 50% of patients with 
distant metastases [4;5]. In such cases, tumor cells lose their radioiodine (131I) 
uptake capability, which is usually associated with an increased growth rate and 
a larger tumor load [6]. As a consequence, whole-body scintigraphy (WBS) with 
131I will yield false negative results, whereas in most cases rising thyroglobulin 
(Tg) levels will be measured during follow-up. For optimal follow-up and 
accurate Tg quantification in such cases, TSH stimulation is required, which can 
be achieved by either discontinuation of hormonal replacement or recombinant 
TSH administration. Radiological techniques such as ultrasonography of the 
head and neck region, chest X-rays or CT scanning are valuable techniques to 
assess tumor recurrence or progression. However, small lesions with diameters 
of less than 1 cm may be missed [7-9]. Positron emission tomography (PET) 
using fluorodeoxyglucose (FDG) can be used to demonstrate tumor recurrence 
or small lesions in the head and neck region. However, tumors in the chest with 
a diameter of less than 1 cm may also be missed by this technique [7;10;11]. In 
addition, systemic treatment options for patients with multiple metastases are 
scarce and therefore alternative techniques are required which give the option of 
visualising but also treating patients with iodine-negative differentiated thyroid 
cancer (DTC) metastases [12;13]. 
Somatostatin receptor scintigraphy (SRS) has established its diagnostic value in 
tumors and metastases which express somatostatin receptors (SSTR), such as 
neuroendocrine tumors [14-16]. In recent reports, high expression of SSTR5 was 
described in papillary thyroid cancer, which offers an opportunity to visualise 
such tumors with octreotide [17;18]. 
In the present prospective study, we evaluated the diagnostic value of 111In-
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octreotide in differentiated thyroid carcinoma with increasing Tg levels but no 
response to treatment with 131I. Furthermore, we studied the prognostic value of 
111In-octreotide scintigraphy in different subgroups. 
 
Materials and methods 
Patients. Twenty-three consecutive patients (13 female, 10 male) (mean age 55 
years, range 13-81 years) with progressive, 131I non-responsive DTC were 
selected for this study. All patients had non-functioning metastases, as defined 
by increased Tg levels and no or slightly elevated 131I uptake on post-treatment 
whole-body scans. Slightly elevated uptake was defined as uptake that could 
hardly be distinguished from background activity. Diagnosis of tumor pro-
gression was based on rising Tg levels and was confirmed by radiological 
examination. The mean interval between the last treatment with 131I and 
scintigraphy with 111In-octreotide was 15 months (SD ±7 months). The mean 
interval between scintigraphy with 111In-octreotide and initial diagnosis was 4 
years. All patients were on hormonal replacement therapy at the time of 
scintigraphy and had relatively low Tg and TSH levels. In some patients with 
disease progression, chemotherapy (generally a combination of adriamycin, 
cisplatinum and/or bleomycin) was administered in an attempt to palliate the 
condition. Data on initial tumor stage, histology, age, gender, Tg levels, TSH 
levels, 131I treatment doses, intervals and survival were gathered. The initial 
(clinical) N stage was based on physical examination, ultrasonography of the 
neck and close clinical follow-up for 1 year (N0). A modified neck dissection 
was performed in patients with clinically palpable lymph nodes or enlarged 
nodes detected by ultrasonography. N1 stage at the time of diagnosis was 
confirmed by histological examination of the neck dissection specimen. The 
initial M stage was based on post-treatment WBS (after ablation with a high 
dose of 131I) as well as follow-up 131I WBS up to 1 year after initial treatment. 
Radiological examination (CT scan, chest X-ray or MRI) was used to confirm 
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the presence of distant metastases (M1) in cases of abnormal uptake outside the 
head and neck region. Patients with persistent elevated Tg levels 12 months after 
ablation without abnormal uptake on 131I WBS were scored as having NxMx 
tumor stage, as locoregional or distant micrometastases cannot be excluded in 
such cases. 
131I whole-body scintigraphy. WBS was performed 7 days after the oral 
administration of 7400 MBq of 131I (Mallinckrodt BV, Petten, The Netherlands). 
The run speed of the dual-head gamma camera (Toshiba GCA 7200, equipped 
with a high-energy collimator) was 15 cm per minute (matrix size 256x256). 
WBS was followed by anterior and posterior planar images of the head and neck 
and chest region (matrix size 256x256, preset time 10 min). 
Somatostatin receptor scintigraphy. SRS was performed 4 and 24 h after the 
injection of 200 MBq of 111In-octreotide (Mallinckrodt, Inc, St. Louis, 
Minnesota). The run speed was 10 cm per minute (Toshiba, GCA 7200, dual-
head gamma camera equipped with a medium-energy collimator) (matrix size 
256x1,024). As this is the minimum speed of the camera system used, 
singlephoton emission computerised tomography of the head and neck region 
and chest was additionally performed (matrix size 128x128) with a 6° step angle 
and a 1-min step time. Images were reconstructed with a Butterworth pre-
processing filter (8 order, 0.12 subset) and filtered back-projection. 
Analysis. Two experienced observers visually analysed all images. The uptake 
was scored according to the criteria described by Krenning et al., ranging from 0 
(=no uptake) to 4 (=intense uptake) [15]. All sites visualised on SRS and 
confirmed by radiological examination were recorded. In addition, sites that 
were seen on CT, MRI and/or ultrasonography, but missed on SRS, were record-
ed separately. Due to the fact that FDG-PET was not available to exclude 
smaller lesions than can be detected with radiological techniques, we decided to 
calculate the results on a patient basis and not based on the number of lesions. 
Quantitative variables were summarised with their mean, standard deviation and 
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range. Tg levels appeared to have a very skewed distribution and therefore their 
median value and range were reported. In subsequent analysis, log Tg was used. 
The comparison between the parameters studied was made using Student's t 
tests, Mann-Whitney U tests or Chi-square tests. Actuarial survival curves were 
calculated according to the Kaplan-Meier technique. Multivariate analysis with 
respect to survival was performed with the Cox regression model (stepwise 




In 11 out of 23 patients, distant metastases were already present at the initial 
stage, i.e. at the time of diagnosis of thyroid cancer, while in five patients, 
lymph node metastases were present at that time. Furthermore, in 15 patients the 
initial primary tumor (T) stage was T3 or T4, indicating advanced disease at the 
time of initial presentation. In ten patients, Tg levels and 131I WBS both nor-
malised as early as 6 months after ablation, which led us to stage these tumors as 
N0M0. Thirteen patients had papillary thyroid cancer and eight patients had 
follicular cancer. Finally, two patients had Hürthle cell carcinoma (Table 1). 
Seven patients died during follow-up. 
The uptake scored on the 111In-octreotide scans was as follows: 0, n=6; 1, n=8; 2, 
n=3; 3, n=3 and 4, n=3. The overall sensitivity for the detection of metastases on 
a patient basis was 74%. The sensitivity was better in patients in whom 131I WBS 
did not show any abnormal uptake (82%; 14/17) than in patients with slight 
uptake (50%; 3/6). As can be seen from Table 1, the most common sites 
containing metastases that were missed were the chest (n=8), spine (n=1) or 
head and neck region (n=2). In Figure 1, appearances in four patients exemplify-
ing the four uptake scores are shown. 
Using Cox regression analysis, log Tg (p=0.001), uptake (p<0.001) and gender 
(p=0.03) were selected as prognostic variable for survival. However, in stepwise 
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analysis, 111In-octreotide uptake was selected as the most prognostic variable for 
survival (hazard rate: 6.25; p=0.006). To increase the number of patients per 
subgroup, they were clustered: group 1 had an uptake score of 0 or 1 (no or 
slight uptake), whereas group 2 had an uptake score of 2, 3 or 4 (moderate to 
intense uptake). Gender, tumor stage (TNM), histology and the intervals 
between SRS and initial diagnosis as well as SRS and 131I WBS were 
comparable in the two groups (Table 2). The mean age was significantly lower 
in group 1, but this was due to patient number 15, who was 13 years old. 
Excluding her from the analysis, age was no longer significantly different 
(p=0.07). Tg levels were significantly different in the two subgroups. Although a 
correlation between Tg levels and uptake scores was expected, the Spearman's ρ 
was 0.67. Some of the patients with rather low Tg levels (patients 2 and 3) had 
high uptake scores, whereas some patients with high Tg levels, such as patients 
9 and 19, had low uptake scores. The 10-year survival rate was significantly 
different between the groups, being 100% in group 1 and 33% in group 2 



























 No Age 
(yrs) 





























1 68 M PTC T2N0M0 7 19.4 0.022 28809 3 B, Li, LR Lu  
2 81 M FTC T4N0M0 9 8.9 1.370 364 4 B, Lu - 
3 67 M PTC T4N0M1 2 27.2 0.694 967 3 B, Lu, C Spine 
4 66 M FTC T2N0M1 11 36.4 0.005 26700 3 B, Lu - 
5 55 M PTC T3N0M0 45 27.6 8.140 380 2 B, Lu - 
6 44 F FTC T4N4M1 2 34.8 0.039 4000 1 B, Lu, Li - 
7 67 F PTC T2N0M1 2 36.5 0.005 586000 4 B, Lu, Br - 
8 55 F PTC T3N1M0 11 38.7 0.032 350 0 - Lu, LR 
9 75 F FTC T2N0M0 8 45.4 0.283 14430 2 Lu - 
10 67 F PTC T4N1Mx 2 33.8 0.008 95 1 Lu Med 
11 53 F FTC  T3N0M0 85 36.5 0.005 73 2 Lu, Med - 
12 69 F PTC T4N0M1 5 30.7 0.459 1069 1 B, Lu - 
















































14 34 F FTC T4N0M1 5 12.0 0.065 2101 1 Lu, Med - 
15 13 F PTC T4N1M1 6 20.3 13.2 70 0 - Lu, Med 
16 55 F PTC T2N0M1 7 36.7 0.007 108 1 Lu - 
17 55 M H T3N0M0 90 NA 12.5 174100 4 B, Lu - 
18 43 F PTC T1N1M1 5 6.1 0.793 310 1 Li, Lu, B - 
19 41 F PTC T4N0M1 2 20.7 0.358 2900 0 - Lu 
20 52 M FTC T4N0M1 2 30.5 0.005 640 1 Lu - 
21 26 M PTC T4N0M0 16 15.4 16.3 22.9 0 - LR 
22 70 M FTC T2N0M0 12 32.1 0.006 16.6 0 - Lu 
23 74 M PTC T4N0M0 4 16.5 0.015 0.8* 1 Lu, Med, LR - 
13 68 F H T2N0M0 - 21.1 0.005 62 0 - Lu 
M , male; F, female; FTC, follicular carcinoma; PTC, papillary carcinoma; H, Hürthle cell carcinoma; 
TSH, thyroid-stimulating hormone; Tg, thyroglobulin; SRS, somatostatin receptor scintigraphy; 
Lu, lungs; Li, liver; Med, mediastinum; B, bones; C, cutaneous; LR, loco-regional recurrence; Br, brain 
* Tg antibody positive. 
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Table 2. Comparison of population characteristics in the groups of patients with an uptake 
score of 0 or 1 (group 1: no or slight uptake) or an uptake score of 2, 3 or 4 (group 2: 
moderate to intense uptake). 
 
  
No or slight 
octreotide uptake 
(score 0 or 1) 
 
 
Moderate to intense 
octreotide uptake 











Gender: (female):  n (total) 10 / 14 3 / 9 0.10 
Interval between diagnosis and scintigraphy 
(months): mean  (SD) 
8.3 (±6.9) 8.7 (±6.4) 0.97 
Follow-up since diagnosis (years): mean (SD) 8.6 (±7.1) 8.4 (±6.0) 0.97 
Cumulative 131I dose (GBq): mean (SD) 24.9 (±10.2) 29.9 (±10.8) 0.27 
Log Tg levels (μg/L): median (range) 5.7 (2.83 – 8.29) 9.5 (4.29 – 13.28) 0.02 



























































Died: n (total number) 0 (14) 7 (9) <0.001 
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Discussion 
In this study, we evaluated the diagnostic and prognostic value of SRS with 
111In-octreotide in progressive papillary and follicular thyroid cancer. The 
overall sensitivity for the detection of metastases on a patient basis was 74%, but 
the highest diagnostic yield was seen in patients with metastases that had 
completely lost the capacity to take up 131I. Furthermore, it was found that the 
111In-octreotide uptake correlated significantly with survival. 
 
Overall prognosis and survival in DTC 
Up to 20% of the patients with DTC have a local recurrence or regional 
metastases [5;6]. Some of these relapses are due to an incomplete initial 
treatment, whereas in others relapse is indicative of an aggressive tumor. Some 
parameters have prognostic value, such as younger age, T4 tumors and certain 
histological subtypes. In the present study, 19 out of 23 patients had T3 or T4 
tumor stage and/or distant metastases indicating an initial bulky tumor stage. 
DTC usually demonstrates a concordance between the 131I uptake and serum Tg 
levels and in these cases prognosis is good. On the other hand, patients with 
recurrent disease that does not concentrate 131I were found to have more invasive 
cancers and to have a poorer outcome. In these patients, the reported 2-, 5- and 
10-year survival rates are 55%, 16% and 11%, respectively, compared to 91%, 
77% and 62%, respectively, in patients with 131I uptake [19;20]. The presence of 
metastases in distant organs other than lungs, such as bones, brain or liver, is an 
important unfavorable prognostic variable. In a study by Casara et al. including 
134 patients with lung metastases, it was shown that the 5- and 10- year survival 
rates were 69% and 62%, respectively, for patients with only lung metastases 
compared to 36% and 10%, respectively, for those with multiple metastases [1]. 
In this study, T and N stages and gender were not significantly related to 
prognosis. Comparable results were found in patients with bone metastases of 
DTC [21]. Again, the reported median survival was significantly different 
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between patients with functioning metastases (4.6 years) and those with non-
functioning metastases (2.4 years). It has to be realised that in approximately 
65% of patients with non-functioning metastases the disease is limited to the 
neck and/or mediastinum. In these patients, the only effective treatment is 
radical surgery, which results in a complete remission in almost 50% of cases. 
Such results confirm the necessity for early detection of recurrent DTC, and also 
show the need to assess whether it is limited to one organ system or not. 
Therefore, it would be helpful to have a diagnostic and prognostic tool in 
patients with non-functioning metastases that identifies patients in whom a more 
aggressive treatment is required to stabilise disease [12]. 
 
Somatostatin receptor expression in thyroid cancer 
In a study by Ain et al., it was shown that normal thyroid tissue shows high 
expression of SSTR3 and 5 and weak expression of SSTR1 and 2 [22]. With 
respect to thyroid cancer tissue, the expression of SSTR2 was only found in 
Hürthle cell carcinomas. In papillary and follicular tumors, high expression of 
SSTR3, 4 and 5 was seen. As 111In-octreotide in general binds to SSTR2, 3 and 
5, it can be concluded that, even though the binding to SSTR3 and 5 is less 
optimal than that to SSTR2, non-functioning thyroid tumors may be visualised 
using this radiopharmaceutical. In 1996, Baudin et al. were the first to report on 
octreotide scintigraphy in DTC in clinical practice [23]. An overall sensitivity of 
80% was described, irrespective of the 131I WBS result. In more recent reports by 
Postema et al. and Gorges et al., comparable results (75% and 74%, 
respectively) were found [16;24]. In these studies, a correlation was found be-
tween the sensitivity and the Tg levels. Finally, Haslinghuis et al. reported that 
thyroxin withdrawal seems to increase the diagnostic yield of 111In-octreotide 
scintigraphy from 67% to 85% in DTC [25]. Our results are in agreement with 
the data found in literature, but we did not discontinue hormonal replacement. In 
a majority of the patients SRS may guide the clinician to alternative treatment 
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options, such as surgery in the presence of locoregional disease or chemotherapy 
in cases of extensive disease. In this respect, however, it is important to note that 
false positive imaging with 111In-octreotide may also occur, especially in the 
region at risk. For example, focally increased uptake in the mediastinum or head 
and neck region can be caused by an infection. More diffuse uptake in this 
region can be seen after surgery, external radiation therapy or in the lungs after 
chemotherapy. 
 
Prognostic stratification and nuclear medicine techniques 
In this study we have shown that patients with non-functioning DTC with 
moderate to high 111In-octreotide uptake (scores 2, 3 and 4) have a significantly 
poorer outcome than patients with no or slight uptake. Although the number of 
patients studied is limited, the results suggest more aggressive tumor behaviour 
in cases of SSTR-positive DTC. In the present study we were not able to 
correctly assess the tumor mass or tumor volume in each patient. Nuclear 
medicine techniques in general cannot be used to assess such a parameter. More-
over, as stated in the introduction, radiological techniques such as 
ultrasonography of the head and neck region, chest-X rays or CT scanning are 
valuable in assessing tumor recurrence or progression and tumor mass. 
However, small lesions with diameters of less than 1 cm may be missed [8;9]. In 
addition, lymph node enlargement may be caused by infection as well as by 
tumor. Therefore, assessment of tumor mass is highly difficult. In this respect, 
some reports have focussed on the correlations between Tg levels, tumor mass 
and prognosis [26-28]. Tg measurement is a highly specific and sensitive test for 
the follow-up of thyroid cancer. During hormonal treatment, serum Tg is 
elevated in most patients with large metastases and is lower or even unde-
tectable in patients with small metastases. After withdrawal of hormonal 
replacement, the serum Tg level increases or becomes detectable in the majority 
of the patients [4;5]. In some of the reports on Tg, a relationship has been 
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suggested to exist between serum Tg level and tumor burden. In a more recent 
report by Bachelot et al., it was shown that the number of metastatic lymph 
nodes and their total surface or volume were significantly associated with serum 
Tg/TSH ratios [29]. In this selected group of patients, lymph node metastases in 
the head and neck region were the only source of serum Tg, resulting in an 
accurate evaluation. In their study, it was shown that this relation was not altered 
by possible confounding factors such as the clinical characteristics, histology 
and previous treatment modalities. On the other hand, it was shown that 
undetectable or very low Tg levels cannot be used as a reliable criterion for 
minimal tumor burden in patients who have been treated with 131I. As shown in 
the study by Bachelot et al., even patients with Tg levels <1 ng/ml had tumor 
volumes up to 7178 mm3. Such values were also observed in patients with Tg 
levels between 1 and 10 ng/ml and patients with Tg levels >10 ng/ml. 
In the present study, Tg levels were used as an indication for tumor mass. As 
probably was to be expected, we found a significant difference in mean Tg 
levels between groups 1 and 2, suggesting a difference in tumor mass between 
the selected groups. In some of the patients in group 1, however, high Tg levels 
were found which did not result in an uptake score of 2, 3 or 4, and conversely, 
some patients with a high uptake score had low Tg levels. Although significant, 
the Spearman's correlation coefficient of 0.67 was rather weak. Despite the fact 
that the number of patients studied is probably too small, the findings suggest 
that tumor mass is not the only parameter responsible for the difference in 
clinical outcome identified in the present study. One has to realise, however, that 
the rather weak correlation might be due to the use of Tg-on levels, i.e. Tg levels 
in the absence of TSH stimulation. Therefore, further studies have already been 
initiated to assess the prognostic value of SRS in patients in whom TSH 
stimulation is achieved via recombinant human TSH administration. 
Regarding the different radiopharmaceuticals used over recent years in patients 
with non-functioning DTC, 201Tl has been most extensively employed in follow-
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up [30-32]. In this respect, it seems to be of predictive value: a high uptake is 
correlated with a poor prognostic outcome [33]. More recent reports have 
focussed on the diagnostic value of 
99mTc-methoxyisobutylisonitrile (MIBI) [34-
37]. Data on the prognostic value of 99mTc-MIBI in thyroid cancer are not 
available. 
Data on the use of FDG-PET in thyroid cancer are increasing [38]. Feine et al. 
showed that FDG uptake seems to be an indicator of poor functional differentia-
tion and possibly higher malignancy grades in thyroid cancer [11]. In a report by 
Sarlis et al., 111In-octreotide scintigraphy was compared with FDG PET in 21 
patients with progressive DTC [39]. The sensitivity of SRS and FDG PET were 
49.5% and 67.7%, respectively. Importantly, SRS detected five unexpected 
lesions, which were negative on FDG PET imaging. This finding underlines the 
unpredictability of the metabolic profile and receptor expression in metastatic 
lesions. The value of such conflicting results is still not clear, but these data 
confirm the necessity of multi-modality imaging to assess tumor burden. 
Nevertheless, in the present study we have shown that scintigraphy with 111In-
octreotide is a valuable diagnostic tool in non-functioning DTC. The long-
standing expression of SSRT, even in cases of dedifferentiation in DTC as 
shown in the present study, may also form the basis for treatment with 
somatostatin analogues. In this respect, a cytostatic, anti-angiogenetic effect of 
octreotide has already been suggested. In the first preclinical in vitro studies by 
Ain et al. [40], dose-dependent growth inhibition in a papillary carcinoma line 
(NPA87) was observed though stimulation of growth was seen in a follicular 
cancer cell line (RO87-M-1). In a study by Hoelting et al. [41], conflicting 
results were found in the treatment of three different follicular thyroid cancer 
cell lines. In vitro studies revealed a biphasic effect, with enhanced growth at 
low cold octreotide concentrations, but an inhibiting effect at high 
concentrations. In their studies in nude mice, however, there was no effect on 
the growth of these cells. In contrast to these findings in animal studies, Robbins 
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et al. demonstrated a reduction in thyroid tumor volumes in two patients who 
had been treated with 3- to 4-month courses of octreotide [42]. Their results 
were observed on follow-up FDG-PET studies in a patient with thyroid cancer 
that was unresponsive to 131I treatment and in another patient with thyroid cancer 
without 131I uptake on WBS. These findings were in contrast to a previous study 
described by Zlock et al. in which subjects were monitored while receiving 
relatively high doses (4 mg daily) of octreotide subcutaneously for up to 12 
months [43]. Octreotide as a single agent did not significantly decrease tumor 
markers (e.g. Tg, calcitonin, carcinoembryonic antigen). The carcinomas 
progressed during treatment, as evidenced by an increase in the size and/or 
number of metastatic lesions. Finally, other reports have focussed on the en-
hancement of the anti-neoplastic effects of tamoxifen and doxorubicin by 
octreotide [44-46]. Despite the fact that these results were observed in breast 
cancer and pancreatic tumor cell lines, it is suggested that octreotide may also 
increase the therapeutic effectiveness in thyroid cancer treatment with 
adriamycin. These results, however, need to be confirmed in large-scale clinical 
trials.  
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Background and aim ¹¹¹In-DTPA-octreotide is internalized by thyroid and 
neuroendocrine cancer cells via somatostatin receptor subtypes and can cause 
DNA damage by the emission of conversion and Auger electrons. The aim of 
the study was to determine the effect of ¹¹¹In-DTPA-octreotide therapy in 
patients with progressive radioiodine non-responsive thyroid cancer in relation 
to ¹¹¹In-DTPA-octreotide uptake by tumor localizations assessed on pre-
treatment diagnostic octreotide scans. 
Methods Eleven consecutive patients, selected on positive pretreatment 
diagnostic scans, were treated with fixed doses of approx. 7400 MBq of ¹¹¹In-
DTPA-octreotide with an interval of 2-3 weeks between the doses. In one 
patient, the dose was adjusted because of sickle-cell disease. To assess the 
effects during treatment with 
111
In-DTPA-octreotide thyroglobulin levels were 
gathered from 2 years before treatment, during treatment and up to 1 year after 
treatment. A computed tomography scan was performed 3 months after the last 
treatment. 
Results Two patients died during and shortly after the treatment course. Death 
was due to a sepsis and an insulin overdose, respectively. In 44% of the patients, 
stable disease was achieved up to 6 months after the first treatment according to 
both criteria. All four had relative low pretreatment thyroglobulin levels (mean 
level 275 µg/l), representing limited metastasized disease. In two patients 
biochemical stable disease was observed, whereas computed tomography 
showed tumor progression. 
Conclusion Treatment with high doses of ¹¹¹In-DTPA-octreotide in 
differentiated thyroid cancer results in a stable disease in a subgroup of patients. 
Our results suggest that a low pre-treatment thyroglobulin level, representing a 
small tumor load, may be a selection criterion for treatment. 
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Introduction 
Follicular and papillary thyroid cancer, so-called differentiated thyroid cancer 
(DTC), is an uncommon tumor, representing approximately 3% of all 
neoplasms. The incidence of DTC is 5-10/ 100000 per year and the overall 
prognosis is good with 10 year survival rates between 92-98% [1;2]. The initial 
treatment consists of surgery, which is followed by ablation with ¹³¹I. To assess 
tumor recurrence and/or metastases, plasma thyroglobulin (Tg) and ¹³¹I whole 
body scintigraphy (WBS) are well-established techniques [3;4]. Recurrences 
and/or metastases can be treated with repeat surgery, ¹³¹I treatment and/or 
radiotherapy. However, a number of patients show disease progression, assessed 
either radiological or by increasing Tg levels, under ¹³¹I treatment or have WBS 
scans with no ¹³¹I uptake. Many reports have focused on the value of 
fluorodeoxyglucose positron emission tomography (FDG PET) for the detection 
of metastatic disease in these patients [5-7]. Iodine negative locoregional disease 
detected by FDG PET can be treated with surgery or external irradiation, but, 
despite an improved locoregional control, it does not affect the overall survival 
[8;9]. Irrespective of the good diagnostic accuracy, there are currently no well-
established treatment options for patients with ¹³¹I non-responsive multiple 
metastases. In such cases, 5 year survival rates decline to 60-82% [10;11]. 
Recent reports have focused on redifferentiation of thyroid cancer by means of 
retinoic acid stimulation. Despite promising results in in vivo studies, in vitro 
studies revealed disappointing results [8;12]. 
As response to chemotherapy and radiotherapy is variable, more effective 
treatment modalities are needed. It has been proposed that endocrine and 
neuroendocrine tumors may be treated with a high dose of radiolabeled ¹¹¹In-
octreotide (111In-DTPA-octreotide). Octreotide is a somatostatin analogue with 
affinity for specific somatostatin receptor subtypes. There are five different 
subtypes (SST 1-5) of the somatostatin receptor. In a study by Forsell-Aronsson 
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et al. [13], a high expression of SST 1, 3, 4 and 5 was found in both papillary 
thyroid cancer and follicular thyroid adenoma. Medullary thyroid cancer cells 
showed expression of all subtypes, whereas neuroendocrine tumors express SST 
1 and 2 and to a lesser extent SST 5 [14]. The somatostatin analogue octreotide 
shows high affinity for subtype 2, average affinity for subtypes 3 and 5, and no 
affinity for SSTs 1 and 4 [15;16]. The expected effect of 111In-DTPA-octreotide 
on tumor tissue is based on the internalization of the radiolabeled octreotide 
through these somatostatin receptors. Once in the cell, short-range Auger 
electrons emitted by the ¹¹¹In will cause DNA damage. The diagnostic value of 
111In- octreotide in thyroid cancer has already been confirmed in some small 
case series [17-20]. 
The aim of this study was to observe the effect of high doses of 111In-DTPA-
octreotide therapy in patients with disseminated and progressive radioiodine 
non-responsive thyroid cancer. 
 
Patients, materials and methods 
Patients 
Eleven consecutive patients (seven women and four men; mean age, 63 years, 
range 44-69) with progressive disseminated thyroid cancer not responding to 
131
I 
treatment were included from 1 February 2000 to 1 December 2001. All patients 
had multiple sites of uptake of 111In-octreotide, an exclusion criterion for 
surgery. 
Tumor progression before entering this study was based on rising Tg levels 
(Figure 1) and confirmed by radiological evaluation. To assess the effects during 
treatment with 111In-DTPA-octreotide Tg levels were gathered from 2 years 
before, during and up to 1 year after treatment. Exclusion criteria were a life 
expectancy <6 months, kidney and liver dysfunction other than caused by 
metastases and no visible 111In-octreotide uptake in metastases. The medical 
ethics committee of our institution approved therapy and all patients gave 
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To assess the octreotide uptake, baseline scans were performed using 220 MBq 
of 111In-DTPA-octreotide. Whole body scintigraphy (run speed 10 cm/min) and 
single photon emission computed tomography (SPECT) of the chest and head 
and neck region were performed at 4 and 24 h p.i. using a dual-head gamma 
camera (Toshiba GCA 7200, Japan). The SPECT images (matrix size 128 x 128; 
with a 6° step angle and a 1 min step time) were reconstructed using filtered 
back-projection and a Butterworth pre-processing filter (8 order, 0.12 subset). 
These scans were used to exclude patients with no 111In-DTPA-octreotide uptake 
from treatment. In this respect, scoring of tumor radioactivity was done visually 
according to the criteria described by Krenning et al. ranging from 0 to 4 [16]. 
All patients underwent a baseline radiological evaluation (computed tomography 
(CT) or magnetic resonance imaging (MRI) approximately a month before or 
immediately after the first therapeutic octreotide dose to determine baseline 
tumor size and extent and number of metastases. A complete biochemical and 
haematological screening was done for all patients as well as the measurement 
of Tg-on and thyroid stimulating hormone (TSH) levels. 
 
111In-DTPA-octreotide therapy 
In this protocol we intended to treat patients with a standard activity of 
approximately 7400 MBq 111In-DTPA-octreotide per injection. A complete 
treatment course was defined as four administrations with an interval between 
two administrations ranging from 2 to 3 weeks. The treatment dose was adjusted 




On days 0, 3, 7, 14 and 21 after each 111In-DTPA-octreotide administration a 
complete biochemical and haematological screening, including tumor markers 
and tumor marker antibodies, were performed. In addition, whole body 
scintigraphy was performed on days 3 and 7 (run speed 20 cm/min) to measure 
the uptake in at least two metastases during treatment using the procedure 
described previously [21]. Tg levels were also measured 3 and 9 months after 
the final ¹¹¹In-DTPA-octreotide administration, which is approximately 6 and 12 
months, respectively, after the first administration. Furthermore, 3 months after 
the last treatment a CT scan was performed. 
 
Treatment evaluation 
Three criteria were used for evaluation: criterion number 1 was a radiographic 
(CT or MRI) response in which images prior to and 6 months after the first 
administration were compared. Radiological stable disease was defined as an 
equalization in tumor size and in number/extent of metastases. Any increase in 
tumor size or number of metastases was defined as progression. Criteria 2a and 
2b were tumor marker response assessed at 3 and 6 months, respectively, after 
the first administration. 
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(A)      (B) 
 
Figure 1. Post-treatment 131I whole body scintigraphy (8000MBq) (A) in a 57-year-old man 
with a history of a T3N0M1 follicular thyroid carcinoma and an increasing thyroglobulin (Tg) 
level showed a normal, physiological distribution. The accumulation in the pelvic region is 
physiological excretion into the bladder and rectum. Whole body scintigraphy after the 




Baseline characteristics and follow-up 
The patients' characteristics are summarized in Table 1. Patient nr 7 received 
3700 MBq [¹¹¹In-DTPA ]-octreotide at the third administration because of a low 
platelet count. Due to this adjustment, the total dose administered to this patient 
was 27.5 GBq. Neither clinical nor haematological side effects were observed in 
the other patients. Patient nr 9 had sickle-cell disease and, therefore, received 
3700 MBq per session up to a total amount of 14.3 GBq. Overall, the total 
amount of [¹¹¹In-DTPA]-octreotide administered ranged from 14.3 to 33.1 GBq. 
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Figure 1 demonstrates a typical example of an ¹³¹I negative whole body scan 
after the treatment with 7400 MBq of ¹³¹I and multiple metastases in the chest 
and spine on the whole body scan after the administration of 7400 MBq of ¹¹¹In-
DTPA-octreotide. 
During the 1 year follow-up three patients died. Patient nr 5 died of an insulin 
overdose at 28 days of follow-up. He had completed the whole treatment course 
with 111In-DTPA-octreotide. Patient nr 6 died of a non-tumor related sepsis 6 
days after the second ¹¹¹In-DTPA-octreotide dose. Since the start of ¹¹¹In-DTPA-
octreotide therapy he had been showing a decrease in tumor marker production. 
Neither patient nr 5 nor nr 6 had had a follow-up CT scan at time of death. 
Patient nr 2 died 2 months after the last treatment course due to tumor 
progression causing pleural effusion and emboli seen on CT performed the day 
before she died. Shortly before she died, which is 5 months after the first 
treatment, a complete biochemical and radiological evaluation was performed. 
Although the 6 month follow-up was not completed, we decided to use these 
data for further evaluation. Finally, in none of the patients was there a 
significant difference measured in tumor uptake between the first and last 
treatment measured on days 3 and 7. 
 
Effect of [¹¹¹In-DTPA]-octreotide therapy 
Effect related to Tg levels at 3 and 6 months follow-up 
Four patients with initial Tg levels <1000 µg/l demonstrated biochemical stable 
disease at 6 months after the start of the treatment course. This effect was 
already observed 3 months after the first administration. An effect of increased 
TSH levels during follow-up compared to the initial levels was excluded (Tables 
1 and 2). Three out of five patients with rather high Tg levels had a further 
increase, which was already observed at the 3 month time interval. 
In Figure 2, Tg levels are presented from before, during and up to 1 year after 
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treatment. Because of the very skewed distribution, log Tg levels are reported. 
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lung, bone, LN 
2 67 F PTC T2N1M1 surg, 131I 131I / 108 0.010 772000 lung, brain, LN 
3 69 F PTC T4N1M1 surg, 131I 131I / 193 0.796 1275 lung, LN 
4 65 F FTC T2N0M1 surg, 131I 131I / 291 <0.020 42610 lung, pleura 
5 67 M FTC T2N0M1 surg, 131I, RT, emb RT / 133 <0.005 27000 bone 
6 67 M PTC T4N0M1 surg, 131I, emb emb / 28 0.040 1367 lung, bone, skin 
7 68 M PTC TxN1M1 surg, 131I, RT RT / 176 0.022 28809 liver, lung, LN 
8 55 F PTC T4N1M1 surg, 131I 131I / 323 0.009 101 lung, LN 
9 44 F FTC T4N1M1 surg, chemo, 131I, 
RT, emb 
131I / 130 <0.005 5277 liver, lung, bone, mediastinum, 
LN 
10 67 F PTC T4N1M1 surg, 131I, RT 131I / 172 <0.005 104 lung, LN 
11 53 F FTC T3N1M1 surg, 131I 131I / 2650 <0.005 78 lung, LN 
          
FTC, follicular thyroid cancer; PTC, papillary thyroid cancer; surg, surgery; chemo, chemotherapy; 
















































































2 3 4 30582 0.137 749000 S S† P† 
3 1 4 30279 0.395 3900 P P P 
4 1 4 31776 <0.005 60400 P P P 
5 2 4 32349 0.019 24300 S NA NA 
6 1 2 16828 NA NA NA NA NA 
7 3 4 27551 <0.005 37150 S S P 
8 1 4 31996 0.017 113 S S S 
9 1 4 14308 <0.005 9711 P P P 
10 1 4 32210 0.015 168 S S S 
11 2 4 31748 <0.005 76 S S S 
*Results 3 months after the first 111In-octreotide therapy; **results 6 months after the first 111In-octreotide therapy; 
***
before 111In-octreotide therapy. †Results 5 months after the first therapy: these data were obtained shortly before  
she died. NA, not available; P, progression; S, stabilization. 
 
Chapter 8 















In-octreotide. The arrow indicates the start of the treatment course with high doses  
of 
111
In-octreotide. Because of the skewed distribution of the Tg levels, log Tg levels  
were used. Symbols represent the nine surviving patients in the study. 
 
Therapeutic effect based on follow-up CT and Tg levels at 6 months 
No patient had a tumor reduction on CTscan. However, in four of the patients 
studied stable disease was seen on CT. These patients had also stable tumor 
markers (mean Tg level 275µg/l; range 76-744µg/l). Five patients had 
radiological progression after ¹¹¹In-DTPA-octreotide therapy, of which three 
also had tumor marker progression. One of these three patients, nr 9, had 
received an adjusted dose because of sicklecell disease. The mean Tg level in 
this group was 180432 µg/l (range, 3900-749000 µg/l ). From these data it is 
concluded that, in small tumors, expressed by rather low Tg levels, an 
antiproliferative effect was observed. In two out of these five patients, 
dissociation was observed between biochemical and radiological response 
criteria, suggesting a metabolic but no anti-proliferative effect. 
The number of patients was too limited to draw any conclusion with respect to  
the uptake score and the therapeutic effect. 
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Discussion 
The purpose of this study was to determine the effect of treatment with high, 
fixed doses of ¹¹¹In-octreotide in patients with progressive iodine non-responsive 
thyroid cancer. Two patients died during follow-up, which was due to a sepsis in 
one and an insulin overdose in the other. Only patients with rather low Tg levels 
(<1000 µg/l) demonstrated both a biochemical and radiological stable disease, 
which reflects the response of small tumors to such large treatment doses as 
used in the present study. 
 
Prognosis and survival 
Thyroid cancer is often a slow growing tumor with a very good long-term 
survival. Of the patients diagnosed with differentiated thyroid cancer, 5-20% 
will develop a local or regional recurrence or metastatic disease [2]. Therapy is 
still the same as that for initial disease: surgery and ¹³¹I treatment. More recent 
reports have focused on the value of external beam radiotherapy in the 
management of locoregional advanced thyroid cancer. In four of the recently 
published studies [8;12;22-24], it was shown that radiotherapy indeed 
significantly improved locoregional control in patients with pT4 tumors or 
lymph node involvement. In the study by Ford et al., even a possible dose 
response was found with a local recurrence rate of 63% and 18% for doses 
<50Gy and >54Gy, respectively [23]. However, in two studies it was shown 
that, despite a better local control by a combination of surgery and external 
irradiation, this strategy did not improve survival in patients with locally 
advanced disease. In these case series, locoregional radiotherapy revealed 5 and 
10 year survival rates of 96%, whereas the results for patients without 
radiotherapy were 94% and 89%, respectively [8;24]. 
In the presence of extensive metastasized disease the overall 5 year survival 
rates declines to 60-82%. In case of ¹³¹I uptake in metastases, the reported 2, 5 
and 10 year survival rates are 91%, 77% and 62%, respectively. In contrast, 
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however, the survival rates are 55%, 16% and 11%, respectively, in the case of 
metastatic disease that lost its capability of ¹³¹I uptake [25;26]. Patients with 
radioiodine non-responsive progressive disease can be treated with radiotherapy 
for recurrent neck disease or chemotherapy (adriamycin) for widely metastatic 
disease. Adriamycin, however, reveals a partial response in only 30-40% of 
patients [10], but these studies were performed in selected patient groups. 
These results support the necessity for early detection and treatment of recurrent 
thyroid cancer that does not concentrate radioiodine. 
 
Somatostatin receptor therapy 
The use of unlabeled somatostatin in the treatment of neuroendocrine tumors is 
well established and is based on its inhibitory effect on hormone production and 
its antagonistic effect with regard to tumor growth factors. Somatostatin binds to 
a family of G-protein-coupled receptors [14]. There are five subtypes (SST 1-5) 
and somatostatin binds to all five. However, due to its short half-life (approx. 3 
min) and its diversity of action, somatostatin is relatively unsuitable for 
treatment purposes. Somatostatin analogues more resistant to enzymatic 
degradation, like octreotide, have been manufactured. Octreotide has a high 
affinity for receptor subtype 2, average affinity for SSTs 3 and 5, and no affinity 
for SSTs 1 and 4. The diagnostic and therapeutic efficacy of octreotide is based 
on the binding with SSTs 2, 3 and 5. Data with respect to the diagnosis and 
treatment of follicular and papillary thyroid cancer with somatostatin analogues, 
however, are still limited. 
Non-medullary differentiated thyroid cancer cells show expression of SSTs 1, 3, 
4 and 5. Octreotide can target thyroid tumors through somatostatin receptor 
subtypes 3 and 5. In this respect, non-radiolabeled somatostatin analogues, like 
octreotide, have proven to be effective in tumor growth reduction. In preclinical 
in vitro studies by Ain et al. [27], a dose dependent growth inhibition in 
papillary carcinoma lines (NPA87) was observed though stimulation of growth 
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was seen in follicular cancer cell lines (RO87-M-1). The authors concluded that 
it might be due to differential stimulation and regulation of distinct somatostatin 
receptors. In a study by Hoelting et al., in vitro experiments in follicular cancer 
cell lines showed comparable results [28]. They found a biphasic effect, 
enhancing growth at low concentrations (1-10 nmol/ml), but inhibiting it at high 
concentrations (100 nmol/ml to 1 µmol/ml). Also a dose dependent biphasic 
effect on the invasion of the cancer cells, inhibiting all cell lines tested at high 
concentration. However, during a 3 week treatment period, octreotide had no 
antiproliferative effect on the growth of the cancer cell lines in nude mice. In 
humans, tumor reduction rates of approximately 10% have been reported in 
gastrointestinal tumors [29]. Data with respect to the treatment of differentiated 
thyroid cancer patients are still limited to case reports. Zlock et al. treated five 
patients with octreotide for 2 to 14 months [30]. All patients had lung metastases 
and they were considered to be untreatable by surgery or radioiodine. Despite 
doses up to 1 mg tid or qid, all patients had progressive disease. Finally, 
Robbins et al. [31] described the treatment of two patients with widely 
metastatic papillary thyroid cancer. In these patients, baseline metabolic activity 
and threedimensional volume of the lesions were determined by FDG PET. 
After 3 or 4 months of octreotide therapy, repeat FDG PET scans showed a 
reduction in tumor volume and decreases in the metabolic activity. Whether this 
reduced activity inhibits the progression of poorly differentiated thyroid 
carcinomas could not be concluded from this report. 
A relative new application, especially in case of DTC, is the use of octreotide 
labeled with ¹¹¹In. Its therapeutic effect is based on the toxicity of short range 
Auger electrons, emitted by ¹¹¹In, on cellular DNA. Due to the short particle 
range of Auger electrons, success depends on the amount of radioligand that can 
be concentrated into the cell and this depends on the rate of internalization, 
degradation and recycling of the ligand and the receptor expression. 
Internalization is receptor mediated and temperature dependent [14]. Of the 
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receptor subtypes, SST 3 is the most efficient at internalization while SST 1 
does not. Reubi et al. [32;33] have evaluated the affinity of various radiolabeled 
somatostatin analogues for the different somatostatin receptor subtypes. They 
found that although radiolabeling with ¹¹¹In decreased the affinity of octreotide 
to somatostatin receptors by 10-fold, its affinity to these was still significant. So, 
¹¹¹In-octreotide still can be sufficiently internalized by tumor cells expressing 
SST 3. 
Most of the reports with regard to the therapeutic value of ¹¹¹In-DTPA-
octreotide are related to neuroendocrine tumors. In a review by McCarthy 
[16;34], results of five institutions, a total of 85 patients with metastatic 
neuroendocrine tumors, are described. Response included radiographic, 
biochemical and/or improvement in Karnofsky performance status, which 
revealed an overall response rate between 62% and 69%. ¹¹¹In-DTPA-octreotide 
doses ranged from 4 to 11.1 GBq per course and were given in two to eight 
courses with an interval of 3-4 weeks per course. Krenning et al. (included in the 
above review), reported that the effectiveness of 111In-DTPA-octreotide therapy 
seems to be related to the amount of ¹¹¹In-DTPA-octreotide uptake by the tumor. 
Response was 86% in patients with high uptake (=intense), 67% in patients with 
average uptake (=higher than liver) and 50% in patients with low uptake (=lower 
than/equal to liver). In contrast to this, in our patient population the response to 
¹¹¹In-DTPA-octreotide therapy was observed in patients with rather low uptake 
scores (scores 1 and 2). The number of patients studied, however, is too small to 
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Thyroglobulin levels and treatment effect 
Caillou et al. [35] as well as Lazar et al. [36] investigated the expression of 
thyroid-tissue specific genes in normal thyroid tissue and in thyroid carcinoma 
tissue. Correlation was found between the expression of the hNIS gene (human 
sodium/iodine symporter gene) and the ability of the tumor to concentrate 
iodine. Expression of the Tg gene in thyroid cancer cells, though 2-fold to 300-
fold less than in normal tissue, remained well preserved in later tumor stages, 
being absent only in undifferentiated cancer cells [37]. Whether this dissociation 
between tumor marker production and tumor growth, as observed in two patients 
in the present study, can be clarified by a further positive selection of poorly 
differentiated cancer cells is not clear yet. If this is the case, labelling octreotide 
with a beta emitter could increase the effectiveness of radiolabeled octreotide 
therapy. However, results of somatostatin receptor scintigraphy (SRS) reported 
by Baudin et al. [17] do not support this theory. Although not fully elucidated, 
an anti-metabolic effect is more likely in the present cases. This effect also has 
been observed in neuroendocrine tumors, which causes a relief in symptoms 
caused by increased hormone production [38-41]. 
 
Radiolabeled octreotide therapy in thyroid cancer and future prospects 
This is one of the scarce studies in which the therapeutic value of 111In-DTPA-
octreotide in patients with progressive radioiodine non-responsive non-
medullary thyroid cancer is evaluated. Our results are comparable to those 
observed in neuroendocrine tumors reported by other institutions, though dosage 
and frequency of 111In-octreotide therapy vary. Krenning et al. [16] reported on 
the effect of ¹¹¹In-octreotide in a patient with papillary thyroid cancer and a 
complete follow-up who showed disease stabilization. This patient received a 
total cumulative dose of at least 20 GBq and had grade 2 uptake. Our study 
population included 11 patients with non-medullary thyroid cancer with uptake 
scores ranging from 1 to 3. In four treatments per patient a cumulative dose of 
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approximately 30 GBq ¹¹¹In-DTPA-octreotide was given. The treatment scheme 
used in the present study was based on data in literature in which a cumulative 
dose of at least 20 GBq is recommended. Furthermore, major side effects with 
single doses up to 14 GBq and cumulative doses up to 75 GBq have not been 
reported [38-41]. 
More recent reports have focused on somatostatin analogues labeled with 
90
Y, a 
beta particle emitter. In contrast to the short range of the Auger electrons, the 
radiation emitted from 
90
Y can extend over several cell diameters. In the theory, 
it can destroy both somatostatin receptor positive and receptor negative tumor 
cells. Görges et al. [18] has reported on three patients treated with a different 
radiolabeled somatostatin analogue, 
90
Y-DOTATOC. One patient had two 
treatments with a cumulative dose of 4400 MBq, the second had one dose of 
1700 MBq and the last patient had four doses with a cumulative dose of 9620 
MBq. In all three patients radiographic progression could not be stopped, 
whereas only one patient had decreasing tumor marker production. Otte et al. 
[42] have reported on results with 
90
Y-DOTATOC in 29 patients with advanced 
neuroendocrine tumors who had no other treatment options. These patients were 
treated with four or more doses of 
90
Y-DOTATOC, with a cumulative dose of 
around 6000 MBq/m
2
. Twenty patients showed disease stabilization, two 
showed tumor reduction of more than 50%, four showed a reduction of the 
tumor mass of less than 50% and three showed tumor progression. Paganelli et 
al. [43] reported results for 30 patients with somatostatin receptor positive 
tumors treated with 
90
Y-DOTA-D-Phe¹-Tyr³-octreotide. Cumulative dosage was 
between 3 GBq and 8 GBq, given in three courses over a period of 6 months. 
The patient population included 23 carcinoid tumors and three medullary thyroid 
cancers. Complete or partial reduction of the tumor mass occurred in 23% of 
patients, 64% had stable disease and 13% progressive disease. In a more recent 
report by Waldherr et al. [44], the value of 
90
Y labeled octreotide (DOTATOC) 
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in differentiated thyroid cancer was described. Twenty patients with therapy 







Y-DOTATOC, administered in one to four injections at 
intervals of 6 weeks. Stable disease was achieved in 35% of the patients, 
whereas progressive disease was found in 65%. They suggested that more 
significant tumor responses in thyroid cancer may be obtained with 
radiopeptides, which more selective bind to SSTs 3 and 5, both receptors 
expressed by thyroid cancer cells. 
Throughout the last decade several somatostatin analogues, such as lanreotide 
and depreotide [45-47], have been introduced on the basis of their recognition 
for SSTs 3 and 5. Preclinical data and clinical studies confirm their potential use 
in diagnosis as well as in therapy of cancer patients. The possible 
antiproliferative effects of these radiolabeled somatostatin analogues may lead 
to a new treatment option in differentiated thyroid carcinoma metastases that do 
not respond to treatment with high doses of ¹³¹I. Based on the present results it 
may be concluded that diagnostic ¹¹¹In-octreotide scintigraphy revealing uptake 
scores ranging from 1 to 4 and measurement of low Tg levels representing a 
small tumor load can be used as selection criteria for treatment. More studies are 
required to assess the value of treatment with ¹¹¹In-octreotide in differentiated 
thyroid cancer. In this respect, however, it is highly important to evaluate and 
discuss the issue of stabilization of Tg levels in patients with radiologically 
confirmed tumor progression. Therefore, further study is required. 
Finally, more recent reports have focused on the use of retinoic acids, as 
proliferation inhibiting and differentiation inducing effects in thyroid cancer 
[48;49]. These acids exert their effects via receptors. It has been shown that 
retinoic acids in various thyroid cell lines regulate NIS expression. In particular, 
the messenger RNA encoding the NIS is upregulated by the retinoic acid 
stimulation. In former clinical pilot studies, 40-50% of the patients with poorly 
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differentiated thyroid carcinomas lacking iodine uptake responded to treatment 
to retinoic acids with an increase of iodine uptake [50-52]. In theory, this 
redifferentiation process of advanced thyroid carcinomas by stimulating the 
hNIS expression makes tumors accessible for radioiodine therapy again. In a 
more recent clinical study, however, it could not be confirmed. Grûning et al. 
[12], studied 25 patients who were treated with retinoic acids at 1 mg/kg for 3 
months followed by ¹³¹I. In two out of 14 patients with raised Tg levels but no 
¹³¹I uptake, a slightly improved uptake was seen. In three out of 11 patients with 
slight uptake a dosimetrically relevant improvement of uptake was seen. Of 
these five responders (20%), two were completely free of symptoms, one 
showed stable disease and two patients worsened. Retinoic acid gave improve- 
ment of ¹³¹I uptake in metastases with low radioiodine uptake, but it did not 
appear to induce uptake in ¹³¹I negative metastases. Consequently, despite the 
mild and reversible side effects, its therapeutic use as a single agent in the 
patients reported in the present study is debatable. A possible enhancement of 
the antiproliferative effect of retinoic acid by phenylacetate is still under study. 
In a report by Eigelberger et al. [53], it was shown that retinoic acid and 
phenylacetate alone inhibited growth in a follicular cell line to 16% and 35%, 
respectively, compared with controls, whereas the combination of the two 
inhibited growth to 60%. This effect is probably due to an upregulation of the 
retinoic acid receptor by phenylacetate. Although an improvement of 131I uptake 
in iodine negative metastases due to this synergistic effect might be expected, its 
role in clinical practice is still unclear and needs further study. 
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The therapy of choice in patients suffering from differentiated thyroid cancer 
(DTC), subdivided into papillary and follicular thyroid carcinoma, is (near-)total 
thyroidectomy. This is routinely followed by the administration of radioiodine 
(RaI)-131 (131I) to destroy any remaining benign or malignant thyroid tissue, so-
called ablation. 
Although many aspects of diagnosis, initial therapy and follow-up procedures 
have been covered in recently published guidelines and consensus papers 
(published by the American and European Thyroid Associations and by the 
Dutch CBO thyroid carcinoma consensus group (www.cbo.nl)) [1;2], many 
questions with regard to the clinical approach to patients with DTC still remain 
to be answered. This thesis has addressed some important clinical questions, 
related to the application of conventional (131I) and experimental therapies with 
radionuclides in DTC. 
Iodine-131 has been used for many years to ablate thyroid remnants following 
thyroid surgery, but a single optimal activity has not yet been established. In this 
respect, data in the literature are inconsistent; some studies conclude that an 
activity of 1110 MBq of 131I may be as effective as a high activity such as 3700 
MBq, whereas other authors suggest that a higher activity of 131I will improve 
the rate of successful remnant ablations. Two protocols are commonly used in 
the Netherlands: the uptake-related ablation strategy in which relatively low 
activities of 131I are used and the fixed-dose or tumor-related ablation strategy in 
which higher ablation activities are used. 
The main aim of this thesis was to study the short-term and long-term outcome 
parameters in DTC according to the uptake-related ablation protocol and to 
compare the success rates of both ablation strategies. Furthermore, we 
investigated whether there was a relation between ablation failure and pre-
ablation 24-hour uptake measurement of 131I (by the so-called stunning effect). 
By assessing the prevalence of second primary tumors in patients treated for 
thyroid cancer we wanted to confirm that 131I can be used safely regarding long-
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term effects. Finally, we focused on 111In-DTPA-octreotide scintigraphy and 
therapy as an alternative tool in progressive radioiodine non-responsive thyroid 
cancer. 
 
In chapter 2 the efficacy of the uptake-related ablation strategy was studied. In 
this strategy relatively low activities of 131I are used. The applied activity 
depends on the measurement of 131I 24-hour neck uptake. In the uptake-related 
ablation protocol, activities of 1100 MBq (uptake >10%), 1850 MBq (uptake 5-
10%) and 2800 MBq (uptake <5%) were used. In this study, 235 patients were 
selected who had been treated by thyroidectomy for DTC, followed by 131I 
ablation. Approximately 6 months after ablation, treatment efficacy was 
evaluated using radioiodine scintigraphy and thyroglobulin (Tg) measurements. 
Successful ablation was defined by two criterions: the absence of radioiodine 
uptake in the neck region (criterion 1) and based on Tg serum values measured 
during TSH stimulation (Tg-off) determined 3–12 months after ablation 
(criterion 2). Based on criterion 1, unsuccessful ablation was found in 43% of 
cases. Based on criterion 2, unsuccessful ablation was found in 52% of patients. 
These data showed a relatively high treatment failure rate of the uptake-related 
ablation strategy. Based on these results we suggested that a lower ablation 
failure rate could be achieved by applying higher 131I activities in the ablation of 
thyroid remnants in DTC patients. Furthermore, in the case of lymph node 
metastases a further adjustment of the applied activity may be recommended. 
 
In chapter 3 we compared the success rate of the above-mentioned uptake-
related ablation protocol with the success rate of a fixed-dose ablation protocol 
in which the applied activity depends on tumor stage. In a fixed-dose ablation 
protocol relatively higher activities of 131I are used, compared to the uptake-
related ablation protocol. All differentiated thyroid carcinoma patients with M0 
disease who had undergone (near-)total thyroidectomy followed by 131I ablation, 
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were included. The activities in the uptake-related ablation protocol are 
mentioned above. In the fixed-dose ablation strategy, activities of 3700 MBq 
(T1-3, N0 stage) and 5550 MBq (N1 and/or T4 stage) were applied. Two criteria 
were used to assess successful ablation: (1) no 131I uptake in the neck, and (2) 
negative 131I whole-body scintigraphy (WBS) combined with Tg-off values 
below cut-off level of the assay used. According to criterion 1 the uptake-related 
ablation protocol was successful in 89 out of 153 patients (58%), compared to 
174 out of 206 patients (84%) treated according to the fixed-dose ablation 
protocol (p<0.001). According to criterion 2 the uptake-related ablation protocol 
was successful in 60 out of 139 patients (43%) versus 111 out of 199 patients 
(56%) for the fixed-dose ablation protocol (p=0.022). From these data, we 
concluded that the fixed-dose 131I ablation protocol is more effective in ablation 
of the thyroid remnant in DTC patients than an uptake-related ablation protocol. 
 
In chapter 4 we focused on the so-called stunning effect. Dosimetric studies 
have shown that activities of 131I as low as 10-20 MBq may deliver a significant 
dosage to thyroid cells and may cause a stunning effect. A result of this stunning 
effect may be a lowered success rate of the ablative 131I therapy. The aim of the 
study described in chapter 4 was to determine whether pre-therapeutic uptake 
measurement with 40 MBq 131I causes a lower success rate of ablation. We 
compared the success rate of ablation in two hospitals in which the ablation 
protocols differed in one respect only: in one hospital no pre-therapeutic 131I was 
applied (group 1), whereas in the other hospital ablation was preceded by a 24-
hour uptake-measurement with 40 MBq 131I (group 2). Data from both groups 
were reviewed retrospectively. All T0-4, N0-1, M0 patients who had undergone 
131I ablation between July 2002 and December 2005, and who had returned for 
131I follow-up, were included. Ablation was considered successful in the case of 
absence of pathological 131I uptake on WBS combined with a TSH-stimulated 
Tg value below cut-off level of the assay used. A total of 99 patients were 
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included (48 in group 1 and 51 in group 2). Overall, ablation was successful in 
31/48 patients (65%) in group 1 and in 17/51 patients (33%) in group 2 
(p=0.002). We concluded that after applying a diagnostic activity of 40 MBq 131I 
before ablation, the success rate of ablation is severely reduced. Consequently, 
the routine application of 131I for diagnostic scintigraphy or uptake measurement 
prior to 131I ablation is best avoided. 
 
In chapter 5 we tried to identify patients with a high risk for recurrent thyroid 
cancer at initial stage, i.e. at the time of ablation. Therefore, we evaluated tumor 
recurrence in consecutive patients treated for DTC. Well known prognostic 
factors were statistically analyzed. In addition we defined prognostic parameters 
based on Tg values, 24-hour 131I uptake rates and TSH values: (a) Tg/TSH, (b) 
Tg/24-hour 131I uptake rate, and (c) Tg/(TSHx24-h 131I uptake). We included 190 
patients (50 male, 140 female; mean age 47 years) with DTC for analysis, 146 
without distant metastases and 44 with M1 tumor stage at initial presentation. 
The mean period of follow-up was 10.4 years (SD ±3.7 years). In 18 out of the 
146 DTC patients with M0 disease (12.4%), tumor recurrence was found during 
follow-up. Although tumor stage, age, and standard biochemical values 
significantly differ between patients with and without recurrent disease or 
between patients with M0 and M1 tumor stage, the newly defined parameter 
Tg/(TSHx24-h 131I uptake) was the best independent significant prognostic 
parameter in the assessment whether patients will develop a tumor recurrence 
during follow-up or not. We concluded that high Tg/(TSHx24-h 131I uptake) 
ratios justify an adjustment of the 131I activity for ablation therapy. To assess the 
optimal cut-off level for an adjustment of the 131I activity, however, further 
studies are required in more patients. 
 
The aim of the study described in chapter 6 was to assess the prevalence of 
second primary tumors in patients treated for thyroid cancer. Furthermore, we 
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assessed the standardized risk rates for all second primary tumors, but especially 
for breast cancer, as data in the literature indicate an excessive risk in DTC 
patients for this tumor. Patients who received ablation treatment with 131I at the 
Leiden University Medical Center between January 1985 and December 1999 
(n=282) were included in the study. The mean period of follow-up was 10.6±4.1 
years. Thirty-five of the 282 patients (12.4%) had a second primary tumor 
(SPT), either preceding or following the diagnosis of thyroid cancer. Five other 
patients had three primary tumors, including DTC. As a result, 40 additional 
tumors were found in this group, revealing an overall prevalence of 14.2%. 
Twenty tumors (7.1%) preceded the thyroid cancer with a mean interval of 5.7 
years (range: 0.5–22.0 years), whereas 20 tumors (7.1%) occurred after this 
tumor with a mean interval of 6.7 years (range: 1.0–15.0 years). In 13 female 
patients, breast cancer was found as SPT. The standardized incidence rate (SIR) 
for all cancers after the diagnosis of DTC in this study population was not 
increased (1.13; confidence interval (CI): 0.68–1.69). However, we found an 
increased SIR of 2.26 (CI: 1.60–3.03) for all cancers either following or 
preceding DTC, which is mainly caused by a SIR of 3.95 (CI: 2.06–6.45) for 
breast cancer. We concluded that patients with DTC have an overall increased 
SIR for second primary tumors (especially for breast cancer) but not for second 
primary tumors following 131I therapy. These findings suggest a common 
etiologic and/or genetic mechanism instead of a causal relation. 
We realize that these findings are in contrast to other publications [3;4]. This has 
led to a more careful positioning of RaI ablation in recent papers [2;5] where 
harmful effects of RaI have been suggested. 
 
In the last two chapters we focused on the minority of DTC patients in whom 
dedifferentiation of the tumor occurred, accounting for a poorer outcome. This 
dedifferentiation is seen in approximately 50% of patients with distant 
metastases. In such cases, tumor cells lose their 131I uptake capability, which is 
 180
Summary and Discussion 
 
 
usually associated with an increased growth rate and a larger tumor load. As a 
consequence, WBS with 131I will yield false negative results, whereas in most 
cases rising Tg values will be measured during follow-up. 
 
In chapter 7 we evaluated the diagnostic and prognostic value of 111In-DTPA-
octreotide scintigraphy in papillary and follicular thyroid carcinoma with 
increasing Tg values, but no response to treatment with 131I. Twenty-three 
consecutive patients (13 female, 10 male; mean age 55 years, range 13–81 
years) with progressive DTC were selected. All patients had non-functioning 
metastases, defined by no or slight uptake of 131I in metastases. Diagnosis of 
tumor progression was based on rising Tg values during follow-up and was 
confirmed by radiological examination. Uptake on octreotide scintigraphy was 
scored from 0 to 4. Seven patients died during follow-up. The overall sensitivity 
for the detection of metastases was 74%. The sensitivity was higher in patients 
in whom 131I WBS did not show any abnormal uptake (82%; 14/17) than in 
patients with low 131I uptake (50%; 3/6). The 10-year survival rate was 
significantly different between patients with an uptake score of 0 or 1 (100%) 
and those with an uptake score of 2, 3 or 4 (33%) (p=0.001). Gender, log Tg and 
uptake on octreotide scintigraphy significantly correlated with survival, but in 
stepwise analysis, 111In-DTPA-octreotide uptake was selected as the most 
prognostic independent variable (hazard rate 6.25, p=0.006). Therefore, we 
concluded that 111In-DTPA-octreotide scintigraphy is a valuable clinical tool for 
the detection of non-functioning DTC metastases. The uptake seems to correlate 
with prognosis and survival. 
 
The aim of the study described in chapter 8 was to determine the effect of 111In-
DTPA-octreotide therapy in patients with progressive radioiodine non-
responsive thyroid cancer in relation to 111In-DTPA-octreotide uptake by tumor 
localizations assessed on pre-treatment diagnostic octreotide scans. Via 
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somatostatin receptor subtypes, 111In-DTPA-octreotide is internalized by thyroid 
and neuroendocrine cancer cells and can cause DNA damage by the emission of 
conversion and Auger electrons. Eleven consecutive patients, selected on 
positive pre-treatment diagnostic scans, were treated with fixed activities of 
approximately 7400 MBq of 111In-DTPA-octreotide with an interval of 2–3 
weeks between the administrations. In one patient, the applied activity was 
adjusted because of sickle-cell disease. To assess the effects during treatment 
with 111In-DTPA-octreotide Tg values were collected from 2 years before 
treatment, during treatment and up to 1 year after treatment. A computed 
tomography scan was performed 3 months after the last treatment. Two patients 
died during and shortly after the treatment course. Their death cause was 
unrelated to the treatment. In 44% of the patients, stable disease was achieved 
up to 6 months after the first treatment according to both criteria (results of 
radiographic studies and Tg values). All four had relative low pre-treatment Tg 
values (mean value 275 μg/l), representing limited metastasized disease. In two 
patients biochemical stable disease was observed, whereas computed 
tomography showed tumor progression. We concluded that treatment with high 
activities of 111In-DTPA-octreotide in metastatic DTC results in stable disease in 
a subgroup of patients. Our results suggest that a low pre-treatment Tg value, 
representing a small tumor load, may be a selection criterion for treatment. 
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- An uptake-related ablation strategy results in a relatively high treatment 
failure rate, which is significantly lower when higher ablation activities 
according to a fixed-dose strategy are used. 
- Pre-therapeutic uptake measurement using 40 MBq 131I reduces the 
success of ablation and, therefore, the routine application of 131I for 
diagnostic scintigraphy or uptake measurement prior to 131I ablation 
should be avoided. 
- High Tg/(TSHx24-h 131I uptake) ratios justify an adjustment of the 131I 
activity for ablation therapy, because this is the best independent 
significant prognostic parameter in the assessment whether patients will 
develop a tumor recurrence during follow-up or not. 
- DTC patients have an overall increased standardized incidence rate for 
second primary tumors (especially for breast cancer), but not for second 
primary tumors following 131I therapy, although this remains a subject of 
debate. 
- Scintigraphy using 111In-DTPA-octreotide is a valuable clinical tool for 
the detection of non-functioning DTC metastases and uptake of this 
radiopharmaceutical seems to correlate with prognosis and survival. 
- Treatment with high activities of 111In-DTPA-octreotide in DTC patients 
with non-functioning metastases results in a stable disease in a subgroup 
of patients. A selection criterion for this treatment may be a small tumor 
load, indicated by a low pre-treatment Tg value. 
 
Prospectives 
Well-differentiated thyroid cancer is characterized by rare occurrence and a 
good prognosis. However, up to 20% of DTC patients develop locoregional 
recurrences, whereas even 8% of patients with such recurrences eventually die 
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from the disease [6] Well differentiated thyroid cancer mostly recurs in the 
cervical lymph nodes and thyroid bed [6-8]. 
In this thesis we focused on scintigraphy and therapy using 131I. However, 
especially in patients with distant metastases a variable degree of 
dedifferentiation may occur. As a consequence, scintigraphy with RaI will yield 
falsely negative results and therapy with 131I is not advantageous anymore. In 
this patient group presenting with detectable Tg, but a normal diagnostic or post-
therapeutic RaI scintigram, staging is difficult and treatment options are few. 
Furthermore, recurrent disease, although less common, can be suspected despite 
normal Tg values. 
High sensitivity rates of 95-100% are given in literature for ultrasound-guided 
fine-needle aspiration biopsy [9;10] However, it cannot be unequivocally 
concluded that ultrasonography should be performed as a solitary first line 
imaging modality. For the assessment of the neck, the most common site of 
metastases in papillary thyroid cancer, it is highly accurate. However, the most 
important findings are that even in patients with locoregional disease distant 
metastases in up to 18% will be missed and that the number of patients with 
distant metastases and no locoregional disease is up to 11% [6]. When MRI is 
performed it may be difficult to differentiate small malignant from small benign 
lesions. 
It is suggested that functional imaging using positron emission tomography 
(PET) with [18F]fluorodeoxyglucose (FDG) could resolve the problems 
described above. In thyroid neoplasms increased uptake of glucose seems to be 
restricted to more aggressive and high-grade tumors. Schönberger et al. [11] 
have shown that overexpression of glucose transporter 1 on the cell membrane 
of thyroid neoplasms, responsible for increased glucose uptake in malignancy, is 
closely related to tumors demonstrating a more aggressive biological behaviour 
and unfavourable prognosis. This is probably the explanation for the differences 
in sensitivity rates for FDG-PET mentioned in literature. High sensitivity rates 
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are given (82-95%) for FDG-PET, especially in patients with non-functioning 
metastases, i.e. more dedifferentiated malignancy [12-15] However, sensitivity 
rates decrease to 50% in patients with uptake on RaI scintigraphy [12]. FDG-
PET could determine the location and extent of recurrence (solitary tumor or 
multiple lesions), facilitating the choice between surgery, radiotherapy or 
radionuclide therapy. Zuijdwijk et al. [15] concluded in their study that FDG-
PET had an impact on patient management in approximately 50% of patients. 
An important issue in imaging with FDG-PET is the serum Tg value. The 
chance of positive findings increases with increasing Tg values, even in 131I-
negative DTC [6], because of the relationship between Tg values and tumor 
burden. This has been described by Bachelot et al. [16] and recently by Robbins 
et al. [17]. 
The use of another iodine isotope (124I) with positron emitting characteristics 
may allow better identification of recurrent disease compared to 123I or 131I 
gamma scintigraphy. Especially combined 124I-PET/CT imaging has a better 
lesion detectability compared to conventional 131I scintigraphy [18]. Therefore, 
this technique could probably identify patients with disseminated iodine avid 
metastases who otherwise would have been classified as iodine non-responsive 
thyroid cancer and thus allowing more patients to be treated with 131I as a 
curative attempt. However, to date large prospective studies on the diagnostic 
value of 124I-PET in the management of advanced DTC are lacking and therefore 
this would be an interesting research field for the future. 
Imaging with a radiolabeled somatostatin analog is another option in the patient 
group with DTC presenting with detectable Tg, but a normal diagnostic or post-
therapeutic RaI scintigram. In the present thesis we evaluated in chapter 7 the 
diagnostic and prognostic value of somatostatin receptor scintigraphy (SRS), 
using 111In-DTPA-octreotide, in DTC patients with non-functioning metastases. 
The advantage of SRS is that it can be used in this group to select patients for 
therapy based on somatostatin receptor binding. In chapter 8 we described the 
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therapeutic effect of high activities of 111In-DTPA-octreotide, which is based on 
the toxicity of short range Auger electrons (emitted by 111In) on cellular DNA. 
However, somatostatin analogues labeled with β-emitting radionuclides 
theoretically should give a better therapeutic effect, because this type of 
radiation can extend over a longer distance and is therefore probably be able to 
destroy both somatostatin receptor positive and somatostatin receptor negative 
tumor cells. Teunissen et al. [19] concluded in a review article that peptide 
receptor radionuclide therapy with β-emitting radionuclides 90Yttrium (90Y) and 
177Lutetium (177Lu) gives the best results in terms of objective tumor response. 
There are only few other therapies in addition to the above-mentioned 
radionuclide therapies in extended radioiodine-resistant DTC. Cytotoxic 
chemotherapy yields low response rates of short duration and does not prolong 
survival. There may be a place for vascular endothelial growth factor (VEGF) 
receptor inhibitors as increased expression of VEGF, a potent angiogenesis 
stimulator, is characteristic of aggressive DTC [20]. In a recent study by 
Sherman et al. [21] and Gupta et al. [22] novel oral tyrosine kinase inhibitors 
(motesanib and sorafenib) are investigated and they concluded that this may be 
an effective treatment in some patients with progressive, metastatic, RaI-
resistant DTC. 
It can be concluded that further studies are required in patients with extended 
RaI-resistant DTC. Probably a combination of peptide receptor radionuclide 
therapy and specific molecular therapies, as mentioned above, are potential 
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De therapie die de voorkeur heeft voor patiënten die lijden aan gedifferentieerd 
schildkliercarcinoom (onderverdeeld in papillair en folliculair 
schildkliercarcinoom) is een (bijna-) totale operatieve verwijdering van de 
schildklier. Deze behandeling wordt gevolgd door toediening van radioactief 
jodium-131 (131I) om alle overblijvende, zowel goedaardige als kwaadaardige, 
schildklierresten te vernietigen. Dit wordt ablatie genoemd. 
Ofschoon vele aspecten van diagnose, initiële therapie en follow-up procedures 
beschreven zijn in recent gepubliceerde richtlijnen (gepubliceerd door de 
Amerikaanse en Europese schildklierverenigingen en door de Nederlandse CBO 
schildkliercarcinoom consensus groep (www.cbo.nl)) [1;2], blijven toch vele 
vragen onbeantwoord met betrekking tot de klinische aanpak van patiënten met 
een gedifferentieerd schildkliercarcinoom. Dit proefschrift richt zich op een 
aantal belangrijke klinische vragen gerelateerd aan de conventionele (131I) en 
experimentele therapieën met radionucliden bij gedifferentieerd 
schildkliercarcinoom. 
Jodium-131 wordt al vele jaren gebruikt voor de ablatie van een schildklierrest 
na chirurgie van de schildklier, maar een optimale eenmalige toegediende 
activiteit van 131I werd nog niet eerder vastgesteld. De gegevens in de literatuur 
zijn wat dat betreft tegenstrijdig; sommige studies concluderen dat een activiteit 
van 1110 MBq 131I net zo effectief is als een hogere activiteit, zoals 3700 MBq. 
Daarentegen wijzen andere auteurs erop dat een hogere activiteit het succes van 
de ablatie juist verhoogt. Twee protocollen worden in Nederland gebruikt: de 
z.g. opname-gerelateerde ablatiestrategie, waarbij een relatief lage hoeveelheid 
activiteit van 131I wordt gebruikt en de z.g. vaste-dosering, ofwel het tumor-
gerelateerde protocol, waarbij een hogere hoeveelheid activiteit wordt toegepast. 
De belangrijkste doelstelling van dit proefschrift is om zowel de resultaten van 
de ablatiebehandeling bij gedifferentieerd schildkliercarcinoom volgens het 
opname-gerelateerde protocol op korte termijn als die op langere termijn te 





Bovendien onderzochten wij in hoeverre er een relatie is tussen het mislukken 
van de ablatie en de pre-ablatie 24-uurs opname-meting (het z.g. stunning 
effect). Door het vaststellen van de prevalentie van tweede primaire tumoren bij 
patiënten die behandeld werden voor schildkliercarcinoom wilden wij bewijzen 
dat behandeling met 131I veilig is met het oog op de lange termijn effecten. 
Tenslotte hebben wij gekeken naar scintigrafie en behandeling met 111In-DTPA-
octreotide bij een progressief schildkliercarcinoom dat niet meer reageert op 
radioactief jodium. 
 
In hoofstuk 2 wordt de effectiviteit van de opname-gerelateerde ablatiestrategie 
bestudeerd. Bij deze strategie wordt een relatief lage hoeveelheid activiteit 131I 
gebruikt. De dosering is afhankelijk van een 131I 24-uurs meting van de opname 
in de hals. Voor het opname-gerelateerde ablatieprotocol wordt 1100 MBq 
(opname >10%), 1850 MBq (opname 5-10%) en 2800 MBq (opname <5%) 
gebruikt. Voor deze studie werden 235 patiënten geselecteerd die primaire 
chirurgie hadden ondergaan voor gedifferentieerd schildkliercarcinoom, gevolgd 
door ablatie met 131I. Ongeveer zes maanden na ablatie werd de effectiviteit 
geëvalueerd m.b.v. een radioactief jodium scintigram en thyroglobuline (Tg) 
metingen. Succesvolle ablatie werd hierbij gedefinieerd op basis van twee 
criteria: de afwezigheid van opname van radioactief jodium in de halsstreek 
(criterium 1) en gebaseerd op Tg serum waarden gemeten gedurende TSH 
stimulatie (Tg-off), bepaald 3-12 maanden na ablatie (criterium 2). Gebaseerd 
op criterium 1 werd bij 43% van de patiënten niet-succesvolle ablatie 
geconstateerd en gebaseerd op criterium 2 was de ablatie mislukt bij 52% van de 
patiënten. Deze gegevens tonen een relatief hoog percentage van niet-
succesvolle ablaties aan bij deze ablatiestrategie. Op basis van deze resultaten 
stelden wij vast dat een lager percentage van niet-succesvolle ablaties kan 
worden bereikt door het toepassen van een hogere hoeveelheid activiteit van 131I 
bij de ablatie van schildklierresten bij patiënten met een gedifferentieerd 
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schildkliercarcinoom. In het geval van lymfkliermetastasen kan een verdere 
aanpassing van de activiteit ook nog raadzaam zijn. 
 
In hoofdstuk 3 vergelijken wij het succespercentage van het eerder genoemde 
opname-gerelateerde ablatieprotocol met het succespercentage van het vaste-
dosis ablatieprotocol, waarbij de hoeveelheid activiteit afhankelijk is van het 
tumorstadium. Bij het vaste-dosisprotocol wordt een relatief hoge hoeveelheid 
activiteit van 131I gebruikt, vergeleken met het opname-gerelateerde 
ablatieprotocol. Alle gedifferentieerd schildkliercarcinoom patiënten met M0 
ziekte die een (bijna-)totale operatieve verwijdering van de schildklier 
ondergingen, gevolgd door 131I ablatie werden in het onderzoek betrokken. De 
toegepaste activiteit bij het opname-gerelateerde ablatieprotocol zijn hierboven 
beschreven. Bij de vaste-dosis ablatiestrategie werd behandeling met 3700 MBq 
(T1-3, N0 stadium) en 5500 MBq (N1 en/of T4 stadium) toegepast. Twee 
criteria werden gebruikt om het ablatieresultaat vast te stellen: (1) 131I-opname in 
de hals en (2) 131I opname op een scintigram van het gehele lichaam 
gecombineerd met Tg-off waarden. Overeenkomstig criterium 1 was het 
opname-gerelateerde protocol succesvol bij 89 van de 153 patiënten (58%), 
vergeleken met 174 van de 206 patiënten (84%) die behandeld werden 
overeenkomstig het vaste-dosis ablatieprotocol (p<0,001). Overeenkomstig 
criterium 2 was het opname-gerelateerde ablatieprotocol succesvol bij 60 van de 
139 patiënten (43%), versus 111 van de 199 patiënten (56%) voor het vaste-
dosis ablatieprotocol (p=0,022). Op basis van deze gegevens concludeerden wij 
dat het vaste-dosis 131I ablatieprotocol doeltreffender is bij de ablatie van 
schildklierresten voor het gedifferentieerd schildkliercarcinoom dan het 
opname-gerelateerde ablatieprotocol. 
 
In hoofstuk 4 hebben wij ons geconcentreerd op het z.g. stunning-effect. 





levert aan de schildkliercellen en daardoor het z.g. stunning effect veroorzaakt. 
Een resultaat van dit stunning effect kan wellicht een lager slagingspercentage 
van de 131I behandeling zijn. De doelstelling van het onderzoek zoals beschreven 
in hoofdstuk 4 is om vast te stellen in hoeverre opname meting met 40 MBq 131I 
voorafgaand aan de ablatie een lager slagingspercentage van de ablatie 
veroorzaakt. Wij hebben het succespercentage van de ablatie in twee 
ziekenhuizen vergeleken, waarbij de ablatieprotocollen verschilden met 
betrekking tot slechts één aspect: in het ene ziekenhuis werd geen opname 
meting met 40 MBq 131I voorafgaand aan ablatie toegepast (groep 1), terwijl in 
het andere ziekenhuis dit wel werd gedaan (groep 2). De gegevens van beide 
groepen werden vervolgens onderzocht. Alle T0-4, N0-1, M0 patienten die een 
ablatie hadden ondergaan tussen juli 2002 en december 2005 en waarbij een 131I 
follow-up scintigram beschikbaar was, werden in het onderzoek betrokken. 
Ablatie werd als succesvol beschouwd in die gevallen waarbij er geen 
pathalogische 131I opname op het scintigram van het gehele lichaam te zien was 
en er ook sprake was van een onmeetbaar Tg onder TSH stimulatie. Een totaal 
van 99 patiënten werd in het onderzoek betrokken (48 in groep 1 en 51 in groep 
2). In totaal was bij 31 van de 48 patiënten (65%) ablatie succesvol in groep 1 en 
bij 17 van de 51 patiënten (33%) in groep 2 (p=0,002). Wij concludeerden 
hieruit dat opname meting met 40 MBq 131I voorafgaand aan ablatie, het succes 
van ablatie vermindert en dat daarom stelselmatige toepassing van 131I voor een 
diagnostisch scintigrafie of opname meting voorafgaand aan 131I ablatie moet 
worden vermeden. 
 
In hoofdstuk 5 hebben wij getracht patiënten in het begin stadium (d.w.z. op het 
moment van de ablatie) te identificeren die een hoog risico hebben op het 
ontwikkelen van een recidief schildkliercarcinoom. Daarvoor evalueerden wij 
het terugkeren van de tumor bij patiënten die waren behandeld voor een 
gedifferentieerd schildkliercarcinoom. Algemeen bekende prognostische 
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factoren werden statistisch geanalyseerd. Wij bepaalden prognostische 
parameters gebaseerd op Tg waarden, 24-uurs 131I opnamewaarden en TSH 
waarden: (a) Tg/TSH, (b) Tg/24-uurs 131I opnamewaarde en (c) Tg/(TSHx24-
uurs 131I opname). Wij includeerden 190 patiënten (50 mannen, 140 vrouwen, 
gemiddelde leeftijd 47 jaar) met een gedifferentieerd schildkliercarcinoom in 
onze analyses, 146 zonder metastasen en 44 met M1 ziekte bij initiële 
presentatie. De gemiddelde follow-up duur was 10,4 jaar (SD ±3,7 jaar). Bij 18 
patiënten van de 146 gedifferentieerd schildkliercarcinoom patiënten met M0 
ziekte (12,4%) werd een recidief van de tumor gevonden gedurende de follow-
up. Alhoewel er tussen tumorstadium, leeftijd en standaard biochemische 
waarden aanzienlijke verschillen zijn tussen patiënten met en zonder een recidief 
of tussen patiënten met M0 en M1 ziekte, is de nieuwe gedefinieerde parameter 
Tg/(TSHx24-uurs 131I opname) de beste onafhankelijke significante 
prognostische parameter bij de schatting in hoeverre patiënten wel of niet een 
recidief zullen ontwikkelen gedurende de follow-up. Wij kwamen tot de 
conclusie dat hoge Tg/(TSHx24-uurs 131I opname) ratio’s een aanpassing van de 
131I activiteit voor ablatie rechtvaardigen. Wat betreft de bepaling van de 
optimale cut-off waarde voor deze aanpassing zijn aanvullende studies met meer 
patiënten nodig. 
 
De doelstelling van de studie beschreven in hoofdstuk 6 is om de prevalentie 
van een tweede primaire tumor bij patiënten die behandeld waren voor 
schildkliercarcinoom te beoordelen. Bovendien beoordeelden wij de standaard 
risico’s voor alle tweede primaire tumoren en in het bijzonder die voor 
borstcarcinoom, omdat gegevens in de literatuur een groot risico aantonen voor 
deze tumor bij patiënten met een gedifferentieerd schildkliercarcinoom. In de 
studie werden patiënten opgenomen die een ablatiebehandeling met 131I 
ondergingen in het Leids Universitair Medisch Centrum in de periode tussen 





10,6±4,1 jaar. Vijfendertig van de 282 patiënten (12,4%) hadden een tweede 
primaire tumor, zowel voorafgaand of volgend op de diagnose 
schildkliercarcinoom. Vijf andere patiënten hadden drie primaire tumoren 
inclusief een gedifferentieerd schildkliercarcinoom. Er werden 40 additionele 
tumoren in deze groep gevonden, dus een prevalentie van 14,2%. Twintig 
tumoren (7,1%) gingen vooraf aan het schildkliercarcinoom met een gemiddeld 
interval van 5,7 jaar (spreiding: 0,5-22,0 jaar), terwijl twintig tumoren (7,1%) 
werden geconstateerd na schildkliercarcinoom met een gemiddeld interval van 
6,7 jaar (spreiding: 1,0-15,0 jaar). Bij dertien vrouwelijke patiënten werd 
borstcarcinoom geconstateerd als tweede primaire tumor. De standaard 
incidentie voor alle carcinomen na de diagnose gedifferentieerd 
schildkliercarcinoom in deze studiepopulatie was niet toegenomen (1,13; 
betrouwbaarheidsinterval: 0,68-1,69). Wij vonden echter een verhoogd 
gestandaardiseerd incidentie percentage (SIR) van 2,26 
(betrouwbaarheidsinterval: 1,60-3,03) voor alle carcinomen, zowel volgend op 
als voorafgaand aan gedifferentieerd schildkliercarcinoom, wat grotendeels 
wordt veroorzaakt door een SIR van 3,95 (betrouwbaarheidsinterval: 2,06-6,45) 
voor borstcarcinoom. Wij kwamen tot de conclusie dat patiënten met een 
gedifferentieerd schildkliercarcinoom in het algemeen een verhoogde SIR 
hebben voor tweede primaire tumoren (in het bijzonder voor borstcarcinoom), 
maar niet voor tweede primaire tumoren volgend op een 131I therapie. Deze 
bevindingen wijzen op een etiologisch en/of genetisch mechanisme in plaats van 
een oorzakelijk verband. 
Wij realiseren ons dat deze bevindingen in strijd zijn met andere publicaties 
[3;4]. Dit heeft geleid tot een zorgvuldigere plaatsing van radioactief jodium in 





In de laatste twee hoofdstukken besteedden wij aandacht aan een minderheid 
van de schildkliercarcinoom patiënten bij wie dedifferentiatie van de tumor is 
opgetreden, waardoor slechtere resultaten van de behandeling met radioactief 
jodium optreden. Deze dedifferentiatie wordt geconstateerd bij 50% van de 
patiënten met afstandsmetastasen. Hierbij verliezen tumorcellen hun vermogen 
om 131I op te nemen, dat doorgaans wordt geassocieerd met een toenemende 
groeisnelheid en een grotere tumormassa. Dientengevolge zal een totale 
lichaamsscintigrafie met 131I onjuiste negatieve resultaten opleveren, terwijl in 
de meeste gevallen stijgende Tg waarden werden gemeten tijdens de follow-up. 
 
In hoofdstuk 7 evalueerden wij de diagnostische en prognostische waarde van 
111In-DTPA-octreotide scintigrafie voor een papillair en folliculair 
schildkliercarcinoom met stijgende Tg waarden en die niet reageerde op de 
behandeling met 131I. Drieentwintig patiënten (13 vrouwen en 10 mannen, 
gemiddelde leeftijd 55 jaar, spreiding 13-81 jaar) met een progressief 
schildkliercarcinoom werden geselecteerd. Alle patiënten hadden metastasen die 
niet meer reageerden op behandeling met 131I, hetgeen bepaald werd op basis 
van geen of slechts een beperkte opname van 131I in die metastasen. De diagnose 
tumorprogressie werd gebaseerd op stijgende Tg waarden gedurende de follow-
up en werd bevestigd door radiologisch onderzoek. De opname die gezien werd 
op het 111In-DTPA-octreotide scintigram werd gescored van 0 tot 4. Zeven 
patiënten overleden gedurende de follow-up. De totale sensitiviteit voor de 
detectie van metastasen was 74%. De sensitiviteit was hoger bij patiënten bij 
wie het 131I scintigram geen pathologische opname toonde (82%; 14/17), 
vergeleken met patiënten met een lage 131I opname (50%; 3/6). De 10-jaars 
overleving was duidelijk verschillend tussen patiënten met een opnamescore van 
0 of 1 (100%) en die met een opnamescore van 2, 3 of 4 (33%) (p=0,001). 
Geslacht, log Tg en opname op het 111In-DTPA-octreotide scintigram 





DTPA-octreotide opname geselecteerd als de meest prognostische 
onafhankelijke variabele (hazard rate 6,25, p=0,006). Op basis hiervan kwamen 
wij tot de conclusie dat 111In-DTPA-octreotide scintigrafie een waardevol 
klinisch hulpmiddel is voor het ontdekken van niet-reagerende metastasen van 
het schildkliercarcinoom. 
 
De doelstelling van de studie zoals beschreven in hoofdstuk 8 is om het effect te 
bepalen van 111In-DTPA-octreotide therapie bij patiënten met een 
schildkliercarcinoom dat progressief is en niet meer reageert op radioactief 
jodium in relatie tot 111In-DTPA-octreotide opname in metastasen, vastgesteld 
op diagnostische octreotidescans. 111In-octreotide wordt via somatostatine 
receptor subtypen geïnternaliseerd door de schildklier en neuroendocriene 
tumoren, hetgeen vervolgens DNA-schade kan veroorzaken door de emissie van 
conversie en Auger electronen. Elf patiënten, geselecteerd m.b.v. diagnostische 
octreotide scans, werden behandeld met 7400 MBq 111In-DTPA-octreotide met 
een interval van 2-3 weken tussen de toedieningen. Bij één patiënt werd de 
hoeveelheid activiteit aangepast in verband met sikkelcelziekte. Om de effecten 
gedurende de behandeling met 111In-DTPA-octreotide te bepalen werden Tg 
waarden van twee jaar vóór de behandeling, gedurende de behandeling en tot 
één jaar na de behandeling verzameld. Drie maanden na de laatste behandeling 
werd computertomografie (CT) uitgevoerd. Twee patiënten overleden gedurende 
en kort na de behandelingskuur. De oorzaak van hun overlijden was niet 
gerelateerd aan de behandeling. Bij 44% van de patiënten was er sprake van een 
stabiele situatie in een periode tot 6 maanden na de eerste behandeling op basis 
van beide criteria (resultaten van radiologische studies en Tg waarden). Deze 
vier patiënten hadden een relatief lage Tg waarde (gemiddelde waarde 275 µg/l) 
vóór behandeling, wat wijst op een beperkte gemetastaseerde ziekte. Bij twee 
patiënten werd een biochemisch stabiele ziekte waargenomen, terwijl CT 
tumorprogressie toonde. Wij concludeerden dat behandeling met een hoge 
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activiteit van 111In-DTPA-octreotide bij gemetastaseerd schildkliercarcinoom 
resulteert in een stabiele ziekte bij een subgroep van patiënten. Onze resultaten 
geven aan, dat een lage Tg waarde vóór behandeling, wijzend op een geringe 





- Bij de ablatiebehandeling van gedifferentieerd schildkliercarcinoom met 
131I resulteert de opname-gerelateerde ablatiestrategie in een relatief hoog 
percentage niet-succesvolle ablaties, in tegenstelling tot een vaste-
dosisprotocol met een hogere activiteit.  
- Diagnostische scintigrafie met 40 MBq 131I voorafgaand aan een 
ablatiebehandeling ter vaststelling van de opname van 131I vermindert het 
succes van ablatie en moet daarom worden vermeden. 
- Hoge Tg/(TSHx24-uurs 131I opname) ratio’s rechtvaardigen een 
aanpassing van de 131I activiteit voor de ablatie, omdat dit de beste 
onafhankelijke prognostische parameter is voor het ontwikkelen van een 
recidief gedurende follow-up. 
- Schildkliercarcinoom patiënten hebben een verhoogde gestandaardiseerde 
incidentie voor tweede primaire tumoren (in het bijzonder voor 
borstcarcinoom) die echter niet samen lijkt te hangen met 131I therapie, 
alhoewel dit een onderwerp blijft voor discussie.  
- 111In-DTPA-octreotide scintigrafie is een waardevolle methode voor het 
opsporen van niet op 131I reagerende metastasen van gedifferentieerd 
schildkliercarcinoom, waarbij de opname van dit radiofarmacon correleert 
met de prognose. 
- Behandeling met een hoge hoeveelheid activiteit van 111In-DTPA-






op 131I reagerende metastasen resulteert in stabiele ziekte bij een subgroep 
van patiënten. Een selectiecriterium voor deze behandeling kan mogelijk 
een geringe tumorload zijn, hetgeen wordt aangetoond door een lage Tg 
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